All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
E1554 Tefinostat(CHR-2845) Mar 27 2024
E1783 Conteltinib(CT-707) Mar 26 2024
E1114 Ifebemtinib Mar 25 2024
S9861 PY-60 PY-60 is a small-molecule activator of the transcriptional coactivator Yes-associated protein (YAP) with EC50 of 1.6 µM, which acts by inhibiting a central scaffolding protein in the Hippo pathway, Annexin A2. It promotes the regenerative repair of cutaneous wounds in pig and human models. Mar 24 2024
E1356 BI-0474 BI-0474 is a potent inhibitor of KRASG12C with an IC50 value of 7.0 nM. It inhibits GDP-KRAS::SOS1 protein-protein interactions. It exhibits anti-proliferative and anti-tumour activity and can be used in cancer research. Mar 24 2024
E1165 JAB-3068 JAB-3068 (SHP2-IN-6) is a potent allosteric inhibitor of SHP2. JAB-3068 enhances the anti-tumor activity of CD8+ T cells and can be used in combination to address non-responsive tumors alongside PD-1/PD-L1 antibodies. Mar 20 2024
E1768 MEDICA16 MEDICA16 is an inhibitor of ATP-citrate lyase and also acts as an agonist of G protein-coupled receptor 40 (GPR40). It functions to blunt the development of insulin resistance in the JCR:LA-cp rat as well as it is a potent triacylglycerol-lowering agent. Mar 14 2024
S9734 Bomedemstat Bomedemstat(IMG-7289) is an orally active and irreversible inhibitor of LSD1(lysine-specific demethylase 1). Bomedemstat exhibits the ability to enhance methylation levels of H3K4 and H3K9, subsequently leading to modifications in gene expression. Bomedemstat demonstrates anti-cancer properties by restraining cancer cell proliferation and prompting apoptosis. Mar 12 2024
E1341 Cerivastatin sodium Cerivastatin sodium, a sodium salt of cerivastatin, is an inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase with Ki of 1.3 nM. It is also a synthetic, enantiomerically pure, pyridine derivative that effectively reduces serum cholesterol levels at microgram doses. Mar 12 2024
E1694 Sardomozide dihydrochloride Sardomozide dihydrochloride (CGP 48664A) is a potent inhibitor of S-adenosylmethionine decarboxylase (SAMDC) with an IC50 of 5 nM. It is also a potent inhibitor of polyamine oxidase and exhibits with broad spectrum antiproliferative and antitumor activity. Mar 07 2024
S7972 Litronesib Litronesib (LY2523355) is a selective allosteric inhibitor of the human mitosis-specific kinesin Eg5. LY2523355 also exhibits highly schedule-dependent, broad-spectrum anticancer activity against tumor models and causes mitotic arrest and apoptosis in cancer cells. Mar 07 2024
E4583 Sodium selenite Sodium selenite is a licensed selenium-containing product and is widely used in medicine, veterinary, and agriculture. It has the potential to cause cell death by an independent pathway of mitochondrial apoptosis, endoplasmic reticulum stress , autophagy, or necrosis. Sodium selenite is used as potential adjuvant therapy for COVID-19. Mar 06 2024
E1754 BRD7389 BRD7389 is an inhibitor of RSK family kinases with IC50 of 1.5 μM, 2.4 μM, and 1.2 μM for RSK1, RSK2, and RSK3, respectively. BRD7389 also increases β-cell–specific gene expression in primary human islet cells.  Mar 06 2024
A2159 Anti-mouse CSF1R (CD115)-InVivo Anti-mouse CSF1R (CD115)-InVivo reacts with mouse colony stimulating factor 1 receptor (CSF1R), also known as macrophage colony-stimulating factor receptor (M-CSFR), and CD115. CSF1R is a single-pass type I membrane protein and member of the platelet-derived growth factor receptor family. Mar 03 2024
E1722 Acetalax(Oxyphenisatin acetate) Oxyphenisatin acetate is the pro-drug of oxyphenisatin. It has antiproliferative activity and also used to be a laxative. Mar 03 2024
E1352 Butyzamide Butyzamide is a non-peptidyl thrombopoietin receptor, activator of Mpl . It also augments the phosphorylation level of JAK2, STAT3, STAT5 and MAPK. It has potential for treatment of thrombocytopenia. Mar 03 2024
A2158 Anti-mouse Ly6G-InVivo Anti-mouse Ly6G-InVivo reacts with mouse Ly6G. Ly6G is a 21-25 kDa member of the Ly-6 superfamily of GPI-anchored cell surface proteins with roles in cell signaling and cell adhesion. Mar 01 2024
E2504 Toyocamycin Toyocamycin(Vengicide), an adenosine analog, acts as an inhibitor of XBP1. Toyocamycin is also a specific inhibitor of CDK9 with an IC50 value of 79 nM. Feb 26 2024
E1787 SN-001 SN-001 is a potent inhibitor of STING that specifically inhibits STING activation and STING-dependent signaling. SN-011 significantly decreases inflammatory cytokine production and osteoclast formation in vivo. Feb 26 2024
E1796 Dimethindene maleate Dimethindene maleate is a selective antagonist of histamine H1 and exhibits antihistamine effects. It suppresses the cromakalim-induced/glibenclamide-sensitive K+ currents in a concentration-dependent and reversible manner. Feb 26 2024
E1698 EN460 EN460 is a small-molecule inhibitor of endoplasmic reticulum oxidation 1(ERO1), which is specific for the reduced active form of ERO1α and prevents re-oxidation. It also protects cells from erastin-induced ferroptosis. Feb 26 2024
E1670 MKI-1 MKI-1(MASTL Kinase Inhibitor-1) is an small-molecule inhibitor of MASTL (microtubule-associated serine/threonine kinase-like) with an IC50 9.9 μM in kinase assay. It also exerts antitumor and radiosensitizer activities through PP2A-mediated c-Myc inhibition in breast cancer models. Feb 26 2024
E1614 OUL232 OUL232 (Compound 27) is an potent inhibitor of mono-ADP-ribosylation (mono-ARTs) PARP10 with IC50 of 7.8 nM. It also inhibits PARP7, PARP11, PARP12, PARP14, and PARP15 at nM potencies. Feb 26 2024
A2150 Polyclonal Armenian hamster IgG-InVivo Polyclonal Armenian hamster IgG-InVivo is purified from Armenian hamster serum. It is ideal for use as a non-reactive control IgG for Armenian hamster antibodies in most in vivo and in vitro applications. Feb 21 2024
A2151 Anti-mouse IL-10R (CD210)-InVivo Anti-mouse IL-10R (CD210)-InVivo reacts with mouse IL-10R (IL-10 receptor) also known as CD210. The IL-10R is a class II cytokine receptor and is expressed by a variety of cell types including thymocytes, T lymphocytes, B lymphocytes, NK cells, monocytes, and macrophages. Feb 21 2024
A2152 Anti-mouse IFNγ (XMG1.2)-InVivo Anti-mouse IFNγ (XMG1.2)-InVivo reacts with mouse IFNγ (interferon gamma) a 20 kDa soluble pleiotropic cytokine and the sole member of the type II class of interferons. Feb 21 2024
A2153 Anti-mouse IL-2 (S4B6-1)-InVivo Anti-mouse IL-2 (S4B6-1)-InVivo reacts with mouse IL-2, a 17 kDa cytokine that is mainly produced by T cells in response to antigenic or mitogenic stimulation. Feb 21 2024
A2154 Anti-mouse CD86 (B7-2)-InVivo Anti-mouse CD86 (B7-2)-InVivo reacts with mouse CD86 also known as B7-2. CD86 is an 80 kDa Ig superfamily member. Feb 21 2024
A2155 Anti-mouse F4/80-InVivo Anti-mouse F4/80-InVivo reacts with mouse F4/80 also known as EMR1. F4/80 is a 160 kDa membrane glycoprotein belonging to the EGF-TM7 family. Feb 21 2024
A2156 Anti-human PD-L1 (B7-H1)-InVivo Anti-human PD-L1 (B7-H1)-InVivo reacts with human PD-L1 (programmed death ligand 1) also known as B7-H1 or CD274. PD-L1 is a 40 kDa type I transmembrane protein that belongs to the B7 family of the Ig superfamily. Feb 21 2024
A2157 Anti-mouse IL-6R-InVivo Anti-mouse IL-6R-InVivo reacts with the mouse IL-6 receptor α chain also known as CD126. CD126 is an 80 kDa type I cytokine receptor and a member of the immunoglobulin superfamily. Feb 21 2024
E1163 MS177 MS177 is an EZH2-targeting PRTOAC degrader and a potent inhibitor of enzymatic EZH2, that effectively depletes both canonical EZH2–PRC2 and noncanonical EZH2–cMyc complexes. MS177 induces leukemia cell growth inhibition, apoptosis, and cell cycle progression arrest. Feb 21 2024
E4578 Trilaciclib dihydrochloride Trilaciclib dihydrochloride(G1T28 dihydrochloride) is a potent inhibitor of CDK4/cyclin D1 and CDK6/cyclin D3 with IC50s of 1 nM and 4 nM for CDK4 and CDK6, respectively. Trilaciclib hydrochloride regulates cell proliferation and protects against chemotherapy toxicity in murine and canine bone marrow cells. Feb 06 2024
A2141 Anti-mouse Ter-119-InVivo Anti-mouse Ter-119-InVivo reacts with mouse Ter-119, a 52 kDa glycophorin A-associated protein that is expressed by erythroid cells from the early proerythroblast stage to mature erythrocytes. Anti-mouse Ter-119-InVivo is commonly used for identifying erythrocytes and cells in the erythroid lineage. Feb 05 2024
A2142 Anti-mouse/rat IL-1β-InVivo Anti-mouse/rat IL-1β-InVivo reacts with precursor and mature secreted forms of mouse and rat IL-1β a 17 kDa pro-inflammatory cytokine produced primarily by monocytes. Feb 05 2024
A2143 Anti-mouse 4-1BB (CD137)-InVivo Anti-mouse 4-1BB (CD137)-InVivo reacts with mouse 4-1BB, a TNF receptor superfamily member also known as CD137. Feb 05 2024
A2144 Anti-mouse TIGIT-InVivo Anti-mouse TIGIT-InVivo reacts with mouse TIGIT (T cell immunoreceptor with Ig and ITIM domains). TIGIT is a 26 kDa, type I transmembrane protein and a member of the poliovirus receptor (PVR) family. Feb 05 2024
A2145 Mouse IgG2b isotype control-InVivo Mouse IgG2b isotype control-InVivo is ideal for use as a non-reactive isotype-matched control for mouse IgG2b antibodies in most in vivo and in vitro applications. Feb 05 2024
A2146 Anti-LCMV nucleoprotein-InVivo Anti-LCMV nucleoprotein-InVivo reacts with lymphocytic choriomeningitis virus (LCMV) nucleoprotein (NP), a 63 kDa structural protein. Feb 05 2024
A2147 Anti-mouse CXCR3 (CD183)-InVivo Anti-mouse CXCR3 (CD183)-InVivo reacts with mouse CXCR3 also known as CD183, a 38 kDa chemokine receptor for CXCL9 (MIG), CXCL10 (IP-10), and CXCL11 (ITAC). Feb 05 2024
A2148 Anti-mouse GM-CSF-InVivo Anti-mouse GM-CSF-InVivo reacts with mouse granulocyte-macrophage colony-stimulating factor (GM-CSF), also known as colony stimulating factor 2 (CSF2). Feb 05 2024
A2149 Anti-mouse CD19-InVivo Anti-mouse CD19-InVivo reacts with mouse CD19, a B cell-specific 95 kDa transmembrane glycoprotein of the immunoglobulin superfamily. Feb 05 2024
E1287 SB 204990 SB-204990, a γ-lactone prodrug of SB-201076, is a potent and specific inhibitor of ATP citrate lyase (ACLY). SB 204990 potently limits SARS-CoV-2 replication in vivo. Feb 04 2024
E1721 TJ-M2010-5 TJ-M2010-5 is a small molecule inhibitor of MyD88 that selectively binds to the Toll/Interleukin-1 receptor (TIR) domain of MyD88, disrupting its homodimerization and subsequently inhibiting the Toll-like receptor (TLR)/MyD88 signaling pathway. TJ-M2010-5 exhibits an anti-hepatic fibrosis effect with the potential to treat liver fibrosis. Feb 04 2024
E1713 FL118 FL118(10,11-(Methylenedioxy)-20(S)-camptothecin), a Camptothecin analog, is a potent and orally active inhibitor of Survivin. FL118 also selectively and independently inhibits three additional cancer-associated survival genes Mcl-1, XIAP, and cIAP2 in a p53 status-independent manner. FL118 displays potent antitumor activity and can be used in cancer research. Feb 04 2024
E1655 KT 474 KT-474 (SAR444656) is a selective small-molecule degrader of IRAK4 in development for the treatment of TLR/IL-1R–driven autoimmune diseases. KT-474 potently downregulates R848 (TLR7/8) and lipopolysaccharide (LPS)-induced IL-6 and IL-8 production in peripheral blood mononuclear cells (PBMCs). Feb 01 2024
E1627 BMS493 BMS493 is an inverse agonist of pan retinoic acid receptor (RAR). It increases nuclear corepressor interaction with RARs and can be used as an inhibitor for the dietary and pharmacologic manipulation of retinoic acid (RA) activity in vivo and in vitro. Feb 01 2024
E1685 D609 D609 is a selective, competitive inhibitor of phosphatidylcholine-specific phospholipase C (PC-PLC) with a Ki of 6.4 μM. It is an antioxidative protector and has antiviral and anti-inflammatory activity and also inhibits angiogenesis by preventing the synthesis of basement membrane (BM). Feb 01 2024
E1748 HG6-64-1 HG6-64-1 (HMSL 10017-101-1) is a highly potent and selective inhibitor of B-Raf with an IC50 of 0.09 μM on B-raf V600E transformed Ba/F3 cells. Feb 01 2024
E1874 Erastin2 Erastin2 is an inducer of ferroptosis. It also selectively inhibits xc(-) cystine/glutamate transporter. It induces ferroptosis in HT-1080, T98G, and A549 cells with the potential to treat neurodegenerative diseases. Feb 01 2024
E1520 NSC 663284 NSC 663284(DA-3003-10) is a potent, cell-permeable, and irreversible dual specificity phosphatase inhibitor of Cdc25, and exhibits an IC50 of 0.21 μM for Cdc25B2 and is 20 and 450-fold highly selective against Cdc25B2. NSC 663284 also inhibits NSD2 with an IC50 of 170 nM via a direct interaction with the catalytic SET domain. Jan 30 2024
E1750 XST-14 XST-14 is a potent, competitive, and highly selective inhibitor of ULK1 and exhibits an IC50 of 26.6 nM in an in vitro ULK1 kinase activity assay, respectively. XST-14 reduces the phosphorylation of the ULK1 downstream substrate and induces autophagy inhibition. It exhibits antitumor effects. Jan 30 2024
E1832 ZK53 ZK53 is a selective activator of mitochondrial caseinolytic protease P (HsClpP). It exhibits an EC50 of 1.37 μM for α-casein hydrolysis by HsClpP. ZK53 treatment allosterically activates HsClpP to uncontrollably degrade the essential mitochondrial proteins and is inactive toward bacterial ClpP proteins. Jan 30 2024
S9852 Orforglipron Orforglipron(LY3502970) is a non-peptidal agonist of glucagon-like peptide 1(GLP-1) receptor. It can be used efficiently in glycemic control and weight reduction in type 2 diabetes mellitus (T2DM), obesity or both. Jan 24 2024
E1749 limertinib limertinib (ASK120067) is an irreversible third-generation inhibitor of EGFRT790M with IC50 of 0.3 nM, with selectivity over EGFRWT having IC50 of 6.0 nM. It exhibits potent anti-proliferation activity in non-small cell lung cancer (NSCLC) tumor cells. Jan 23 2024
E4449 AG 825 AG-825 (Tyrphostin AG-825) is a potent and selective inhibitor of ErbB2 with IC50 values of 0.15 µM. It also inhibits PDGFR autophosphorylation with IC50 value of 40 µM. It exhibits anti-cancer activity and significantly induces apoptosis in cancer cells. Jan 22 2024
E1810 dCeMM1 dCeMM1 is a degrader of RBM39. dCeMM1 functions by altering the activity of the CRL4DCAF15 ligase, and also decreases RBM39 expression levels in wild-type KBM7 cells. Jan 22 2024
E1752 JNJ-42226314 JNJ-42226314 is a potent, selective, and reversible noncovalent inhibitor of monoacylglycerol lipase (MAGL). It enhances the expression of endocannabinoid 2-arachidonoylglycerol (2-AG) and exhibits antinociceptive efficacy in models of neuropathic and inflammatory pain. Jan 22 2024
E4453 Cathepsin G Inhibitor I Cathepsin G Inhibitor I exhibits reversible, competitive cathepsin G inhibition with IC50 and Ki values of 53 nM and 63 nM respectively. It can be used in antigen-processing studies and for modulation of T cell response in situ and in vivo. Jan 22 2024
E1711 FHT-1015 FHT-1015 is a potent, small-molecule, allosteric inhibitor of SMARCA4/SMARCA2 ATPase with IC50 values ≤10 nM. FHT-1205 decreases PD1+TIM3+ cells and cytokine expression in vivo. Jan 21 2024
E1634 CH6953755 CH6953755 is a potent, orally active, and selective inhibitor of YES1 kinase with an IC50 of 1.8 nM. CH6953755 demonstrates antitumor activity against YES1 gene-amplified cancers. Jan 21 2024
S6392 SHIN1(RZ-2994) SHIN1 (RZ-2994) is an inhibitor of SHMT1/2 (human serine hydroxymethyltransferase 1 and 2) with IC50 values of 5 and 13 nM, respectively, in in vitro assay. SHIN1 hinders cell growth by gradually reducing purine levels. Jan 21 2024
E4580 Sovleplenib Sovleplenib(HMPL-523) is a highly potent and selective SYK inhibitor with IC50 of 0.025 μM, that exhibits anti-tumor activities in vitro and in vivo. Sovleplenib exhibits synergistic activities in combination with BTK, PI3Kδ, and Bcl2 family inhibitors in killing human-diffused large B cell lymphoma (DLBCL). Jan 17 2024
E1769 Merbarone Merbarone(NSC 336628) is a catalytic inhibitor of topoisomerase II with IC50 of 120 μM, with anti-proliferative activity against human cancer cells. Merbarone acts primarily by blocking topoisomerase II-mediated DNA cleavage. Jan 17 2024
E1604 Vevorisertib trihydrochloride Vevorisertib trihydrochloride(ARQ 751 trihydrochloride) is a selective, allosteric inhibitor of pan-AKT and AKT1-E17K mutant with Kd values of 1.2 nM and 8.6 nM, respectively. It also has IC50 values of 0.55, 0.81, and 1.3 nM for AKT1, AKT2, and AKT3, respectively and can be used for the research of cancer. Jan 16 2024
A3176 Human IgG2sa isotype control Human IgG2sa isotype control is suitable for use as a non-targeting isotype control in various in vitro and in vivo studies, is the isotype control of human IgG2sa antibody. Jan 15 2024
E1667 LY2880070 LY2880070 is an orally active inhibitor of CHK1. LY2880070 can be used as an anticancer agent and shows promise in preclinical models of pancreatic ductal adenocarcinoma (PDAC) when used in combination with DNA-damaging agents. Jan 10 2024
E1812 N6F11 N6F11 is an inducer of ferroptosis. N6F11 is bound to the RING domain of the E3 ubiquitin ligase tripartite motif containing 25 (TRIM25) in cancer cells to trigger TRIM25-mediated K48-linked ubiquitination of glutathione peroxidase 4 (GPX4), resulting in proteasomal degradation. Jan 10 2024
E1739 MST-312 MST-312(Telomerase Inhibitor IX) is an inhibitor of telomerase. MST-312 is a chemically modified derivative of green tea epigallocatechin gallate (EGCG). MST-312 exhibits high chemical stability, lowers the effective dose in the induction of telomere shortening, and lowers drug resistance. MST-312 can be used for the research of cancer. MST-312 can also be used as a promising strategy in the treatment of multiple myeloma (MM). Jan 10 2024
E1658 PRT543 PRT543 is a potent and selective inhibitor of protein arginine methyltransferase 5 (PRMT5) with broad antitumor activity in vitro and in vivo. It also inhibits the methyltransferase activity of the PRMT5/MEP50 complex with an IC50 of 10.8 nM. Jan 09 2024
E1744 UNC5293 UNC5293 is a potent, highly selective, orally available inhibitor of MER receptor tyrosine kinase (MERTK) with IC50 of 0.9 nM and Ki 0.19 nM. Jan 09 2024
E1742 Reversan Reversan (CBLC4H10) is a selective and nontoxic inhibitor of multidrug resistance-associated protein 1 (MRP1) and P-glycoprotein (P-gp), with the potential to treat neuroblastoma and other MRP1-overexpressing drug-refractory tumors. Jan 09 2024
E1723 NSC16168 NSC16168 is a specific inhibitor of ERCC1-XPF, and exhibits an IC50 value of 0.42 μM in a high throughput screen (HTS) assay, respectively. NSC16168 inhibits DNA repair and potentiates cisplatin efficacy in cancer. Jan 09 2024
E1746 Protokylol hydrochloride Protokylol hydrochloride(Caytine hydrochloride, JB-251 hydrochloride) is a salt form of protokylol and is an agonist of β-adrenergic receptor. Protokylol hydrochloride is also used as a bronchodilator. Jan 07 2024
E1727 Pimicotinib Pimicotinib (ABSK021) is an orally bioavailable inhibitor of colony stimulating factor 1 receptor (CSF1R). It enhances antitumor T-cell immune responses and inhibits the proliferation of tumor cells having potential immunomodulatory and antineoplastic activities. Jan 07 2024
E1564 BI-2493 BI-2493, a structural analogue of BI-2865, is a highly selective inhibitor of pan-KRAS. BI-2493 attenuates tumor growth and can be used for cancer research. Jan 07 2024
E1620 Fluorofurimazine Fluorofurimazine is a novel furimazine analogue, with increased aqueous solubility enabling higher signal emission than furimazine for bioluminescence imaging. Fluorofurimazine enables higher substrate loading and improved optical imaging sensitivity in in-vivo. Jan 04 2024
A3175 Blinatumomab (Anti-CD3 & CD19) Blinatumomab (Anti-CD3 & CD19) is a BiTE-class (bi-specific T-cell engager) constructed monoclonal antibody with unique anti-tumor efficacy. Blinatumomab enables CD3-positive T cells to recognize and eliminate CD19-positive acute lymphoblastic leukemia (ALL) blasts. Jan 03 2024
E1435 Tinengotinib Tinengotinib (TT-00420) is a novel multiple kinase inhibitor that strongly inhibits Aurora A/B with IC50 values of 1.2/3.3 nM respectively. It also exhibits potent inhibitory activity on FGFR1/2/3, VEGFR1, JAK1/2, and CSF1R and can be used to treat several prominent signaling pathways in triple-negative breast cancer(TNBC). Jan 01 2024
E1649 Exarafenib Exarafenib(KIN-002787, KIN-2787, RAF/KIN_2787) is an orally-available, selective inhibitor of pan-RAF. Exarafenib is effective in RAF-dependent cancers, including all classes of BRAF alterations. Exarafenib suppresses MAPK signaling in RAF-dependent melanoma cell lines. KIN-2787 exhibits low nanomolar to picomolar potency against RAF1, BRAF, and ARAF with an IC50 of 0.06-3.46 nM with minimal activity towards non-RAF kinases. Dec 28 2023
E1708 Solutol HS-15 Solutol HS-15(Polyethylene glycol 12-hydroxystearate) is a Macrogol 15 hydroxy stearate, which improves permeability by disrupting the membrane structure/fluidity change. Dec 27 2023
S9463 Demecarium Bromide Demecarium Bromide, an anticholinesterase, is an inhibitor of monoamine oxidase (MAO). It induces long-term miosis and decreases intraocular pressure (IOP) in normotensive eyes of Beagles and of eyes of Beagles with inherited glaucoma. Dec 26 2023
E1538 PRGL493 PRGL493 is a potent and selective inhibitor of long-chain acyl-CoA synthetase 4 (ACSL4). PRGL493 blocks cell proliferation and tumor growth in both breast and prostate cellular and animal models. PRGL493 is used for cancer research. Dec 26 2023
E1775 2,4-Thiazolidinedione 2,4-Thiazolidinedione (Thiazolidinedione), an insulin sensitizer, is a specific agonist of peroxisome proliferator-activated receptor (PPAR)γ. Thiazolidinedione treatment corrects impaired muscle insulin action in vivo. Dec 26 2023
E1773 Fasoracetam (NS 105) Fasoracetam (NS 105) is a metabotropic glutamate receptor activator with a potential to treat vascular dementia. Dec 26 2023
E1714 B022 B022 is a potent and selective NF-κB-inducing kinase (NIK) inhibitor with a Ki of 4.2 nM. B022 protects liver from toxin-induced inflammation, oxidative stress, and injury. Dec 26 2023
E1734 OD36 OD36 is an inhibitor of RIPK2 with an IC50 value of 5.3 nM. OD36 is a macrocyclic inhibitor with potent binding to the ALK2 kinase ATP pocket. Dec 24 2023
E2983 PF-04957325 PF-04957325 is a highly potent and selective inhibitor of PDE8, with IC50 values of 0.7 nM and 0.3 nM for PDE8A and PDE8B, respectively. PF-04957325 greatly potentiates steroidogenesis in wild type adrenal cells. Dec 20 2023
E1618 TC-S 7009 TC-S 7009 is a potent and selective inhibitor of HIF-2α with a Kd value of 81 nM. TC-S 7009 is more selective for HIF-2α than HIF-1α. It disrupts HIF-2α heterodimerization, decreases DNA-binding activity, and reduces HIF-2α target gene expression. Dec 20 2023
S2520 CD437(AHPN) CD437(AHPN), a synthetic retinoid, is a selective Retinoic acid Receptor γ ( RARγ) agonist. It exhibits an antiproliferative effect and induces apoptosis via activation of AP-1 in vitro. Dec 18 2023
E1780 Alexidine dihydrochloride Alexidine dihydrochloride, a dibiguanide compound, is an effective and selective inhibitor of protein tyrosine phosphatases localized to mitochondrion 1 (PTPMT1) with an IC50 of 1.08 μM in vitro. It has the potential to treat type II diabetes. Dec 18 2023
E1605 Avotaciclib trihydrochloride Avotaciclib trihydrochloride(BEY1107 trihydrochloride) is a potent and orally active inhibitor of cyclin dependent kinase 1 (CDK1). It can be used for the research of locally advanced or metastatic pancreatic cancer. Dec 17 2023
E1678 SPOP-i-6lc SPOP-i-6lc is a selective speckle-type POZ protein (SPOP) E3 ubiquitin ligase inhibitor with IC50 of 2.1 μM and 3.5 μM, in A498 and OS-RC-2 cell lines, respectively. In vitro, It suppresses viability and proliferation of A498 and OS-RC-2 kidney cancer cell lines. Dec 17 2023
E1743 VX-561(CTP-656, Deutivacaftor) VX-561 (Ivacaftor-D9, CTP-656, Deutivacaftor), a deuterated ivacaftor analog, is a potent CFTR modulator and exhibits an EC50 value of 255 nM for CFTR potentiation in G551D/F508del HBE cells. Dec 17 2023
A3174 Mosunetuzumab (Anti-CD20 & CD3e) Mosunetuzumab (Anti-CD20 & CD3e) is expressed from CHO. The heavy chain type is IgG1, and the light chain type is hukappa. MW: 146.72 kDa. Dec 14 2023
E1028 POMHEX POMHEX, is a potent ENO2 -specific inhibitor of enolase and a racemic mixture, a cell-permeable pivaloyloxymethyl (POM) prodrug of HEX. It is also glycolysis inhibitor and can be used for the research of cancer. Dec 13 2023
E1203 Sirpiglenastat Sirpiglenastat (DRP-104) is a broad acting glutamine antagonist. It has anticancer effects by directly targeting tumor metabolism and simultaneously inducing a potent antitumor immune response with immunomodulatory and antineoplastic activities. Dec 13 2023
S8091 25-Hydroxycholesterol 25-Hydroxycholesterol is a side-chain oxysterol and a selective suppressor of IgA production by B cells with an EC50≈65 nM. It affects the immune system and has a key role in the pathogenesis of atherosclerosis. Dec 12 2023
E1409 Zidesamtinib Zidesamtinib (NVL-520) is a potent brain-penetrating inhibitor of ROS1 tyrosine kinase with IC50 of 0.7 nM for wild-type ROS1 . It acts as a potential antineoplastic agent and can be used for the research of cancer. Dec 11 2023
S8395 INDY INDY, a benzothiazole derivative is a potent and ATP-competitive inhibitor of Dyrk1A and Dyrk1B with an IC50 value of 0.24 μM and Ki value of 0.18 μM, respectively. INDY diminishes the self-renewal capacity of normal and tumorigenic cells in primary Glioblastoma (GBM) cell lines and neural progenitor cells. Dec 11 2023
E1636 MV1035 MV1035, an inhibitor of ALKBH5 significantly reduces GBM U87-MG cell migration and invasiveness through inhibition of the RNA demethylase ALKBH5. Dec 11 2023
F0011 p70 S6 Kinase Rabbit mAb Dec 11 2023
E1598 VT103 VT103 is an orally active and selective inhibitor of TEAD1 protein palmitoylation with anti-proliferative and anti-tumor activity. It also inhibits YAP/TAZ-TEAD promoted gene transcription, blocks TEAD auto-palmitoylation and disrupts interaction between YAP/TAZ and TEAD. Dec 07 2023
E1735 PK11007 PK11007 is a thiol-reactive anticancer agent that stabilizes p53 via selective alkylation of two surface cysteines without compromising its DNA binding. It induces mutant p53 cancer cell death by increasing reactive oxygen species (ROS) levels. Dec 07 2023
E1684 C1632 C1632 (Lin28-let-7 antagonist 1) is a RNA-binding protein and a potent antagonist of Lin28/pre-let-7 interaction. It inhibits Lin28A binding to pre-let-7a-2, with an IC50 of 8 μM as well as inhibits proliferation in human cancer cells. Dec 07 2023
E1512 M3541 M3541 is a potent and selective inhibitor of ATM kinase activity with an IC50 value of 0.25 nM in cell-free assays. M3541 suppresses double-strand breaks (DSB) repair, clonogenic cancer cell growth and potentiates antitumor activity of ionizing radiation in cancer cell lines. Dec 06 2023
E1638 ALKBH5 inhibitor 2 (Cpd 20m) ALKBH5 inhibitor (Cpd 20m) is a potent and selective inhibitor of RNA m6A demethylase AlkB homolog 5 ALKBH5 with IC50 of 21 nM. Dec 05 2023
A3173 Minretumomab (CC-49) Minretumomab (CC-49) is a monoclonal antibody against TAG-72 (tumor-associated glycoprotein 72). Minretumomab can be used in cancer and immunity research. Dec 04 2023
A2136 Anti-mouse CD40-InVivo Anti-mouse CD40-InVivo reacts with mouse CD40 also known as Bp50. CD40 is a type I transmembrane glycoprotein that belongs to the tumor necrosis factor receptor (TNFR) superfamily. Dec 04 2023
A2137 Anti-mouse CD8β (Lyt 3.2)-InVivo Anti-mouse CD8β (Lyt 3.2)-InVivo reacts with mouse CD8β also known as Lyt 3.2. The CD8 antigen is a transmembrane glycoprotein that acts as a co-receptor for the T cell receptor (TCR). Dec 04 2023
A2138 Anti-mouse IL-2-InVivo Anti-mouse IL-2-InVivo reacts with mouse IL-2, a cytokine that is mainly produced by T cells in response to antigenic or mitogenic stimulation Dec 04 2023
A2140 Anti-mouse/human/rat CD47 (IAP)-InVivo Anti-mouse/human/rat CD47 (IAP)-InVivo reacts with mouse CD47 otherwise known as integrin-associated protein (IAP). CD47 is an approximately 50 kDa glycosylated five transmembrane protein that is ubiquitously expressed by both hematopoietic cells such as T and B lymphocytes, monocytes, platelets and erythrocytes and non-hematopoietic cells. Dec 04 2023
E1603 ACT001(DMAMCL) ACT001(DMAMCL, dimethylaminomicheliolide) is a PAI-1 inhibitor and exerts antitumor effects on neuroblastoma (NB) both in vitro and in vivo. It also exerts synergistic effects in combination with cisplatin through the inhibition of the PAI-1/PI3K/AKT pathway. Nov 29 2023
E1497 Tulmimetostat Tulmimetostat (CPI-0209) is an orally bioavailable and selective inhibitor of EZH2 that has therapeutic potential for androgen receptor-dependent prostate cancer. Nov 26 2023
E4037 L-Canavanine sulfate L-Canavanine sulfate is a selective inhibitor of inducible NO synthase. L-Canavanine sulfate exhibits IC50 values ranging from 5 to 10 mM in arginine-rich media and causes a limited degree of cytotoxicity in HeLa, Hep G2, and SK-HEP-1 cells. Nov 26 2023
E1731 JW74 JW74 is a specific inhibitor of the canonical Wnt signaling with IC50 790 nM in the ST-Luc assay. It inhibit the growth of tumor cells in both mouse xenograft model of colorectal cancer and in ApcMin mice. Nov 26 2023
E4031 8-Cyclopentyl-1,3-dimethylxanthine 8-Cyclopentyl-1,3-dimethylxanthine is a selective adenosine A1 receptor antagonist with Ki's of 10.9 nM and 1440 nM for A1 receptor and A2 receptor, respectively. Nov 26 2023
E1733 PBIT PBIT is a specific inhibitor of the Jumonji AT-rich Interactive Domain 1 (JARID1) enzymes. It inhibits JARID1B (KDM5B/PLU1), JARID1Aand JARID1C with an IC50 of 3 μM, 6 μM and 4.9 μM respectively. It is capable of inhibiting the multiplication of breast cancer cell lines expressing high levels of JARIDB1. Nov 26 2023
E1574 FSEN1 FSEN1 is a potent and non-competitive FSP1 inhibitor with an IC50 value of 313 nM. It triggers iron death in cancer cells by inhibiting FSP1 and can be used in research of cancer. Nov 26 2023
E1579 UCL-TRO-1938 UCL-TRO-1938 is a potent allosteric activator of PI3Kα with an EC50 value of approximately 60 μM. UCL-TRO-1938 can induce cell proliferation and has cardioprotective and neural regeneration effects. Nov 22 2023
E4466 Saquinavir Mesylate Saquinavir mesylate (Ro 31-8959/003) is a potent inhibitor of HIV Protease used in antiretroviral therapy. It blocks proteolysis of polyproteins containing either wild-type or single-chain dimer retroviral proteinase (PR). Nov 22 2023
S9460 Ethotoin Ethotoin (Peganone) is a hydantoin derivative and an orally active anticonvulsant agent. It also exerts an antiepileptic effect and can be used in epilepsy research. Nov 21 2023
S8545 TEN-010 (RG6146,Ro-6870810,(S)-JQ-35) TEN-010 (RG6146, Ro-6870810,(S)-JQ-35) is an inhibitor of the Bromodomain and Extra-Terminal(BET) family bromodomain-containing proteins with potential antineoplastic activity. Nov 21 2023
E4454 DL-Thiorphan Thiorphan (DL-3-Mercapto-2-benzylpropanoylglycine) is a selective NEP (neprilysin) inhibitor with an IC50 of 6.9 nM. It is also a potent inhibitor of enkephalinase, with antinociceptive activity. Nov 19 2023
E1490 IAG933 IAG933 (YAP-TEAD-IN-3) is a small molecule and acts as a YAP/TAZ-TEAD inhibitor. It also inhibits NCI-H2052 and can be used in research of tumor invasion and metastatic spread of solid tumors. Nov 19 2023
E1651 CD532 CD532 is a potent  Aurora A kinase inhibitor with an IC50 of 45 nM. It breaks the native conformation of Aurora-A, drives the degradation of N-Myc in N-Myc-driven cancers, and also exhibits anti-proliferative effects. Nov 19 2023
E1732 Itacnosertib (TP-0184) Itacnosertib (TP-0184) is a small-molecule inhibitor of the BMP type 1 receptor ALK2 (also known as ACVR1). Itacnosertib reduces hepcidin induction and elevated serum iron levels in turpentine and lung cancer mouse models of ACD. Nov 19 2023
E2986 ONO-AE3-208 ONO-AE3-208(AE 3-208) is a selective and orally active EP4 receptor antagonist with a Ki of 1.3 nM, less potent to EP3, FP, and TP receptors with Ki of 30 nM, 790 nM, and 2400 nM, respectively. Nov 19 2023
S8617 Acriflavine Acriflavine is a HIF-1 dimerization inhibitor and have potent inhibitory effects on tumor growth and vascularization. It is used as fluorescent dye for labeling high molecular weight RNA. Nov 14 2023
E1709 Fialuridine Fialuridine(FIAU, DRG-0098, NSC 678514) is a nucleoside analog with antiviral activity. It blocks DNAsynthesis in human cytomegalovirus and hepatitis B, as well as herpes simplex. Nov 10 2023
E1716 SR9011 SR9011 is a REV-ERBα/β agonist with IC50s of 790 nM and 560 nM for REV-ERBα and REV-ERBβ, respectively. It is specifically lethal to cancer cells and oncogene-induced senescent cells, including melanocytic naevi. Nov 10 2023
E1507 Zilurgisertib fumarate Zilurgisertib fumarate(INCB-000928 fumarate, NBU-928 fumarate) is a selective ALK 2 inhibitor.It is under development for the treatment of heterotopic ossification and fibrodysplasia ossificans progressiva. Nov 08 2023
E1712 FM19G11 FM19G11 is a hypoxia-inducible factor-1-alpha (HIF-1α) inhibitor, and it inhibits hypoxia-induced luciferase activity with an IC50 of 80 nM in HeLa cells. Nov 08 2023
E4447 Coenzyme Q1 Coenzyme Q1 (CoQ1) is localized to the hydrophobic domain of the phospholipid bilayer of mitochondria, plasma lipoproteins, and other biological membranes. CoQ1 reduction has a strong rotenone-insensitive component and can be used to measure the mitochondrial respiratory chain complex 1 activity. Nov 08 2023
E1529 ART812 ART812 is an orally active DNA polymerase Polθ inhibitor with an IC50 value of 7.6 nM. Nov 06 2023
E1509 Bezuclastinib Bezuclastinib(CGT9486; PLX 9486) is a potent inhibitor of c-kit and c-kit D816V with an IC50 value of <1 μM. Bezuclastinib is also an inhibitor of tyrosine kinase. Nov 05 2023
E1573 ARV-766 ARV-766 (Luxdegalutamide) is an orally active and potent degrader of proteolysis targeting chimera (PROTAC) protein. ARV-766 degrades wild-type androgen receptor (AR) but also relevant AR LBD mutants, including the most prevalent AR L702H, H875Y, and T878A mutations. Nov 05 2023
E1661 Adaptaquin Adaptaquin is an inhibitor of hypoxia-inducible factor prolyl hydroxylase 2 (HIF-PHD2), with an IC50 of 2 μM. Adaptaquin also inhibits lipid peroxidation and maintains mitochondrial function. Nov 05 2023
E4448 EGTA tetrasodium EGTA tetrasodium(Ethylene glycol-bis(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid tetrasodium salt) is a calcium chelator, used for the determination of calcium in the presence of magnesium. EGTA tetrasodium significantly inhibits the substrate adherence capacity of inflammatory macrophages. Nov 01 2023
E1478 BDTX-1535 BDTX-1535 (EGFR-IN-76) is an orally available, highly potent, selective, and irreversible EGFR inhibitor that can penetrate the blood-brain barrier, with the potential to treat Glioblastoma or Non-Small Cell Lung Cancer. Nov 01 2023
E1599 VT107 VT107 is an enantiomer analogous to VT10 and is a potent inhibitor of pan-TEAD auto-palmitoylation with IC50 of 4.93 nM that blocks TEAD-mediated gene transcription by preventing its association with YAP/TAZ. Oct 31 2023
E1537 MMRi62 MMRi62 is a ferroptosis inducer, targeting MDM2-MDM4 with Kd value of 1.39 μM. It exhibits a P53-independent pro-apoptotic activity against pancreatic ductal adenocarcinoma (PDAC) cells and induce autophagy. Oct 31 2023
E1689 NADPH tetrasodium salt NADPH tetrasodium salt is a ubiquitous coenzyme that acts as an electron donor in many reactions utilizing dehydrogenase and reductase enzymes. It plays a crucial role as a cofactor in the biosynthesis of nucleotides, proteins, and fatty acids. It is essential for neutralizing elevated levels of reactive oxygen species (ROS) generated by increased metabolic activity. Oct 31 2023
S9459 Mecamylamine Hydrochloride Mecamylamine hydrochloride is an orally active, nonselective, noncompetitive nAChR(nicotinic acetylcholine receptors) antagonist.It is also a ganglionic blocker and can across the blood-brain barrier. It can be used in the research of neuropsychiatric disorders, hypertension, antidepressant area. Oct 30 2023
E4477 Lumateperone Lumateperone (ITI-007) is an antagonist of 5-HT2A receptor with Ki of 0.54 nM. It has anticancer activity and can also be used in studies of psychiatric disorders such as schizophrenia. Oct 29 2023
E4587 Sodium alginate Sodium alginate is a sodium salt of alginic acid, can be extracted and purified from the cell walls brown seaweed Laminaria japonica. It has chelating activity and can be used to adsorb heavy metal ions, also has mucosal-protective and hemostatic effects and used in food additives and pharmaceuticals. Oct 29 2023
E1280 Ubrogepant Ubrogepant (MK-1602) is an antagonist of human calcitonin gene-related peptide receptor (CGRP). It potently blocks human α–CGRP–stimulated cAMP responses with an IC50 of 0.081 nM in human CGRP receptor-expressing HEK293 cells. Oct 27 2023
E1495 PF-07220060 (CDK4/6-IN-6) PF-07220060 (CDK4/6-IN-6) is a potent CDK4/CDK6 inhibitor with a Ki of 0.6 nM and 13.9 nM for CDK4/Cyclin D1 and CDK6/Cyclin D3, respectively. Oct 27 2023
S8418 Zeocin (Phleomycin D1, zeomycin) Zeocin (Phleomycin D1, Zeomycin, PLM D1), a glycopeptide antibiotic, is a member of the Bleomycin/Phleomycin family. It causes cell death by binding and cleaving DNA. It shows antiproliferative activities and strong cytotoxicity against HT-29 cells. Oct 27 2023
E4026 Poly(2-hydroxyethyl methacrylate) Poly(2-hydroxyethyl methacrylate) is one of the most important hydrogels in the world of biomaterials. It is the basic component of contact lenses and is also used in the implantation of soft tissues, synthetic transplant for gristle and bone, regeneration of neurotic tissue, transmission of agents, etc. Oct 27 2023
E2981 PI4KIIIbeta-IN-10 PI4KIIIbeta-IN-10 is a potent inhibitor of PI4KIIIβ with an IC50 of 3.6 nM. It also exhibits weak inhibition of PI3KC2γ, PI3Kα, and PI4KIIIα, and <20% inhibition at concentrations up to 20 µM for PI4K2α, PI4K2β, and PI3Kβ. Oct 27 2023
E1517 ZEN-3694 ZEN-3694 is an orally bioavailable bromodomain extraterminal inhibitor (BETi) that leads to down-regulation of expression of AR-signaling in metastatic castrationresistant prostate cancer (mCRPC) models. Oct 24 2023
E4474 Infigratinib Phosphate Infigratinib Phosphate (NVP-BGJ398 phosphate) is the phosphate salt form of infigratinib, an orally bioavailable pan-inhibitor of human fibroblast growth factor receptors (FGFRs) with IC50 of 0.9 nM, 1.4 nM, 1 nM, and 60 nM for FGFR1, FGFR2, FGFR3, and FGFR4 respectively. It also has potential antiangiogenic, antineoplastic and antitumor activities. Oct 24 2023
E1691 Muvalaplin(LY3473329) Muvalaplin(LY3473329) is an orally administered small molecule that inhibits lipoprotein (a) (Lp (a)) formation by blocking the apo(a)-apo B100 interaction. It can be used in research of atherosclerotic disease and aortic stenosis. Oct 23 2023
E4468 Cabotegravir Sodium Cabotegravir (GSK-1265744) sodium is a orally active and long-acting HIV integrase strand transfer inhibitor. It also inhibits organic anion transporter 1/3 (OAT1/OAT3) with IC50 of 0.41 μM and 0.81 μM for OAT3 and OAT1, respectively. Oct 19 2023
E4505 Deoxyribonucleic acid, single stranded from salmon testes Deoxyribonucleic acid, single-stranded from salmon testes, is a ready-to-use solution of a high-quality, sonicated, single-stranded template nonspecific DNA blocking agent that reduces background in nucleic acid hybridization. Oct 19 2023
E4472 Clavulanic acid Clavulanic acid is a naturally occurring, powerful bacterial β-lactamase inhibitor. The beta-lactam ring found in clavulanic acid binds to the active site of beta-lactamase, resulting in enzyme inactivation and enhancing the antibacterial activity of beta-lactam antibiotics like amoxicillin. Oct 19 2023
E1692 BAY 2965501 BAY 2965501 is a potent selective inhibitor of diacylglycerol kinases zeta (DGKζ), restores T-cell cellular DAG level, and induces pERK activation in anergic T-cells via DGK inhibition to assist T-cell mediate tumor cell kill. Oct 19 2023
A2126 Anti-mouse VEGFR-2-InVivo Anti-mouse VEGFR-2-InVivo (Clone: DC101) monoclonal antibody reacts with mouse VEGFR-2 (vascular endothelial growth factor receptor 2) also known as CD309, KDR, and Flk-1 and inhibit VEGFR-2 signaling in vivo. VEGFR-2 plays a key role in vascular development and permeability. Oct 17 2023
A2127 Anti-human CD28-InVivo Anti-human CD28-InVivo (Clone: 9.3) monoclonal antibody reacts with human CD28, a 45 kDa costimulatory receptor and a member of the Ig superfamily. It stimulate the proliferation of human T cells in vitro. Oct 17 2023
A2129 Anti-mouse Thy1.2 (CD90.2)-InVivo Anti-mouse Thy1.2 (CD90.2)-InVivo(clone 30H12) is a monoclonal antibody reacts with mouse Thy1.2 also known as CD90.2. It induces Ca2+ flux in thymocytes and is particularly useful for depleting T lymphocytes. Oct 17 2023
A2130 Anti-mouse LFA-1α (CD11a)-InVivo Anti-mouse LFA-1α (CD11a)-InVivo(clone M17/4) is a monoclonal antibody reacts with mouse LFA-1α (lymphocyte function-associated antigen 1 alpha) also known as integrin alpha L chain and CD11a. It plays a central role in leukocyte intercellular adhesion through interactions with its ligands, ICAM-1 (CD54), ICAM-2 (CD102), and ICAM-3 (CD50), and also functions in lymphocyte costimulatory signaling. Oct 17 2023
A2131 Anti-mouse TIM-3 (CD366)-InVivo Anti-mouse TIM-3 (CD366)-InVivo monoclonal antibody reacts with mouse TIM-3 (T cell immunoglobulin and mucin domain-3) also known as CD366. TIM-3 is specifically expressed at high levels on the surface of Th1 lymphocytes. This B8.2C12 antibody binds to the BALB/c allele of TIM-3 while reactivity to the C57Bl/6 allele. Inhibition of TIM-3 signaling in mice exacerbates experimental autoimmune encephalomyelitis and promotes IFNγ production and Th1 cell proliferation. Oct 17 2023
A2132 Anti-mouse/human/rat CCL2 (MCP-1)-InVivo Anti-mouse/human/rat CCL2 (MCP-1)-InVivo (Clone: 2H5) antibody reacts with mouse, human, and rat CCL2, also known as monocyte chemoattractant protein 1 (MCP-1). MCP-1 is a 13 kDa chemokine produced mainly by monocytes/macrophages and is a potent monocyte-attracting chemokine. The 2H5 antibody has been shown to neutralize the biological effects of CCL2 in vivo. Oct 17 2023
A2133 Anti-mouse LAG-3-InVivo Anti-mouse LAG-3-InVivo (Clone: C9B7W) monoclonal antibody reacts with mouse LAG-3 also known as CD223. LAG-3 promotes immune responses by activating antigen-presenting cells. The C9B7W antibody has been reported to block the function of murine LAG-3 in vivo and in vitro. Oct 17 2023
A2134 Anti-mouse IL-18-InVivo Anti-mouse IL-18-InVivo (Clone:YIGIF74-1G7) monoclonal antibody reacts with mouse IL-18. IL-18 an 18 kDa pro-inflammatory cytokine is expressed by activated macrophages, keratinocytes, Kupffer cells, intestinal epithelial cells, and osteoblasts. Oct 17 2023
A2135 Anti-mouse Ly6G/Ly6C (Gr-1)-InVivo Anti-mouse Ly6G/Ly6C (Gr-1)-InVivo reacts strongly with mouse Ly6G and weakly with mouse Ly6C previously referred to as GR-1. Ly6G is a 21-25 kDa member of the Ly-6 superfamily of GPI-anchored cell surface proteins with roles in cell signaling and cell adhesion. Oct 17 2023
E4465 Potassium clavulanate cellulose Potassium clavulanate cellulose (Potassium clavulanate:cellulose (1:1)) is a mixture of potassium clavulanate and cellulose, is a bacterial β-lactamase inhibitor. Potassium clavulanate with the combination of amoxicillin can be used for the research of different infections caused by bacteria, such as sinusitis, pneumonia, ear infections, bronchitis, urinary tract infections, and infections of the skin. Oct 17 2023
E1469 ITF3756 ITF3756 is a selective histone deacetylase 6 (HDAC6) inhibitor bearing a pentaheterocyclic scaffold. It can be used in research of autoimmune disorders, neurodegenerative diseases, and cancer. Oct 17 2023
E1575 EN450 EN450 is a cysteine-reactive covalent molecular glue degrader targeting NF-κB. It interacts with allosteric C111 in the E2 ubiquitin ligase UBE2D that induces the ternary complex formation between UBE2D and NFKB1. It exhibits anti-proliferative effects through a Cullin E3 ligase and proteasome-dependent mechanism. Oct 17 2023
E4467 Temozolomide Acid Temozolomide acid is a carboxylic acid derivative of Temozolomide. It has an anticancer activity by causing breaks in DNA double strand, cell cycle arrest, and eventually cell death. Oct 16 2023
E4473 Lactate Lactate (Lactic acid) is the product of glycolysis, produced due to lack of oxygen in contracting skeletal muscle in vivo, and can be utilised under fully aerobic conditions. It plays a key role as a metabolic intermediate and can be used as hemodynamic marker and resuscitation endpoint in several cohorts of critically ill patients. Oct 16 2023
E4478 Acetrizoic acid Acetrizoic acid is a first monomeric, water-soluble, iodinated ionic compound used as an X-ray contrast agent having nephrotropic property that can be intravenously administered for clinical applications. Oct 16 2023
E4016 Phenylarsine oxide Phenylarsine oxide (Oxophenylarsine) is a membrane-permeable protein tyrosine phosphatase inhibitor with IC50 18 µM. It Stimulates 2-deoxyglucose transport in insulin-resistant human skeletal muscle. Oct 13 2023
E1318 Mavorixafor Mavorixafor (AMD-070) is a potent, selective CXCR4 antagonist, with an IC50 value of 13 nM against CXCR4 125I-SDF binding. Oct 13 2023
E4464 Hexythiazox Hexythiazox is a selective acaricide with ovicidal, larvicidal and nymphicidal activities. It is widely used for chemical control of mites on cotton, fruits and vegetables. Oct 13 2023
A2817 Anti-CD34 Anti-CD34 is a humanized monoclonal antibody against CD34 surface antigen on human stem cells. MW: 145.9 KD. Oct 11 2023
A3081 Anti-CAPRIN1 Anti-CAPRIN1 is a humanized antibody targeting CAPRIN-1. It is used as a novel and universal target for cancer therapies. MW :141.44 KD. Oct 11 2023
E1486 Zamaporvint (RXC004) Zamaporvint (RXC004) is an orally active and selective inhibitor of Wnt. It targets membrane-bound o-acyltransferase Porcupine and inhibits Wnt ligand palmitoylation, secretion, and pathway activation. RXC004 exhibits potent antiproliferative effects in Wnt ligand-dependent colorectal and pancreatic cell lines and possesses multiple antitumor mechanisms. Oct 11 2023
A2831 Anti-CD59 Anti-CD59 is a humanized monoclonal antibody against CD59 with the potential to treat anti-tumour activity. MW: 145.08 KD. Oct 11 2023
E4432 3,3-Dimethyl-1-butanol 3,3-Dimethyl-1-butanol (Neohexanol) is an orally active inhibitor of trimethylamine (TMA) and trimethylamine N-oxide (TMAO). 3,3-dimethyl-1-butanol negatively inhibits the signalling pathways of p65 NF-κB and  TGF-β1/Smad3. 3,3-dimethyl-1-butanol has potential applications in cardiovascular disease (CVD). Oct 11 2023
E1526 Zasocitinib Zasocitinib( NDI-034858, TAK-279) is a TYK2 inhibitor, which is currently being investigated in a phase IIb trial for moderate-to-severe plaque psoriasis. Oct 11 2023
E4443 S-Nitrosoglutathione S-nitrosoglutathione (GSNO, RVC-588, S-Nitroso-L-glutathione,Nitrosoglutathione) is an amino acid and nitric oxide donor that, under physiological conditions, spontaneously releases nitric oxide. S-nitrosoglutathione (GSNO) selectively inhibits platelet and NF-κB activation. It induces apoptosis in T cells in low concentrations (< 0.6 mM) while protecting T cells from apoptosis in higher concentrations (1-2 mM). Oct 11 2023
A3090 Anti-DCSTAMP Anti-DCSTAMP is an antibody targeting Dendritic cell-specific transmembrane protein, DC-STAMP. It is essential for cell-to-cell fusion to form multinucleated osteoclasts (OCs) during osteoclastogenesis. MW :146.2 KD. Oct 11 2023
A3091 Anti-GAD65 Anti-GAD65 is an autoantibody targeting glutamic acid decarboxylase (GAD65). It is used in treatment of Stiff person syndrome (SPS). MW :146.38 KD. Oct 11 2023
A3092 Anti-MICB Anti-MICB is an antibody that specifically target human major histocompatibility complex class I chain-related A and B (MICA/B). It can be used in treating a cancer. MW :143.66 KD. Oct 11 2023
A2837 Anti-CD83 Anti-CD83 is a humanized monoclonal antibody against CD83 with the potential to treat auto-immune diseases. MW: 144.8 KD. Oct 11 2023
A2838 Anti-CD9 Anti-CD9 is a humanized monoclonal antibody against CD9 with potential anti-tumor activity. MW: 145.98 KD. Oct 11 2023
A2839 Anti-CDH1 / E-cadherin / CD324 Anti-CDH1 / E-cadherin / CD324 is an IgG1 monoclonal antibody against E-cadherin, an epithelial adhesion molecule. MW: 146.6 KD. Oct 11 2023
E4218 L-Cysteine (hydrochloride hydrate) L-Cysteine hydrochloride hydrate is an essential amino acid, which acts as a precursor for biologically active molecules such as hydrogen sulphide (H2S), glutathione, and taurine. L-Cysteine hydrochloride hydrate suppresses ghrelin and reduces appetite in rodents and humans. Oct 11 2023
A2844 Anti-Clathrin Heavy Chain / CHC Anti-Clathrin Heavy Chain / CHC is a human monoclonal antibody against clathrin heavy chain (CHC) with potential anti-angiogenesis and anti-tumor activity. MW: 145.62 KD. Oct 11 2023
E1479 I-138 I-138 is an orally active, potent reversible inhibitor of USP1-UAF1 with IC50 0f 4.1 nM. I-138 is structurally related to ML323 and induces the monoubiquitination of FANCD2 and PCNA in MDA-MB-436 cells and increases PCNA and FANCD2 monoubiquitination in HAP-1 USP1 WT cells. Oct 11 2023
A3103 Anti-TrkB / NTRK2 Anti-TrkB / NTRK2 is an antibody targeting TrkB. It is used to improve nerve function, including treatment of peripheral neuropathies. MW :146.68 KD. Oct 11 2023
E1650 Opevesostat (ODM208) Opevesostat (ODM208) is the first-in-class, selective, nonsteroidal, oral CYP11A1 inhibitor. ODM208 exhibits a rapid, complete, durable, and reversible inhibition of the steroid hormone biosynthesis in an adrenocortical carcinoma cell model in vitro, in adult noncastrated male mice and dogs, and in patients with CRPC. Oct 11 2023
E4469 Sodium Montmorillonite Sodium Montmorillonite is a layered clay mineral (2:1 phyllosilicate) that belongs to a class of the smectite group. It can be used for preparation of new drug delivery systems, especially for slow release of protonable drugs due to its high degree of surface area and high capacity for cation exchange. Oct 11 2023
E4470 Potassium Chloride Potassium chloride is an inorganic salt commonly used in fertilizer industry. It is also extensively used as a potassium supplement. Oct 11 2023
A3106 Volociximab (Anti-Integrin a5b1 (ITGA5 & ITGB1)) Volociximab (Anti-Integrin a5b1 (ITGA5 & ITGB1)) is a monoclonal antibody targeting Integrin a5b1 (ITGA5 & ITGB1). It can be used in treatment of solid tumors, renal cell carcinoma, melanoma, pancreatic cancer, lung cancer, and ovarian cancer. MW :145.52 KD. Oct 11 2023
E4471 Nonaethylene glycol Monododecyl ether Nonaethylene glycol monododecyl ether is a non-ionic surfactant. It has been used to assess a procedure for analyzing total lipid and triacylglycerol using bovine liver tissue. Oct 11 2023
A3107 Anti-VCAM1 / CD106 Anti-VCAM1 / CD106 is a conjugated liposome targeting vascular cell adhesion molecule (VCAM)-1. It serves as a drug delivery system with dual functions: targeted delivery and solubilizing capacity. MW :143.4 KD. Oct 11 2023
A2596 Tilvestamab (Anti-AXL / UFO) Tilvestamab (Anti-AXL / UFO) is a humanized antibody targeting AXL.Tilvestamab can be used in cancer research, particularly in AXL overexpressing renal cell carcinomas. MW :146.16 KD. Oct 11 2023
A2601 Amivantamab (Anti-HGFR / c-Met) Amivantamab (Anti-HGFR / c-Met) is a human bispecific antibody targeting EGFR-MET.It has immune anticancer activity in non-small cell lung cancer (NSCLC). MW :146.1 KD. Oct 11 2023
A2857 Anti-Sphingosine-1-phosphate Anti-Sphingosine-1-phosphate is a human IgG1 monoclonal anti-Sphingosine-1-phosphate antibody that targets lysosphingolipids, thereby lowering the concentration of S1P in the extracellular fluid. MW: 145.74 KD. Oct 11 2023
A3116 Anti-GLP1R Anti-GLP1R is a humanized antibody targeting GLP-1 receptor (GLP-1R). It can be used in therapy for type 2 diabetes mellitus. MW : 144.5 KD. Oct 11 2023
A3123 Setoxaximab (Anti-Shiga toxin (E.coli)) Setoxaximab (Anti-Shiga toxin (E.coli)) is a mouse chimeric IgG1(kappa) antiboy that target shiga toxin 1 and shiga toxin 2, produced by E. coli. It can be used in the treatment of hemolytic-uremic syndrome (HUS). MW :147.08 KD. Oct 11 2023
A2615 Anti-PMEL Anti-PMEL is a monoclonal antibody targeting human PMEL protein. It is used as a target for antibody drug conjugate (ADC) therapy in melanoma. MW :145.38 KD. Oct 11 2023
A2873 Anti-ICAM3 / CD50 Anti-ICAM3 / CD50 is an IgG1 monoclonal antibody against intercellular adhesion molecules-3 (ICAM-3, also known as CD50)) with the potential to have anti-proliferative activities. MW: 145.22 KD. Oct 11 2023
A2874 Anti-MUC17 Anti-MUC17 is an IgG1 monoclonal antibody against MUC17, a membrane-bound protein highly expressed on the surface of intestinal cells. MW: 146.66 KD. Oct 11 2023
A2875 Anti-TEM7R / PLXDC2 Anti-TEM7R / PLXDC2 is a humanized IgG1 monoclonal antibody against PLXDC1 (tumor endothelial marker 7 or TEM7), a cell-surface receptor for PEDF, with anti-tumor activity. MW: 143.94 KD. Oct 11 2023
A2627 Anti-Complement C5aR1 (G2_anti-C5aR) Anti-Complement C5aR1 (G2_anti-C5aR) is a rat monoclonal antibody that detects Complement 5a receptor (C5aR). It exhibit potent proinflammatory stimulus with immunomodulatory activities. MW :146.08 KD. Oct 11 2023
A2633 Anti-OX2R / CD200R1 Anti-OX2R / CD200R1 is a monoclonal antibody targeting CD200. It exhibited potential in regulating tissue inflammation during skin wound healing. MW :146.58 KD. Oct 11 2023
E4265 Pyrimidine Pyrimidine is an endogenous metabolite. It is used to study the photoinduced ion chemistry of the halogenated pyrimidines, a class of prototype radiosensitizing molecules, and is also used to assess pyrimidine/purine asymmetry quantitatively. Oct 11 2023
D4060 Anti-FOLR1 (mirvetuximab-MMAE) Anti-FOLR1 (mirvetuximab-MMAE) is an ADC targeting FOLR1 (folate receptor 1). It can be used in ovarian and other FRα-positive cancer research. MW :145.96 KD. Oct 11 2023
D4061 Anti-GPC3 / Glypican-3 (Codrituzumab-MMAE) Anti-GPC3 / Glypican-3 (Codrituzumab-MMAE) is an ADC targeting GPC3 (glypican-3). It induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth and can be used in the research of hepatocellular carcinoma (HCC). MW :145.58 KD. Oct 11 2023
A2640 Anti-CHI3L1 Anti-CHI3L1 is a monoclonal antibody targeting Chitinase 3–like 1 (CHI3L1). It proves a promising therapy for pulmonary metastasis and progression. MW :147.04 KD. Oct 11 2023
D4062 Anti-KAAG1 (ADCT-901-MMAE) Anti-KAAG1 (ADCT-901-MMAE) is an ADC composed of a humanized monoclonal antibody (3A4) targeting human KAAG1. It is used for the treatment of advanced solid tumors including platinum resistant ovarian cancer and triple negative breast cancer. MW :145.28 KD. Oct 11 2023
A2642 Zolbetuximab (Anti-CLDN18.2) Zolbetuximab (Anti-CLDN18.2) is a monoclonal antibody targeting Claudin-18.2. It can be used for the research of gastrointestinal adenocarcinomas and pancreatic tumors. MW :150 KD. Oct 11 2023
A3154 Anti-CDH17 / Cadherin-17 (10C12) Anti-CDH17 / Cadherin-17 (10C12) is a humanized monoclonal antibody targeting Cadherin-17 (CDH17), a prominent cancer biomarker. It has growth inhibitory effect on liver and stomach tumour cells. It can be used as therapeutics for treating lung metastasis of hepatocellular carcinoma (HCC). MW :143.68 KD. Oct 11 2023
A2643 Anti-CLDN6 (IMAB027) Anti-CLDN6 (IMAB027) is a fully humanized antibody targeting CLDN6. It gets conjugated to monomethyl auristatin E( MMAE) resulting in the potential therapeutic CLDN6–23-ADC. It exhibits antitumor efficacy in ovarian epithelial carcinomas.MW :144.42 KD. Oct 11 2023
A2899 Margetuximab (Anti-ERBB2 / HER2 / CD340) Margetuximab (Anti-ERBB2 / HER2 / CD340) is a Fc-domain optimized IgG monoclonal antibody directed against the human epidermal growth factor receptor 2 (HER2) with potential immunomodulating and antineoplastic activities. MW: 146.1 KD. Oct 11 2023
A3155 Anti-CDH17 / Cadherin-17 (PTA001_A4) Anti-CDH17 / Cadherin-17 (PTA001_A4) is a humanized monoclonal antibody targeting Cadherin-17 (CDH17), a prominent cancer biomarker. It has growth inhibitory effect on tumour cells. It can be used as therapeutics for treating various cancers, including colorectal cancer. MW :149.12 KD. Oct 11 2023
A2645 Anti-CXADR Anti-CXADR is a monoclonal antibody (MAb) targeting CXADR/CAR. It exhibits anti-cancer activity. MW :150 KD. Oct 11 2023
A2646 Anti-CXCL9 Anti-CXCL9 is an antibody targeting CXCL9 chemokine. It has the potemtial of inhibiting inflammation. MW :150 KD. Oct 11 2023
A2648 Anti-DC-SIGN / CD209 Anti-DC-SIGN / CD209 is a humanized monoclonal antibody that specifically targets DC-SIGN. It inhibits infection caused by human cytomegalovirus (CMV) in immunocompromised patients, namely in organ-transplanted recipients or AIDS patients. ME :146.62 KD. Oct 11 2023
A3161 Gemtuzumab (Anti-Siglec-3 / CD33) Gemtuzumab (Anti-Siglec-3 / CD33) a monoclonal antibody targeting CD33 antigen, which present on leukemic myeloblasts of acute myeloid leukemia (AML). It can be used for the research of acute myeloid leukemia.MW :145.22 KD. Oct 11 2023
A2650 Anti-TNFRSF21 / DR6 / CD358 Anti-TNFRSF21 / DR6 / CD358 is a humanized monoclonal antibody that specifically targets TNFRSF21. It can be used in treatment of cancer. MW :150 KD. Oct 11 2023
A2909 Anti-FGFR1 / CD331 Anti-FGFR1 / CD331 is a monoclonal antibody againts human fibroblast growth factor receptor 1. MW: 150 KD. Oct 11 2023
A2910 Anti-TSPAN8 Anti-TSPAN8 is a monoclonal IgG1 antibody (mAb) directed against Co-029, a membrane protein of the family of tetraspanins (TSPAN8 or TM4SF3). MW: 145.94 KD. Oct 11 2023
A2656 Anti-CSF3R / G-CSFR Anti-CSF3R / G-CSFR is an antibody that targets G-CSF. I t can be used in the research of inflammatory diseases. MW :150 KD. Oct 11 2023
A2914 Ivuxolimab (Anti-TNFRSF4 / OX40 / CD134) Ivuxolimab (Anti-TNFRSF4 / OX40 / CD134) is an agonistic antibody that recognizes the co-stimulatory receptor OX40 (CD134; TNFRSF4) with potential immunostimulatory activity. MW: 144.18 KD. Oct 11 2023
A3170 Tidutamab (Anti-CD3 & SSTR2) Tidutamab (Anti-CD3 & SSTR2) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). It can be used in neuroendocrine tumors (NETs) and small cell lung cancer (SCLC). MW :147.36 KD. Oct 11 2023
A2659 Anti-Haptoglobin Anti-Haptoglobin is an antibody targeting the human haptoglobin (HP). It can be used for immunoblotting after isoelectric focusing to determine Hp alpha subtypes. MW :150 KD. Oct 11 2023
A2915 Anti-ERG Anti-ERG is a monoclonal IgG1 antibody (mAb) directed against the proto-oncogene ETS-related gene (ERG). It has the potential to treat prostate cancer, Ewing's sarcoma, acute myeloid leukemia, endothelial cancer, and colon cancer. MW: 145.4. Oct 11 2023
A2661 Ficlatuzumab (Anti-HGF / SF) Ficlatuzumab (Anti-HGF / SF) is a monoclonal antibody (McAb) targeting human hepatocyte growth factor (HGF). It inhibits c-Met receptor-mediated cancer cell proliferation, migration, and invasion and can be used to treat head and neck squamous cell carcinoma (HNSCC). MW :150 KD. Oct 11 2023
A2662 Emibetuzumab (Anti-HGFR / c-Met) Emibetuzumab (Anti-HGFR / c-Met) is a humanized bivalent MET antibody targeting both HGF-dependent and HGF-independent MET pathway activation and tumor growth. It can be used in study of cancer. MW :144.56 KD. Oct 11 2023
E4294 (-)-CAMPHOR (-)-CAMPHOR is obtained from the wood of the camphor tree and is used as a remedy for treating a variety of symptoms such as inflammation, ingestion, infection, congestion, pain, and irritation. Few components of the camphor tree have suppressive and anti­mutagenic effects on a number of human cancer cells without harming the healthy cells. Oct 11 2023
A2663 Anti-IDO2 Anti-IDO2 is a monoclonal antibody targeting Indoleamine 2,3-dioxygenase 2 (IDO2). It exhibits potency that ameliorates arthritis and autoimmune disease. MW :151.06 KD. Oct 11 2023
A2665 Anrukinzumab (Anti-IL-13) Anrukinzumab (Anti-IL-13) is a humanized monoclonal antibody targeting IL-13. It reduces lung inflammation and can be used in studies of ulcerative colitis (UC) as well as asthma. MW :150 KD. Oct 11 2023
E4298 (-)-Carvone (-)-Carvone is an insect neurotoxin and is an irreversible inhibitor of acetylcholinesterase (AChE). It can be used as a bird repellent, inhibits larval growth, decreases pupation rate, and increases the mortality of larvae. Oct 11 2023
A2666 Anti-IL-13Ra2 / CD213a2 Anti-IL-13Ra2 / CD213a2 is a humanized monoclonal antibody targeting IL-13Ra2. It exhibits potentcy against malignant gliomas (MG), head and neck tumors, ovarian cancer and kidney cancer. MW :150 KD. Oct 11 2023
E4299 Chitosan Chitosan(Deacetylated chitin (MW 150000); Poly(D-glucosamine) (MW 150000)) is a polycationic linear polysaccharide derived from chitin with the molecular weight of 150000. Chitosan is an versatile biomaterial because of its non-toxicity, low allergenicity, biocompatibility and biodegradability. Chitosan also has antitumor, antibacterial, antifungal, and antioxidant activities. Oct 11 2023
A2923 Lodapolimab (Anti-B7-H1 / PD-L1 / CD274) Lodapolimab (Anti-B7-H1 / PD-L1 / CD274) is a fully human IgG1λ monoclonal antibody that binds to human PD-L1 with high affinity and inhibits interactions of PD-L1 with its two cognate receptors, PD-1 and CD80. MW: 143.86 KD. Oct 11 2023
A2668 Etokimab (Anti-IL-33) Etokimab (Anti-IL-33) is a humanized monoclonal antibody that targets IL-33. It can be used for the research of atopic dermatitis. MW :146.56 KD. Oct 11 2023
A2925 Anti-GPR64 / ADGRG2 Anti-GPR64 / ADGRG2 is a monoclonal antibody (mAb) against G protein-coupled receptor 64 isoform 4 (anti-GPR64) with potential anti-tumour activity. MW: 146.1. Oct 11 2023
A2672 Anti-MAGEA3 Anti-MAGEA3 is an antibody that targets MAGE-A. It can be used in the treatment of metastatic cancer treatment. MW :145.56 KD. Oct 11 2023
A2929 Anti-KID3 Anti-KID3 is a monoclonal antibody (MAb) directed against KID3, a carbohydrate epitope found in the colon and several forms of cancer. MW: 147.04 KD. Oct 11 2023
A2681 Brontictuzumab (Anti-NOTCH1) Brontictuzumab (Anti-NOTCH1) is a monoclonal antibody that targets Notch1 signal. It inhibits tumor cell proliferation and can be used in the research of leukemia and lymphoma. MW :150 KD. Oct 11 2023
A2684 Anti-PDGFC / VEGFE Anti-PDGFC / VEGFE is a monoclonal antibody targeting PDGF-CC. It can be used in the research of cancer, fibrosis and neuropathologies. MW :145.9 KD. Oct 11 2023
A2689 Anti-RSPO1 Anti-RSPO1 is a monoclonal antibodies against R-spondin1 gene (RSPO1) with potential anti-tumor activity . MW: 150 KD. Oct 11 2023
A2691 Anti-SIRPa / CD172a Anti-SIRPa / CD172a is an immunoglobulin G1 (IgG1) monoclonal antibody targeting human signal-regulatory protein alpha (SIRPa; CD172a), with potential immune checkpoint inhibitory, phagocytosis-inducing and antineoplastic activities. MW : 147.06 kD. Oct 11 2023
A2948 Nipocalimab (Anti-FcRn) (FCGRT & B2M) Nipocalimab (anti-FcRn) (FCGRT & B2M) is a fully human monoclonal antibody that targets the neonatal crystallizable fragment receptor (FcRn) with potential immunomodulating activity. MW: 142.12 KD. Oct 11 2023
A2695 Anti-TGFb1 (M7824) Anti-TGFb1 (M7824) is a bifunctional monoclonal antibody targeting programmed death ligand 1 (PD-L1) and transforming growth factor beta 1 (TGFb1). It exhibits anti-tumor efficacy against breast and colon carcinomas. Oct 11 2023
E4074 p-Toluic acid p-Toluic acid (4-Methylbenzoic acid) is a methylbenzoic acid and can be used as an intermediate for the synthesis of para-aminomethylbenzoic acid (PAMBA), p-tolunitrile, etc. It also exhibits hepatotoxicological potential in humanised-liver mice. Oct 11 2023
A2700 Anti-CD48 Anti-CD48 is a monoclonal anti-CD48 antibody with the potential to treat treatment of allergic conditions and inflammatory conditions. MW: 144.22 KD. Oct 11 2023
A2705 Anti-vWF Anti-vWF is a monoclonal anti-VWF antibody with the potential to treat thrombotic thrombocytopenic purpura. MW: 145.62 KD. Oct 11 2023
A2961 Anti-F8 / Factor VIII Anti-F8 / Factor VIII is a monoclonal IgG anti-factor VIII antibody that hydrolyzes FVIII in acquired hemophilia. MW: 145.14 KD. Oct 11 2023
A2706 Anti-CXCR3 / GPR9 / CD183 Anti-CXCR3 / GPR9 / CD183 is a monoclonal antibody binds to Chemokine (C-X-C motif) receptor 3 (CXCR3, also known as G protein-coupled receptor 9 (GPR9)) . It has the potentially to be used in the treatment of diabetes mellitus type I (T1D). MW: 146.38 KD. Oct 11 2023
A2708 Anti-TPSAB1 Anti-TPSAB1 is a humanized monoclonal antibody against human β-tryptase with the potential to treat mast cell-mediated severe asthma. MW: 150 KD. Oct 11 2023
A2709 Anti-GPR44 / PTGDR2 / CD294 Anti-GPR44 / PTGDR2 / CD294 is a monoclonal antibody against a transmembrane G-protein-coupled receptor (GPR44, also known as CRTH2, PTGDR2,or CD294) with the potential to treat asthma. MW: 147.66 KD. Oct 11 2023
A2710 Anti-GOLM1 Anti-GOLM1 is a monoclonal antibody against Golgi protein-73 (GP73, Golgi Membrane Protein 1, GOLM1) with the potential to be used in research on hepatocellular carcinoma (HCC). MW: 145.62 KD. Oct 11 2023
A2711 Anti-GREM1 / Gremlin Anti-GREM1 / Gremlin is a monoclonal antibody that binds to human gremlin-1 (GREM1) with potential anti-tumor activity. MW: 144.58 KD. Oct 11 2023
E4087 Sodium oleate Sodium oleate (Oleic acid sodium salt) is an abundant monounsaturated fatty acid sodium. It is a Na+/K+ ATPase activator and inhibits cancer cell growth and survival in low metastatic carcinoma cells, such as gastric carcinoma SGC7901 and breast carcinoma MCF-7 cell lines. Oct 11 2023
A2713 Anti-Nogo Receptor / NgR Anti-Nogo Receptor / NgR is a monoclonal anti-NgR antibody with the potential to promote axonal regeneration. MW: 146.18 KD. Oct 11 2023
A2714 Anti-Complement Factor P / Properdin Anti-Complement Factor P / Properdin is a monoclonal anti-Properdin antibody with the potential to treat chronic complement-mediated and complement-associated disorders. MW: 145.54 KD. Oct 11 2023
E4345 L-Norvaline L-Norvaline is a non-proteinogenic amino acid, an isomer of valine, and an inhibitor of arginase and p70 ribosomal S6 kinase 1 (p70S6K1) kinase. L-norvaline enhances NO production from activated macrophages. Oct 11 2023
A2715 Anti-TAT226 Anti-TAT226 is a monoclonal antibody that binds to TAT226 with potential anti-tumor activity. MW: 144.66 KD. Oct 11 2023
A2716 Anti-TMPRSS2 Anti-TMPRSS2 is a monoclonal antibody with possible antiviral activity that detects transmembrane serine protease 2 (TMPRSS2). MW: 146.06 KD. Oct 11 2023
A2717 Anti-HGFA Anti-HGFA is a monoclonal anti-HGFA antibody that detects endogenous levels of HGFA protein in biological samples. MW: 141.18 KD. Oct 11 2023
E4092 Ricinoleic acid Ricinoleic acid is a hydroxy fatty acid. It is an attractive feedstock for the production of high-performance lubricants, cosmetics, polymers, surfactants, and coatings. Oct 11 2023
A2718 Anti-KLK5 / Kallikrein 5 Anti-KLK5 / Kallikrein 5 is a monoclonal antibody kallikrein-related peptidase 5 (KLK5) with the potential to be used in research on immune-based therapies. MW: 144.76 KD. Oct 11 2023
A2719 Anti-Orai1 Anti-Orai1 is a human monoclonal anti-Orai1 antibody (mAb) with the potential to treat autoimmune diseases. MW: 143.86 KD. Oct 11 2023
A2720 Anti-SERPINE1 Anti-SERPINE1 is a monoclonal antibody that specifically binds to Plasminogen Activator Inhibitor Type-1 (PAI-1, SERPINE1) with the potential to be used in cardiovascular diseases. MW: 145.72 KD. Oct 11 2023
A2721 Anti-CXCL4 / PF4 Anti-CXCL4 / PF4 is a monoclonal antibody against anti-CXC chemokine ligand 4 (CXCL4, also called PF4). MW: 144.86 KD. Oct 11 2023
A2722 Anti-Albumin Anti-Albumin is a human monoclonal antibody that is specific for human serum albumin (HSA) and has the potential to be used in research on type 1 diabetes. MW: 144.24 KD. Oct 11 2023
E4353 Ampicillin Ampicillin (D-(-)-alpha-Aminobenzylpenicillin) is a broad-spectrum beta-lactam antibiotic against a variety of gram-positive and gram-negative bacteria. It exhibits a good minimum inhibitory concentration for Staphylococcus aureus, Escherichia coli, Hemophilus influenzae, and Streptococcus pneumoniae with MICs of 0.6–1 mg/L, 4 mg/L, 0.25 mg/L, and 0.03-0.06 mg/L, respectively. Oct 11 2023
A2723 Anti-STOP1 Anti-STOP1 is a human monoclonal antibody against stable tubule-only polypeptides (STOP), a protein responsible for microtubule cold stabilization. MW: 145.78 KD. Oct 11 2023
A2724 Anti-TMEFF2 Anti-TMEFF2 is a human monoclonal anti-TMEFF2 antibody with potential anti-tumor activity. MW: 144.08 KD. Oct 11 2023
A2725 Anti-TIE2 / CD202b Anti-TIE2 / CD202b is a fully human monoclonal antibody that binds to human Tie2 and blocks the interaction between Tie2 or Tie2 ligands (angiopoietin). It has the potential to treat angiogenesis disorders. MW: 146.6 KD. Oct 11 2023
E4356 Pseudotropine Pseudotropine(3β-Tropanol, ψ-Tropine) is an alkaloid and a plant metabolite of the tropane tropinone that has been found in A. belladonna. It is used in the preparation of novel nicotinic receptor agonists. Oct 11 2023
A2726 Anti-ANO1 / TMEM16A Anti-ANO1 / TMEM16A is a humanized monoclonal antibody that binds to human TMEM16A and modulates its activity, with potential anti-tumor activity. MW: 146.8 KD. Oct 11 2023
A2982 Anti-IL-6Ra / CD126 (APX007) Anti-IL-6Ra / CD126 (APX007) is a monoclonal antibody targeting IL-6R/CD126. It can be used in the pathogenesis of multiple myeloma. MW :144.6 KD. Oct 11 2023
A2727 Anti-Polyubiquitin Anti-Polyubiquitin is a monoclonal anti-Polyubiquitin antibody used for isolating polyubiquitin chain-tagged proteins. MW: 144.98 KD. Oct 11 2023
A2728 Anti-SCN9a / Nav1.7 Anti-SCN9a / Nav1.7 is a fully human antibody that binds to human Nav1.7 (hNav1.7, SCN9a) with the potential to treat acute or chronic pain conditions or inflammatory conditions. MW: 145.72 KD. Oct 11 2023
E4105 Quinizarin Quinizarin (1,4-Dihydroxyanthraquinone) is a part of the anticancer agents such as Doxorubicin, Daunorubicin, and Adriamycin, interacts with DNA by intercalating mode. It is used as a fungicide and pesticide chemical and has shown the ability to inhibit tumor cell growth. Oct 11 2023
A2730 Anti-Histone H3 Anti-Histone H3 is a monoclonal anti-Histone H3 antibody antibody used for detection of Histone H3 (histone 3-H3). MW: 150 KD. Oct 11 2023
A2732 Anti-ANGPTL8 Anti-ANGPTL8 is a monoclonal antibody againts Angiopoietin-like protein (ANGPTL8) with potential to treat hypertriglyceridemia. MW: 145.16 KD. Oct 11 2023
E4363 L-Cystine (dihydrochloride) L-Cystine dihydrochloride is used as a cell culture media component for the commercial biomanufacture of therapeutic recombinant proteins and monoclonal antibodies and as a sulfur-containing precursor of glutathione (GSH) synthesis. L-Cystine dihydrochloride homeostasis is also important for GSH functions. Oct 11 2023
A2733 Anti-CXC-ELR Anti-CXC-ELR is a monoclonal antibody that binds to an ELR+ CXC chemokine and inhibits its biological activity. MW: 146.56 KD. Oct 11 2023
A2991 Etaracizumab (Anti-Integrin aVb3 (ITGAV & ITGB3)) Etaracizumab (Anti-Integrin aVb3 (ITGAV & ITGB3)) is an IgG1 monoclonal antibody targeting αvβ3 integrin. It inhibits angiogenesis and melanoma tumor growth and can be used to research anticancer. MW :144.18 KD. Oct 11 2023
E4112 Menthol Menthol is a natural analgesic compound that causes a feeling of coolness due to stimulation of ‘cold’ receptors by inhibiting Ca++ currents of neuronal membranes. Oct 11 2023
A2737 Anti-Matriptase Anti-Matriptase is a monoclonal matriptase-specific antibody. MW: 144.28 KD. Oct 11 2023
E4114 Arabinose Arabinose((±)​-​Arabinose; DL-​Arabinose; dl-​Arabinose) is an endogenous metabolite. It is a natural sugar molecule that exhibits sweetness profiles similar to sucrose, making it a valuable alternative in low-calorie foods and excipients or cocrystallization agents in pharmaceutical formulations. Oct 11 2023
A2739 Anti-158P1D7 Anti-158P1D7 is a monoclonal anti-158P1D7 antibody used in the production of antibody drug conjugates (adc) that bind to 158P1D7 proteins. MW: 146.0 KD. Oct 11 2023
A2740 Anti-Dysadherin Anti-Dysadherin is a monoclonal antibody against dysadherin with anti-metastasis activity. MW: 147.56 KD. Oct 11 2023
A2741 Anti-TMEFF1 / Tomoregulin-1 Anti-TMEFF1 / Tomoregulin-1 is a monoclonal antibody against TMEFF1 (a transmembrane protein with EGF-like and two Follistatin-like domains, Tomoregulin 1), a type I transmembrane glycoprotein. MW: 146.08 KD. Oct 11 2023
E4372 Phosphatidylserine Phosphatidylserine (Distearoylphosphatidylserine) is a negatively charged glycerophospholipid found mainly in the plasma membrane (PM) and in the late secretory/endocytic compartments, where it regulates cellular activity and can mediate apoptosis It also inhibits inflammatory responses.This product has poor solubility, animal experiments are available, cell experiments please choose carefully! Oct 11 2023
A2742 Anti-c-RET Anti-c-RET is a monoclonal antibody against the receptor tyrosine kinase Ret (c-Ret) expressed in cells of neuroblastoma and substantia nigra, a responsive locus of Parkinson's disease. MW: 146.74 KD. Oct 11 2023
E4118 (-)-Menthone (-)-Menthone is a monoterpene component of the essential oil of maturing peppermint. (+)-Neomenthyl-β-d-glucoside is a metabolite of (-)-Menthone. Mortality of two biological forms of Anopheles stephensi (larvae) exposed to about 45 ppm (-)-Menthone is 27.67% and 94.92%. Oct 11 2023
A3000 Orilanolimab (Anti-FcRn (FCGRT & B2M)) Orilanolimab (Anti-FcRn (FCGRT & B2M)) is a humanized monoclonal antibody targeting FcRn. It disrupts the interaction of FcRn and IgG for the treatment autoimmune diseases. MW :144.28 KD. Oct 11 2023
A2745 Anti-Integrin a11 / ITAG11 Anti-Integrin a11 / ITAG11 is a monoclonal antibody against Integrin alpha 11 (ITGA11), a transmembrane glycoprotein expressed in adult cardiac and uterine smooth muscle and developing myocytes. MW: 145.7 KD. Oct 11 2023
A3001 Anti-AXL / UFO (ORY012) Anti-AXL / UFO (ORY012) is a polyclonal antibody that targets receptor tyrosine kinase AXL (UFO). It can be used in research of glioblastoma multiforme (GBM) and pancreatic cancers. MW :146.28 KD. Oct 11 2023
A3002 Anti-Mesothelin (BMS-986148) Anti-Mesothelin (BMS-986148) is a fully human IgG1 monoclonal antibody targeting mesothelin. It is used to synthesize antibody-drug conjugate (ADC). It has potential multimodal therapeutic strategies in patients with advanced solid tumors. MW :150 KD. Oct 11 2023
A2749 Anti-DSG3 Anti-DSG3 is an anti-desmoglein 3 (Dsg3) monoclonal antibody that depletes desmosomes of Dsg3 and has the potential to be used in research on Pemphigus vulgaris (PV). MW: 146.54 KD. Oct 11 2023
A3006 Anti-INHBB / Activin B Anti-INHBB / Activin B is a monoclonal antibody targeting the betaB subunit of Activin B. It has potent uses in treatment of fatigue syndrome/myalgic encephalomyelitis (CFS/ME). MW:146.02 KD. Oct 11 2023
A2752 Anti-MUSK Anti-MUSK is a monoclonal IgG antibody against muscle-specific kinase (MuSK) with the potential to treat Myasthenia gravis. MW: 145.24 KD. Oct 11 2023
A2756 Anti-SCN11a / Nav1.9 Anti-SCN11a / Nav1.9 is a monoclonal anti-Nav1.9 (SCN11A) antibody used in antigen-specific immunodetection in biological samples. MW: 143.94 KD. Oct 11 2023
A2757 Anti-TLR7 Anti-TLR7 is a monoclonal antibody against Toll-like receptor 7 (TLR7) with the potential to treat autoimmune disease. MW: 145.04 KD. Oct 11 2023
A2761 Abrilumab (Anti-Integrin a4b7 ITGA4 & ITGB7) Abrilumab (Anti-Integrin a4b7 ITGA4 & ITGB7) is a fully human monoclonal immunoglobulin G2 antibody that targets the alpha4beta7 integrin and prevents interaction with MADCAM-1. It has the potential to be used in research on inflammatory bowel disease (IBD). MW: 143.8 kD. Oct 11 2023
A3017 Anti-PCLA Anti-PCLA is a fully human IgG4 monoclonal antibody targeting prostate cancer lipid-like antigen (PCLA) It can be used in treatment of prostate cancer. MW :145.52 KD. Oct 11 2023
A3019 Anti-MRC2 / CD280 Anti-MRC2 / CD280 is a monoclonal antibody targeting ENDO180. It can be used as therapeutic strategy of sarcoma subtypes, primary tumor and in metastatic disease. MW :142.92 KD. Oct 11 2023
E4141 Octadecanedioic acid Octadecanedioic acid(1,18-Octadecanedioic acid), an endogenous metabolite, is a long-chain dicarboxylic acid. Octadecanedioic acid when mono-conjugated via an ester linkage to paclitaxel exhibits higher maximum tolerated doses and increased efficacy in vivo in multiple subcutaneous murine xenograft models of human cancer. Oct 11 2023
A3024 Anti-PCSK9 (RG7652) Anti-PCSK9 (RG7652) is a fully human immunoglobulin G1 (IgG1) monoclonal antibody targeting proprotein convertase subtilisin/kexin type 9 (PCSK9). It exhibits potential efficacy in coronary heart disease (CHD). MW :144.84 KD. Oct 11 2023
A3026 Anti-ASIC1 Anti-ASIC1 is a mouse monoclonal antibody targeting acid-sensing ion channel-1 (ASIC1). It exhibits potential application in pain,neurodegenerative diseases, and psychiatric diseases. MW :144.04 KD. Oct 11 2023
E4147 Indole-3-carboxaldehyde Indole-3-carboxaldehyde (3-Formylindole), a banlangen extract, is the product of the oxidative degradation of indole-3-acetic acid (IAA) by crude enzyme preparations from etiolated pea seedlings. It is identified as an active principle component in Marinomonas sp., and it efficiently inhibits biofilm formation by Vibrio cholerae O1 (VCO1) without selection pressure. Oct 11 2023
A2773 Anti-MSPR / RON / CD136 Anti-MSPR / RON / CD136 is a monoclonal antibody that blocks RON binding to its ligand, macrophage-stimulating protein (MSP), and can be used in cancer research. MW: 139.86 KD. Oct 11 2023
A2776 Batoclimab (Anti-FcRn (FCGRT & B2M)) Batoclimab (anti-FcRn (FCGRT & B2M)) is a human monoclonal antibody directed against the neonatal crystallizable fragment receptor (FcRn) with potential immunomodulating activity. It has the potential to be used in research on autoimmune diseases mediated by pathogenic IgG antibodies. MW: 143.76 kD. Oct 11 2023
E4407 Thiobarbituric acid Thiobarbituric acid (2-Thiobarbituric acid) is a colorimetric reagent commonly used in the detection of malondialdehyde (MDA), a marker of lipid peroxidation. Oct 11 2023
A2782 Sudubrilimab (Anti-B7-H1 / PD-L1 / CD274) Sudubrilimab (Anti-B7-H1 / PD-L1 / CD274) is an immunoglobulin G1-kappa, anti-(homo sapiens CD274 (programmed death ligand 1, PDL1, pd-l1, B7 homolog 1, B7H1)), monoclonal antibody. MW: 144.6 kD. Oct 11 2023
E4416 Stearamide Stearamide is a a primary fatty acid amide that displays cytotoxic and ichthytoxic activity. Stearamide is also used as a lubricating agent in the polymer industry. Oct 11 2023
E4420 NADP sodium salt NADP sodium salt, a nicotinamide adenine dinucleotide, is a coenzyme that plays a vital role in various metabolic reactions within living cells. NADP sodium salt is a key cofactor for electron transfer in the metabolism, being alternately oxidized (NADP+) and reduced (NADPH). Oct 11 2023
A3046 Anti-CYR61 / CCN1 Anti-CYR61 / CCN1 is a monoclonal antibody targeting cysteine-rich protein 61(CCN1/Cyr61) . It can be used in breast cancer treatment. MW :144.42 KD. Oct 11 2023
A2792 Anti-ABCB5 Anti-ABCB5 is a monoclonal antibody (mAb) against ABCB5 (ATP-binding cassette transporter, sub-family B (MDR/TAP), member 5) with the potential to be used in research on melanoma. MW: 147.74 KD. Oct 11 2023
A2793 Anti-CD151 Anti-CD151 is an anti-CD151 monoclonal antibody (mAb) with potential anti-metastatic and anti-tumor activity activity. MW: 146.76 KD. Oct 11 2023
A3049 Anti-RAMP3 Anti-RAMP3 is a polyclonal antibody targeting RAMP2. It is useful in the treatment of cancer. MW :147.04 KD. Oct 11 2023
A2794 Anti-EMMPRIN / CD147 Anti-EMMPRIN / CD147 is a monoclonal antibody against extracellular matrix metalloproteinase inducer (EMMPRIN; CD147) with potential anti-proliferative activity. MW: 1145.42 KD. Oct 11 2023
A2797 Anti-IL-25 Anti-IL-25 is a humanised monoclonal antibody against Interleukin-25 (IL-25) with the potential to treat airway hyperresponsiveness (AHR). MW: 146.02 KD. Oct 11 2023
A3053 Anti-BST2 / CD317 Anti-BST2 / CD317 monoclonal antibody that targets Bone marrow stromal antigen 2. It can be used in cancer research. MW :145.52. KD. Oct 11 2023
E4175 (±)-Naringenin (±)-Naringenin is a naturally occurring flavonoid. (±)-Naringenin displays a vasorelaxant effect on endothelium-denuded vessels via activating BKCa channels in myocytes. Oct 11 2023
D4058 IMGN779 IMGN779 is an antibody-drug conjugate (ADC) targeting CD33. It exhibits promising therapeutic approaches in acute myeloid leukemia (AML). MW :146.48 KD. Oct 11 2023
A3065 Tadocizumab (Anti-Integrin a2b3 (ITGA2 & ITGB3)) Tadocizumab (Anti-Integrin a2b3 (ITGA2 & ITGB3)) is a humanized monoclonal antibody tageting integrin αIIbβ3. It has antiplatelet and antithrombotic effects, and can be used for cardiovascular disease research. MW :145.3 KD. Oct 11 2023
D4001 Trastuzumab deruxtecan (DS-8201a, T-DXd) Trastuzumab deruxtecan (DS-8201a, T-DXd) is an antibody-drug conjugate (ADC) composed of an anti-HER2 (human epidermal growth factor receptor 2) antibody and a cytotoxic topoisomerase I inhibitor. Trastuzumab deruxtecan shows durable antitumor activity. Trastuzumab deruxtecan has a molecular weight of 153KDa. This product is supplied as 10mg/ml PBS solution. Oct 09 2023
D4002 Sacituzumab govitecan Sacituzumab govitecan (IMMU-132) is an antibody-drug conjugate (ADC) targeting Trop-2 for delivery of SN-38, showing anticancer activity. Sacituzumab govitecan has a molecular weight of 160KDa. This product is supplied as 10mg/ml PBS solution. Oct 09 2023
D4003 Trastuzumab Emtansine(T-DM1) Trastuzumab Emtansine(T-DM1,Ado-Trastuzumab emtansine) is an antibody-drug conjugate (ADC) that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity of the microtubule-inhibitory agent DM1.Trastuzumab emtansine has a molecular weight of 145kDa.This product is supplied as 10mg/ml PBS solution. Oct 09 2023
E4312 CSRM617 hydrochloride CSRM617 hydrochloride is a selective small-molecule inhibitor of the transcription factor ONECUT2 (OC2, a master regulator of androgen receptor) with a Kd of 7.43 uM in SPR assays, binding to OC2-HOX domain directly. It induces apoptosis by appearance of cleaved Caspase-3 and PARP and is well tolerated in the prostate cancer mouse model. Oct 08 2023
E1657 Gamcemetinib (CC-99677) Gamcemetinib (CC-99677,BMS-986371) is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (MK2) (MAPKAPK2 (MK2)) pathway in both biochemical (IC50=156.3 nM) and cell based assays (EC50=89 nM). Oct 08 2023
E1656 AS601245 AS601245 is an orally active, selective, ATP-competitive JNK (c-Jun NH2-terminal protein kinase) inhibitor with IC50 of 150, 220, and 70 nM for three JNK human isoforms hJNK1, hJNK2, and hJNK3, respectively. Oct 08 2023
E4445 3-Benzoylpropionic acid 3-Benzoylpropionic acid is a carboxylate compound which can be used as a fungicide and an oligonucleotide synthesis reagent. Sep 27 2023
E4451 Pyronin Y Pyronin Y is a fluorescent probe which stains double stranded RNA in living or fixed cells as well as in tissues. Sep 25 2023
E4444 Soy Phospholipids Soy Phospholipids is a mixture of phospholipids. Sep 25 2023
E1474 BI-2865 BI-2865 is a none-covalent pan-KRAS Inhibitor. It binds to WT, G12C, G12D, G12V and G13D mutant KRAS with KDs of 6.9, 4.5, 32, 26, 4.3 nM respectively and inhibits the proliferation of G12C, G12D or G12V mutant KRAS expressing BaF3 ce Sep 24 2023
E4446 S-(5'-Adenosyl)-L-methionine p-toluenesulfonate salt S-(5′-Adenosyl)-L-methionine p-toluenesulfonate salt (AdoMet) is a methyl donor and cofactor for enzyme-catalyzed methylations including catechol O-methyltransferase (COMT) and DNA methyltransferases (DNMT). It has an anti-apoptotic activity and can be used for the treatment of depression, liver cirrhosis, cholestasis and degenerative joint disease. Sep 24 2023
E4452 Trypsin Trypsin(Cocoonase) is a serine protease enzyme, and hydrolyzes proteins at the carboxyl side of the Lysine or Arginine. It activates PAR2 and PAR4 and induces cell-to-cell membrane fusion in PDCoV infection by the interaction of S glycoprotein of PDCoV and pAPN. It also promotes cell proliferation and differentiation and can be used in the research of wound healing and neurogenic inflammation. Sep 24 2023
E4450 N6-Cyclopentyladenosine N6-Cyclopentyladenosine is an adenosine derivative and a potent adenosine receptor agonist with Ki values of 2.3 nM, 790 nM and 43 nM for human A1, A2A and A3 receptors, respectively. It acts as an anticonvulsant and might exhibit protective actions against aminophylline (AMPH)-induced seizures. Sep 24 2023
E1445 Palovarotene Palovarotene (R 667; Ro 3300074) is a nuclear retinoic acid receptor γ (RAR-γ) agonist. It reduces heterotopic ossification (HO) in cultures and in murine and rat fibrodysplasia ossificans progressiva (FOP) models. Sep 24 2023
E1483 IK-930 IK-930 is a selective, small-molecule inhibitor of TEAD that prevents palmitate binding and thereby disrupts aberrant TEAD-dependent transcription. IK-930 demonstrates antitumor activity in mouse xenograft models with Hippo pathway genetic alterations. Sep 24 2023
E1480 DJ4 DJ4 (EX-A7863) is a potent, selective ATP-competitive inhibitor of ROCK1/2 and MRCKα/β with IC50 of 5/50 nM and 10/100 nM respectively. It blocks stress fiber formation and inhibits migration and invasion of multiple cancer cell line Sep 21 2023
E1477 EP4-IN-1 EP4-IN-1 is a potent prostanoid EP4 receptor inhibitor. It exhibits prospects in tumor immunity and anti-inflammatory analgesia research. Sep 21 2023
E1549 AZD0095 AZD0095 is a selective and orally active Monocarboxylate transporter 4 (MCT4) inhibitor with IC50 of 1.3 nM and effectively inhibits the tumor growth in NCI-H358 xenografts in combination with Cediranib. Sep 21 2023
E2985 Capadenoson Capadenoson (BAY 68-4986) is an orally bioavailable, non-nucleoside partial adenosine A1 receptor agonist that exhibits an anti-ischemic effect. Sep 21 2023
E1433 LY3537982 (KRAS G12C inhibitor 19) LY3537982 (KRAS G12C inhibitor 19) is a highly selective and potent inhibitor of the  KRAS-G12C protein. LY3537982 selectively inhibits the growth of KRAS G12C mutant cells H23 G12C, H358 G12C, and H2122 G12C with IC50s of 1.04 nM, 1.16 nM, and 11.38 nM, respectively. Sep 21 2023
E1578 garsorasib (D-1553 ) Garsorasib (D-1553 ) is a potent and selective oral KRASG12C inhibitor with antitumor activity. It has the potential to treat KRAS G12C-mutated non-small cell lung cancer (NSCLC). Sep 21 2023
E1606 RMC-6291 RMC-6291 is an orally active and covalent inhibitor of KRASG12C(ON). RMC-6291 forms a tri-complex within tumor cells between KRASG12C(ON) and cyclophilin A (CypA). Sep 21 2023
E1535 icFSP1 icFSP1 is a potent, selective human ferroptosis suppressor protein-1 (hFSP1) inhibitor, promotes ferroptosis and indirectly inhibits FSP1 by inducing condensate formation. Sep 21 2023
E1596 AOH1996 AOH1996 is an orally active small-molecule PCNA inhibitor with potential anti-tumor activity. It enhances the interaction between PCNA and RPB1, the largest subunit of RNA polymerase II. Sep 21 2023
E1413 DEG-77 DEG-77 is a cereblon-dependent degrader of IKZF2 and casein kinase 1α (CK1α). It blocks cell growth and delays leukemia progression in murine and human acute myeloid leukemia (AML) mouse models. Sep 17 2023
E1412 DEG-35 DEG-35 is a cereblon-dependent degrader of IKZF2 and casein kinase 1α (CK1α). It blocks cell growth and delays leukemia progression in murine and human acute myeloid leukemia (AML) mouse models. Sep 17 2023
E4034 Fluorescent Brightener 28 Fluorescent Brightener 28 (Tinopal UNPA-GX) is a viability stain used for identification of structure chitin and fungi. It is also used as a fluorescent brightening agent for cellulose and polyamide fabrics, paper and in detergents and soaps. Sep 17 2023
E1602 Lotiglipron Lotiglipron (PF-07081532) is an orally active GLP-1R agonist. It reduces glucose and body weight, and has the potential to be used in Type 2 diabetes mellitus (T2DM) research. Sep 17 2023
E4029 Tyramine hydrochloride Tyramine Hydrochloride is a hydrochloride salt of the naturally occurring monoamine derived from the amino acid tyrosine. Tyramine acts as a catecholamine-releasing agent but cannot cross the blood-brain barrier. Sep 14 2023
E4024 Poly-D-lysine hydrobromide Poly-D-lysine hydrobromide is a synthetic polymeric substrate most widely used in neural cell culture. It removes proteinase K-resistant PrP from prion-infected SN56 neuroblastoma cells without affecting PrPC. Sep 14 2023
E4042 5,5-Dimethyl-1-pyrroline N-oxide 5,5-Dimethyl-1-pyrroline N-oxide (DMPO) is a cell-permeable hydrophilic spin trap agent for superoxide detection. It acts as a neuroprotective agent and incubating lymphocytes with DMPO decreases DNA damage by NiCl2. Sep 14 2023
E4035 Ficoll(R) 400 Ficoll(R) 400 (sucrose-epichlorohydrin copolymer) is a macromolecular crowder that plays a pivotal role in promoting liquid-liquid phase separation (LLPS) of proteins. It is currently utilized in the isolation of serum and peripheral blood mononuclear cells (PBMC) from the whole blood of Parkinson's disease (PD) patients. Sep 14 2023
E4038 Cyclic AMP sodium Cyclic AMP Sodium (Cyclic adenosine monophosphate sodium, Adenosine cyclic 3', 5'-monophosphate sodium) is an adenosine triphosphate derivative and an intracellular signaling molecule responsible for directing cellular responses to extracellular signals. It plays a crucial role as a second messenger in numerous biological processes. Sep 14 2023
S9969 RMC-4630 RMC-4630 (SSE15206) is an inhibitor of microtubule polymerization with a GI50 of 197 nM in HCT116 cells. It can overcome multidrug resistance and cause aberrant mitosis, resulting in G2/M arrest due to incomplete spindle formation in cancer cells. Sep 14 2023
E4039 (S)-(-)-Bay K8644 (S)-(-)-Bay K8644, a conventional racemic mixture of Bay K 8644, is a voltage-sensitive L-type calcium channel agonist. It also activates Ba2+ currents (Iba) with EC50 of 32 nM. Sep 14 2023
E4022 Sodium propionate Sodium propionate (sodium propanoate), a short chain fatty acid, is a white crystalline salt derived from propionic acid with anti-inflammatory properties. Sodium propionate is used as a supplement in transgalactic-oligosaccharides (TOS) medium for the isolation of bifidobacteria and as a supplement in the SCFA (short-chain fatty acid) diet prepared for mice. Sep 13 2023
E4021 3-(Trimethoxysilyl)propyl methacrylate 3-(Trimethoxysilyl)propyl methacrylate (TMPSM) is a reactive monomer and silane coupling agent. It is widely used in thepreparation and fabrication of organic/inorganic hybrid nanomaterials. Sep 13 2023
E4030 N-p-Tosyl-L-phenylalanine chloromethyl ketone N-p-Tosyl-L-phenylalanine chloromethyl ketone (Tosyl phenylalanyl chloromethyl ketone, TPCK) is an irreversible inhibitor of chymotrypsin-like proteases that affect cell proliferation, apoptosis, and tumorigenesis. Sep 11 2023
E4032 5'-Deoxy-5'-(methylthio)adenosine 5'-Deoxy-5'-(methylthio)adenosine (Methylthioadenosine, MTA) is a naturally occurring sulfur-containing nucleoside produced by the decarboxylation of S-adenosylmethionine. This nucleoside is a potent agonist of adenosine receptors with Ki of 0.15, 1.13, 13.9, and 0.68 μM for A1, A2A, A2B, and A3, respectively. Sep 11 2023
E4033 4-Nitrophenyl beta-D-glucopyranoside 4-Nitrophenyl beta-D-glucopyranoside is a chromogenic β-D-glucosidase substrate, producing a yellow solution upon cleavage. It is degraded by hydrolysis of enzyme β-glucosidase and quantified by colorimetric detection at 405 nm as a measure of β-glucosidase activity. Sep 11 2023
E4025 Nitrotetrazolium Blue chloride Nitrotetrazolium Blue chloride (Nitro blue tetrazolium chloride, NBT) is a chromogenic substrate used for detecting oxygen metabolites in cells, staining histological tissue sections, and labeling probe-target interactions. Nitrotetrazolium blue chloride is paired with 5-bromo-4-chloro-3-inolyl phosphate (PCIB) to detect alkaline phosphatase activity. Sep 11 2023
P1169 Protamine sulfate Protamine sulfate is a polycationic, highly positively charged protein derived from salmon sperm protein, used to neutralize unfractionated heparin administration (UFH)-induced anticoagulation following cardiovascular surgical procedures. Sep 11 2023
E1425 Nesuparib Nesuparib (JPI-547, NOV140201) is a potential inhibitor of both PARP and tankyrases, with IC50 of 0.005 μM, 0.001 μM, 0.002 μM, and ND for TNKS1, TNKS2, PARP1, and PARP2, respectively. Nesuparib exhibits anti-tumor activity in BRCA-deficient xenograft models. Sep 06 2023
E1502 Deutenzalutamide Deutenzalutamide (HC-1119, MDV3100) is an androgen receptor (AR) antagonist with an IC50 of 36 nM in LNCaP prostate cells. It can be used in a treatment of advanced prostate cancer. Sep 04 2023
E4020 1-Oleoyl-rac-glycerol 1-Oleoyl-rac-glycerol (Monoolein) is an endogenous metabolite, also an example of lipid-based nanomaterial. It is commonly utilized to prepare lyotropic cubic liquid crystalline drug delivery systems due to its physicochemical properties. Sep 04 2023
E1429 T1-44 T1-44 is a selective inhibitor of protein arginine methyltransferase 5 (PRMT5). It exhibits anti-tumor activity in pancreatic cancers. Aug 31 2023
E4018 Ammonium sulfate Ammonium sulphate (Mascagnite) is an inorganic sulfate salt used for the purification of enzymes and antibodies. Aug 31 2023
E4017 Calcium chloride dihydrate Calcium chloride dihydrate is a moisture-resistant, cheap, and commonly available calcium salt. It is used as a calcium supplement in the DMEM (Dulbecco's modified Eagle's medium) for use in cell culture studies and to prepare the synthetic brine solution. Aug 30 2023
E4019 Polyethylenimine Polyethylenimine (PEI) is a hydrophilic cationic polymer that acts as a low toxicity and efficient gene vector. Aug 30 2023
E4013 Melanin Melanin is a unique pigment with myriad functions. It is multifunctional, providing defense against environmental stresses such as ultraviolet (UV) light, oxidizing agents and ionizing radiation. Aug 29 2023
E1214 KSQ-4279 KSQ-4279 (USP1-IN-1) is an orally bioavailable selective inhibitor of the ubiquitin specific protease 1 (USP1) with anti-proliferative activity. KSQ-4279 also exhibits synergistic activity in combination with PARP inhibitors. Aug 29 2023
E1388 ISA-2011B ISA-2011B is an inhibitor of phosphatidylinositol-4-phosphate 5-kinase-α (PIP5Kα). ISA-2011B exhibits anti-proliferative activity and induces apoptosis in prostate cancer cells. Aug 28 2023
E4014 4-Nitrophenyl alpha-D-glucopyranoside 4-Nitrophenyl alpha-D-glucopyranoside is a chromogenic substrate in the α-glucosidase inhibition assay. Aug 27 2023
S9469 Haloperidol Decanoate Haloperidol decanoate (Halomonth) is a depot form of haloperidol with antipsychotic activity. It has potential to be used in the research of schizophrenia and schizoaffective disorder. Aug 24 2023
E4006 Ribonucleic acid Ribonucleic Acid (RNA) is the substrate for the RNase enzyme, which can be used for studying ribonuclease activities of enzymes such as ribonuclease-A, ribonuclease T1 (RNAase), and bougainvillea xbuttiana antiviral protein 1 (BBAP1). Aug 23 2023
E4015 4-Methylumbelliferyl N-acetyl-beta-D-glucosaminide 4-Methylumbelliferyl N-acetyl-beta-D-glucosaminide is a fluorogenic substrate used for assays of N-acetyl-β-D-glucosaminidase (NAGase). Aug 21 2023
E2996 Xylene Cyanol FF Xylene Cyanol FF is an acid triphenylmethane dye. It can be used for histochemical staining of hemoglobin peroxidase or as a tracking dye for DNA sequencing in electrophoresis. Aug 21 2023
E4010 L-3,4-Dihydroxyphenylalanine methyl ester hydrochloride L-3,4-Dihydroxyphenylalanine methyl ester hydrochloride(Melevodopa hydrochloride) is a precursor to L-DOPA. It is an antiparkinsonian agent L-DOPA methyl ester that elicits antitumor functionality in leukemia and melanoma. Aug 17 2023
E4012 4-Methylumbelliferyl beta-D-glucopyranoside 4-Methylumbelliferyl beta-D-glucopyranoside(MUD) is a β-D-glucoside, is a fluorogenic substrate for β-glucosidase. It is utilized in the assay of beta-glucosidase activity. Aug 17 2023
E1436 A2ti-2 A2ti-2 is a selective and low-affinity inhibitor of annexin A2/S100A10 heterotetramer (A2t)with an IC50 of 230 μM. It specifically disrupts the protein-protein interaction (PPI) between A2 and S100A10 and also prevents human papillomavirus type 16 (HPV16) infection. Aug 17 2023
E4008 Safranin O Safranin O(Safranin T) is an important and classical phenazinium dye. It has been extensively used in the academic field as a spectroscopic probe and indicator. It can be used as a redox indicator in the determination of metal ion concentration. Aug 17 2023
E4009 Sodium DL-lactate solution Sodium DL-lactate solution (60% w/w aq. soln.) is the product of glycogenolysis and glycolysis. It is mainly used as a buffer and pH adjuster for injection solutions. It also has antimicrobial activity, which can be used as a food preservative. Aug 17 2023
E4011 Glycogen (from bovine liver) Glycogen (from bovine liver) is a glycolytic intermediates and high-energy phosphates that can serve as a form of energy storage in humans, animals, fungi, and bacteria. Aug 17 2023
E4000 Agar Agar is a jelly like substance that contains agarose and agar gel isolated from the cell walls of red algae species such as Gelidium and Gracilaria (Ogonori). It is widely used in food additives, plant tissue culture, microorganisms culture media, fingerprint recognition, and medical fields. Aug 17 2023
E2979 DL-AP5 (2-APV) DL-AP5 (2-APV, DL-2-Amino-5-phosphonovaleric acid) is a competitive antagonist of NMDA (N-methyl-D-aspartate) receptor. It shows significantly antinociceptive activity and specifically blocks on channels in the rabbit retina. Aug 16 2023
E2998 Acetylthiocholine iodide Acetylthiocholine iodide(S-Acetylthiocholine iodide; ATCh iodide) is used as a substrate in the preparation of acetylcholine esterase (AChE) assay working solution for AChE activity assay. In addition, the compound is used in some medical research, for example in the fields of neuroscience and organ physiology. Aug 16 2023
E2997 (+)-Biotin N-hydroxysuccinimide ester (+)-Biotin N-hydroxysuccinimide ester(Biotin-NHS; NHS-Biotin) is an amino reactive biotin reagent used in the preparation of biotinylated surfaces or polypeptides. Aug 16 2023
E2999 Dimethyl pimelimidate dihydrochloride Dimethyl pimelimidate dihydrochloride (DMP) is a homobifunctional amine-reactive crosslinker which is readily hydrolyzed at neutral pH. Aug 16 2023
E4002 Potassium D-gluconate Potassium D-gluconate(Potassium Gluconate) is an orally active carboxylic acid by the oxidation with antiseptic and chelating properties. Aug 16 2023
E4003 N,N'-Methylenebisacrylamide N,N'-Methylenebisacrylamide(Methylenebisacrylamide) is a biochemical,cross-linking agent reagent that can be used as a biological material, during the formation of polymers or organic compound for life science related research. Aug 16 2023
E4004 DL-beta-Hydroxybutyric acid sodium salt DL-beta-Hydroxybutyric acid sodium salt(β-Hydroxybutyric acid sodium) is a metabolite that is elevated in type I diabetes. It can modulate the properties of membrane lipids. Aug 16 2023
E4005 Decamethylcyclopentasiloxane Decamethylcyclopentasiloxane(Cyclomethicone 5) is an organosilicon compound. It is used in cosmetic and personal products as a skin emollient. Aug 16 2023
E4007 L-Sulforaphane L-Sulforaphane ((R)-Sulforaphane) is a highly potent inducer of the Keap1/Nrf2/ARE pathway. It is a more potent inducer of the carcinogen-detoxifying enzyme systems in rat liver and lung than the S-isomer. Aug 15 2023
E2984 GSK-7975A GSK-7975A is a potent and orally available inhibitor of CRAC channel. It reduces FcεRI-dependent Ca2+ influx and reduces the release of histamine, leukotriene C4, and cytokines (IL-5/-8/-13 and TNFα). Aug 15 2023
E4001 Sodium pyrophosphate decahydrate Sodium pyrophosphate decahydrate acts as a buffering agent, a chelator and a hydrated salt nucleating agent. Sodium pyrophosphate decahydrate can also be used to a raw material for synthetic laundry scent additives. Aug 15 2023
E1410 Fluspirilene Fluspirilene(R 6218; Redeptin) is a non-competitive antagonist of L-type calcium channels with an IC50 of 0.03 μM in cell-free assays. Fluspirileneis a long-acting injectable depot antipsychotic agent used for schizophrenia. Aug 13 2023
E1468 MSU-42011 MSU-42011 is an orally active agonist of retinoid X receptor (RXR). MSU-42011 inhibits the expression of iNOS and p-ERK protein. It exhibits immunomodulatory and antitumor activity. MSU-42011 can be used for cancer research. Aug 13 2023
A2370 Elezanumab (Anti-RGMA) Elezanumab (Anti-RGMA) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway with IC50 of 97 pM. MW: 146.44 kD. Aug 10 2023
A2371 Anti-PVRIG Anti-PVRIG is a humanized, hybridoma monoclonal antibody against the poliovirus receptor-related immunoglobulin (PVRIG; PVR Related Immunoglobulin Domain Containing Protein; CD112R), with potential immune checkpoint inhibitory and antineoplastic activities.MW: 145.5 kD. Aug 10 2023
A2372 Apamistamab (Anti-PTPRC / CD45) Apamistamab (Anti-PTPRC / CD45) is an IgG1 anti-CD45 monoclonal antibody (MoAb). Note: This antibody is not labeled with the radioisotope iodine (-131). MW: 145.5 kD. Aug 10 2023
A2373 Neihulizumab (Anti-PSGL1 / CD162) Neihulizumab (Anti-PSGL1 / CD162) is a humanized, agonistic monoclonal antibody against P selectin glycoprotein ligand-1 (PSGL-1, SELPLG, CD162) with potential immunosuppressive activity. It can halt the progression of T-cell-mediated autoimmune diseases and acute graft-versus-host disease (GvHD). MW: 150 kD. Aug 10 2023
A2374 Crizanlizumab (Anti-P-Selectin / CD62p) Crizanlizumab (Anti-P-Selectin / CD62p) is a humanized monoclonal immunoglobulin G1 anti-P-selectin antibody with vaso-protective and anti-vaso-occlusive properties. MW: 144.24 kD. Aug 10 2023
A2375 Rolinsatamab (Anti-PRLR / Prolactin Receptor) Rolinsatamab (Anti-PRLR / Prolactin Receptor) is a fully humanized bispecific monoclonal antibody that targets IL-4 and IL-13. MW: 145.5 kD. Aug 10 2023
A2376 Anti-Phosphorylcholine Anti-Phosphorylcholine is a antibody targeting phosphorylcholine (PC).They are known to contribute to the immune defense against a variety of microbial infections. MW: 145.5 kD. Aug 10 2023
A2377 Bavituximab (Anti-Phosphatidylserine) Bavituximab (Anti-Phosphatidylserine) is a chimeric, IgG1 monoclonal antibody directed against anionic phospholipids with potential antineoplastic activity. MW: 145.5 kD. Aug 10 2023
A2378 Rinucumab (Anti-PDGFRB / CD140b) Rinucumab (Anti-PDGFRB / CD140b) is an anti-platelet-derived growth factor receptor beta (anti-PDGFR-beta) monoclonal antibody and has a potential to study neovascular age-related macular degeneration. MW: 145.5 kD. Aug 10 2023
A2379 Olaratumab (Anti-PDGFRA / CD140a) Olaratumab (IMC-3G3; LY3012207) is a fully human IgG1 monoclonal antibody directed against the platelet-derived growth factor receptor alpha (PDGFR alpha) with potential antineoplastic activity. MW: 145.5 kD. Aug 10 2023
A2381 Serplulimab (Anti-PDCD1 / PD-1 / CD279) Serplulimab (Anti-PDCD1 / PD-1 / CD279) is a humanized monoclonal antibody directed against the negative immunoregulatory human cell receptor programmed cell death protein 1 (PD-1; PDCD1; CD279), with potential immune checkpoint inhibitory and antineoplastic activities. MW: 145.5 kD. Aug 10 2023
A2384 Anti-PAR2 Anti-PAR2 is a antibody against Protease-Activated Receptor 2 (PAR2). MW: 145.5 kD. Aug 10 2023
A2385 Zelminemab (Anti-PAC1) Zelminemab (AMG-301) is a human monoclonal antibody that inhibits the PACAP type I (PAC1) receptor. MW: 145.5 kD. Aug 10 2023
A2386 Orticumab (Anti-oxLDL) Orticumab (MLDL1278A) is an antibody targeting oxidized or malondialdehyde-modified lipoprotein (LDL) that specifically inhibits oxidised low-density lipoproteins (oxLDL). Orticumab is involved in the modulation of autoimmune responses against oxLDL and improves atherosclerosis in an animal model. MW: 145.5 kD. Aug 10 2023
A2387 Anti-Osteopontin Anti-Osteopontin is an antibody used in antigen-specific immunodetection in biological samples. MW: 145.5 kD. Aug 10 2023
A2388 Mupadolimab (Anti-NT5E / CD73) Mupadolimab (Anti-NT5E / CD73) is a type II humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the ectoenzyme 5'-ecto-nucleotidase (cluster of differentiation 73; CD73; 5'-NT; ecto-5'-nucleotidase; NT5E), with potential immunomodulating and antineoplastic activities. MW: 145.5 kD. Aug 10 2023
A2389 Tarextumab (Anti-NOTCH3) Tarextumab (Anti-NOTCH3) is an anti-Notch2/3 fully human IgG2 monoclonal antibody with anti-tumor activity. MW: 145.5 kD. Aug 10 2023
A2390 Tesnatilimab (Anti-NKG2D / CD314) Tesnatilimab (Anti-NKG2D / CD314) is a recombinant human immunoglobulin G4 (IgG4) monoclonal antibody against the immune activating receptor natural-killer group 2, member D receptor protein (NKG2D or KLRK1), with potential immunomodulating and anti-inflammatory activities. MW: 146.5 kD. Aug 10 2023
A2392 Enfortumab (Anti-Nectin-4) Enfortumab (Anti-Nectin-4) is a monoclonal antibody targeting Nectin-4 and has potential for research into urothelial cancer. MW: 145.44 kD. Aug 10 2023
A2393 Lorvotuzumab (Anti-NCAM1 / CD56) Lorvotuzumab (Anti-NCAM1 / CD56) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine. MW: 145.5 kD. Aug 10 2023
A2394 Ensituximab (Anti-MUC5AC) Ensituximab (Anti-MUC5AC) is a chimeric monoclonal IgG1 antibody targeting a variant of MUC5AC with specificity for colorectal and pancreatic cancer. MW: 145.5 kD. Aug 10 2023
A2395 Imaprelimab (Anti-MUC18 / MCAM / CD146) Imaprelimab (Anti-MUC18 / MCAM / CD146) is a humanized IgG1κ anti-melanoma cell adhesion molecule (MCAM) monoclonal antibody with antineoplastic activity. MW: 145.5 kD. Aug 10 2023
A2396 Abagovomab (Anti-MUC16) Abagovomab (Anti-MUC16) is a murine IgG1 monoclonal anti-idiotype antibody containing a variable antigen-binding region that functionally mimics the three-dimensional structure of a specific epitope on the ovarian cancer tumor-associated antigen CA-125 with potential antineoplastic activity. MW: 145.5 kD. Aug 10 2023
A2397 Clivatuzumab (Anti-MUC1) Clivatuzumab (Anti-MUC1) is a humanized anti-mucin monoclonal antibody targeting an epitope in the MUC1 antigen expressed in most pancreatic cancers. MW: 145.5 kD. Aug 10 2023
A2398 Narnatumab (Anti-MSPR / RON / CD136) Narnatumab (Anti-MSPR / RON / CD136) is a fully human monoclonal antibody against RON (recepteur d'origine nantais; macrophage stimulating 1 receptor) with potential antineoplastic activity. MW: 145.5 kD. Aug 10 2023
A2399 Andecaliximab (Anti-MMP9) Andecaliximab (Anti-MMP9) is a recombinant chimeric IgG4 monoclonal antibody (mAb) that targets matrix metalloproteinase 9 (MMP9). Andecaliximab shows antifibrotic efficacy in idiopathic pulmonary fibrosis mouse models. MW: 145.5 kD. Aug 10 2023
A2400 Imalumab (Anti-MIF) Imalumab (Anti-MIF) is a human, recombinant monoclonal antibody (MoAb) against macrophage migration inhibitory factor (MIF), with potential immunomodulating, anti-inflammatory, and antineoplastic activities. MW: 145.5 kD. Aug 10 2023
A2401 Amatuximab (Anti-Mesothelin) Amatuximab (Anti-Mesothelin) is a chimeric IgG1 monoclonal antibody against human mesothelin with potential anti-tumor activity. Amatuximab specifically targets mesothelin, a cell surface glycoprotein involved in cell adhesion and overexpressed in many epithelial-derived cancer cells. MW: 145.5 kD. Aug 10 2023
A2402 Anti-Melanotransferrin / CD228 Anti-Melanotransferrin / CD228 is an antibody against the melanotransferrin with potential antineoplastic activity.MW: 145.5 kD. Aug 10 2023
A2403 Narsoplimab (Anti-MASP2) Narsoplimab (Anti-MASP2) is a monoclonal antibody against mannan-binding lectin (MBL)-associated serine protease-2 (MASP-2), with potential anti-thrombotic and immunomodulating activities. MW: 145.5 kD. Aug 10 2023
A2404 Ontamalimab (Anti-MADCAM1) Ontamalimab (Anti-MADCAM1) is a fully human IgG2 monoclonal antibody targeting mucosal addressin cell adhesion molecule-1 (MAdCAM-1) with potential for the research of Crohn's disease. MW: 145.5 kD. Aug 10 2023
A2405 Lupartumab (Anti-LYPD3 / C4.4A) Lupartumab (Anti-LYPD3 / C4.4A) is an anti-LYPD3 (C4.4A) monoclonal antibody that can be used for the synthesis of the antibody-drug conjugate Lupartumab Amadotin. MW: 145.5 kD. Aug 10 2023
A2406 Anti-Ly6E  Anti-Ly6E is an antibody against the tumor-associated antigen (TAA) lymphocyte antigen 6 complex locus E (Ly6E) with potential antineoplastic activity.MW: 145.5 kD. Aug 10 2023
A2407 Samrotamab (Anti-LRRC15 / LIB) Samrotamab (Anti-LRRC15 / LIB) is a fully human monoclonal antibody against LRRC15. MW: 145.5 kD. Aug 10 2023
A2408 Simtuzumab (Anti-LOXL2) Simtuzumab (Anti-LOXL2) is a monoclonal antibody directed against Lysyl oxidase like-2 (LOXL2) with potential antineoplastic activity. MW: 145.5 kD. Aug 10 2023
A2409 Ladiratuzumab (Anti-LIV-1 / SLC39A6) Ladiratuzumab (Anti-LIV-1 / SLC39A6) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. MW: 145.5 kD. Aug 10 2023
A2410 Opicinumab (Anti-LINGO1) Opicinumab (BIIB033) is a monoclonal antibody against LINGO-1 and has potential applications in acute optic neuritis and relapsed multiple sclerosis. MW: 145.5 kD. Aug 10 2023
A2411 Polzastobart (Anti-LILRB2 / ILT4 / CD85d) Polzastobart (Anti-LILRB2 / ILT4 / CD85d) is a humanized monoclonal antibody directed against the inhibitory immune checkpoint receptor leukocyte immunoglobulin-like receptor subfamily B member 2 (LILRB2; immunoglobulin-like transcript 4; ILT4; lymphocyte immunoglobulin-like receptor 2; LIR2; monocyte/macrophage immunoglobulin-like receptor 10; MIR-10; CD85d), with potential immunomodulating and antineoplastic activities. Aug 10 2023
A2412 Falbikitug (Anti-LIF) Falbikitug (Anti-LIF) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody against leukemia inhibitory factor (LIF), with potential immunomodulating and antineoplastic activities.  MW: 145.24 kD. Aug 10 2023
A2413 Mibavademab (Anti-LEPR / CD295) Mibavademab (Anti-LEPR / CD295) is a humanized monoclonal antibody against LEPR (Leptin receptor). MW: 145.5 kD. Aug 10 2023
A2414 Anti-LAMP1 / CD107a Anti-LAMP1 / CD107 is a monoclonal antibody against lysosome-associated membrane protein 1 (LAMP1) with potential antineoplastic activity. MW: 145.5 kD. Aug 10 2023
A2416 Anti-Klotho Beta Anti-Klotho Beta is an antibody targeting Beta Klotho (KLB). MW: 145.24 kD. Aug 10 2023
A2417 Anti-KLK2 / Kallikrein 2 Anti-KLK2 / Kallikrein 2 is a radioimmunoconjugate containing h11B6, a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets human kallikrein-2 (hK2), conjugated with the bifunctional, macrocyclic chelating agent tetra-azacyclododecanetetra-acetic acid (DOTA), and labeled with the alpha-emitting radioisotope actinium Ac 225, with potential antineoplastic activity. MW: 145.5 kD. Aug 10 2023
A2418 Lacutamab (Anti-KIR3DL2 / CD158k) Lacutamab (Anti-KIR3DL2 / CD158k) is a humanized monoclonal antibody against the immune receptor human killer cell immunoglobulin-like receptor, three domains, long cytoplasmic tail, 2 (KIR3DL2), with potential immunomodulating and antineoplastic activities. MW: 150 kD. Aug 10 2023
A2419 Lirilumab (Anti-KIR) Lirilumab (Anti-KIR) is a  fully human monoclonal antibody against killer-cell immunoglobulin-like receptors (KIR), with potential antineoplastic activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research. MW: 150 kD. Aug 10 2023
A2420 Anti-Integrin b1 / ITGB1 / CD29 Anti-Integrin b1 / ITGB1 / CD29 is a humanized monoclonal antibody directed against the human integrin receptor beta-1 subunit (CD29), with potential antineoplastic activity. MW: 145.5 kD. Aug 10 2023
A2421 Efalizumab (Anti-Integrin aL / ITGAL / CD11a) Efalizumab (Anti-Integrin aL / ITGAL / CD11a) is a humanized IgG1 monoclonal antibody directed against CD11a, the alpha subunit of human leukocyte-function-associated antigen type 1 (LFA-1), with immunosuppressant activity. MW: 145.5 kD. Aug 10 2023
A2422 Garetosmab (Anti-INHBA / Activin A) Garetosmab (Anti-INHBA / Activin A) is a fully human IgG4 monoclonal antibody that specifically inhibits activin A. Garetosmab can be used for fibrodysplasia ossificans progressiva (FOP) research. MW: 145.5 kD. Aug 10 2023
A2423 Enokizumab (Anti-IL-9) Enokizumab (Anti-IL-9) is a humanized monoclonal antibody directed against the cytokine interleukin-9 (IL-9), with potential immunomodulating activity. MW: 145.5 kD. Aug 10 2023
A2424 Anti-IL-7Ra / CD127 Anti-IL-7Ra / CD127 is a monoclonal antibody against human IL-7Rα with therapeutic benefit against T-ALL (T-cell acute lymphoblastic leukemia). MW: 145.5 kD. Aug 10 2023
A2427 Benralizumab (Anti-IL-5Ra/ CD125) Benralizumab (Anti-IL-5Ra/ CD125) is an afucosylated, humanized monoclonal antibody against the alpha chain of the interleukin-5 receptor (IL-5Ra) with potential anti-asthmatic activity. MW: 145.5 kD. Aug 10 2023
A2428 Mepolizumab (Anti-IL-5) Mepolizumab (Anti-IL-5) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed against interleukin-5 (IL-5) with anti-asthmatic and potential immunosuppressive activity. MW: 145.5 kD. Aug 10 2023
A2430 Pascolizumab (Anti-IL-4) Pascolizumab (Anti-IL-4) is a humanized anti-IL-4 monoclonal antibody. Pascolizumab has the potential for asthma research. MW: 145.5 kD. Aug 10 2023
A2431 Talacotuzumab (Anti-IL-3Ra / CD123) Talacotuzumab (Anti-IL-3Ra / CD123) is a humanized IgG1 monoclonal antibody against CD123 (Interleukin-3 receptor alpha chain or IL3RA) with potential antineoplastic activity. MW: 146.06 kD. Aug 10 2023
A2432 Itepekimab (Anti-IL-33) Itepekimab (Anti-IL-33) is a monoclonal antibody against IL-33. Itepekimab reduces airway inflammation and related tissue damage in previous clinical studies. MW: 145.5 kD. Aug 10 2023
A2433 Nemolizumab (Anti-IL-31Ra) Nemolizumab (Anti-IL-31Ra) is a humanized monoclonal antibody, targeting IL-31Ra. It inhibits the binding of interleukin-31 (IL-31) to its receptor and subsequent signal transduction. Nemolizumab can used be in research of atopic dermatitis (AD). MW:145.5 KD. Aug 10 2023
A2434 Daclizumab (Anti-IL-2Ra / CD25) Daclizumab (Anti-IL-2Ra / CD25) is a recombinant monoclonal antibody interleukin-2 receptor antagonist. MW:145.5 KD. Aug 10 2023
A2435 Basiliximab (Anti-IL-2Ra / CD25) Basiliximab (Anti-IL-2Ra / CD25) is a recombinant, chimeric, human-murine monoclonal antibody directed against the alpha subunit of the interleukin-2 receptor (IL-2R alpha) with immunosuppressant activity. MW:145.58 KD. Aug 10 2023
A2437 Tildrakizumab (Anti-IL-23a) Tildrakizumab (Anti-IL-23a) is a humanized monoclonal antibody directed against the p19 protein subunit of interleukin-23 (IL-23), with immunomodulating activity. MW:145.5 KD. Aug 10 2023
A2438 Guselkumab (Anti-IL-23) Guselkumab (Anti-IL-23) is a recombinant human IgG1 monoclonal antibody. It targets the key IL-23 and inhibits the production of cytokines lying downstream of the IL-23 signaling pathway and can be used for reatment of psoriatic arthritis, Crohn's disease, and ulcerative colitis. MW : 145.5 KD. Aug 10 2023
A2439 Anti-IL-22Ra Anti-IL-22Ra is an affinity isolated polyclonal antibody, targeting IL-22R. It is used in the treatment of psoriasis, psoriatic arthritis, atopic dermatitis. MW :145.5 KD. Aug 10 2023
A2440 Fezakinumab (Anti-IL-22) Fezakinumab (Anti-IL-22) is a monoclonal antibody targeting IL-22. It can be used for the research of inflammatory disease, such as psoriasis and rheumatoid arthritis. MW :145.5 KD. Aug 10 2023
A2441 Fletikumab (Anti-IL-20) Fletikumab (Anti-IL-20) is a monoclonal antibody, targeting IL-20. It can be used for inflammation research, such as rheumatoid arthritis and psoriasis. MW : 145.5 KD. Aug 10 2023
A2442 Spesolimab (Anti-IL-1RL2 / IL-36R) Spesolimab (Anti-IL-1RL2 / IL-36R) is an humanized antagonistic monoclonal antibody targeting IL-36 receptor. It can be used for treatment of palmoplantar pustulosis (PPP) and generalized pustular psoriasis (GPP). MW : 145.5 KD. Aug 10 2023
A2443 Astegolimab (Anti-IL-1RL1 / ST2 / IL-33R) Astegolimab (Anti-IL-1RL1 / ST2 / IL-33R) is a human IgG2 monoclonal antibody that blocks IL-33 signaling by targeting ST2, the IL-33 receptor. It has the potential for chronic obstructive pulmonary disease (COPD), asthama treatment. MW :145.5 KD Aug 10 2023
A2444 Nidanilimab (Anti-IL-1RAP / IL-1R3) Nidanilimab (Anti-IL-1RAP / IL-1R3) is a fully humanized monoclonal antibody targeting IL1RAP and blocks IL1α and IL1β signaling. It also stimulates the immune system to destroy tumour cells. It can be used in treatment of non-small lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). MW :143.56 KD. Aug 10 2023
A2445 Anti-IL-1R1 / CD121a Anti-IL-1R1 / CD121a is a fully humanized monoclonal antibody that targets interleukin-1 (IL-1), inhibiting the activity of IL-1a and IL-1b. It can be beneficial in treatment of osteoarthritis (OA) and rheumatoid arthritis. MW :145.5 KD. Aug 10 2023
A2446 Canakinumab (Anti-IL-1b) Canakinumab (Anti-IL-1b) is a recombinant human anti-IL-1β monoclonal antibody targeting IL-1β and neutralizing IL-1β signaling. It can be used in treatment of disorders of autoimmune origin like familial mediterranean fever, mevalonate kinase deficiency, tumor necrosis factor receptor-associated periodic syndrome (TRAPS). MW :145.5 KD. Aug 10 2023
A2447 Bermekimab (Anti-IL-1a) Bermekimab (Anti-IL-1a) is a human monoclonal antibody that targets interleukin-1alpa (IL-1α). It prevents tumour-related inflammation. MW :145.5 KD. Aug 10 2023
A2448 Anti-IL-18 Anti-IL-18 is a fully humanized, high-affinity monoclonal antibody targeting IL-18. It has the potential for the treatment of autoinflammatory diseases research, including adult-onset Still’s disease (AOSD). MW :150 KD. Aug 10 2023
A2450 Anti-IL-17c Anti-IL-17c is a fully humanized recombinant IgG1 monoclonal antibody targeting IL-17C. It can be used in a clinical treatment of atopic dermatitis. MW :145.5 KD. Aug 10 2023
A2451 Ordesekimab (Anti-IL-15) Ordesekimab (Anti-IL-15) is a fully human monoclonal antibody targeting IL-15 and inhibiting the interaction of IL-15 with the IL-2Rβ. It has the potential for treatment of nonresponsive celiac disease (NRCD). MW :143.82 KD. Aug 10 2023
A2452 Anti-IL-13Ra1 / CD213a1 Anti-IL-13Ra1 / CD213a1 is a monoclonal antibody targeting IL13RA1. It can be used in research of therapeutic antibody for biological drug discovery. MW :145.5 KD. Aug 10 2023
A2453 Tralokinumab (Anti-IL-13) Tralokinumab (Anti-IL-13) is a fully human IgG4 monoclonal antibody specifically targeting IL-13 with high affinity. It can be used for the research of the atopic dermatitis (AD). MW :145.5 KD. Aug 10 2023
A2454 Abrezekimab (Anti-IL-13) Abrezekimab (anti-IL-13) is a humanized, high-affinity, neutralizing, anti-human-IL-13 antibody fragment that binds to IL-13. Abrezekimab prevents binding to the IL-13Rα1 subunit. It can be used in research of asthma. MW: 145.5 KD. Aug 10 2023
A2455 Teprotumumab (Anti-IGF-1R / CD221) Teprotumumab (Anti-IGF-1R / CD221) is an IGF-1 receptor (IGF-1R) blocking human monoclonal antibody. Teprotumumab binds to the ligand binding extracellular α-subunit domain of IGF-1R. Teprotumumab inhibits TSH and IGF-1 action in fibrocytes. Teprotumumab can be used for thyroid-associated ophthalmopathy research.MW: 145.5 KD. Aug 10 2023
A2456 Ganitumab (Anti-IGF-1R / CD221) Ganitumab (Anti-IGF-1R / CD221) is a recombinant human monoclonal antibody to the human type 1 insulin-like growth factor receptor (IGF1R). Ganitumab recognizes murine IGF1R with sub-nanomolar affinity (KD=0.22 nM) and inhibits the interaction of murine IGF1R with IGF1 and IGF2. MW: 145.5 KD. Aug 10 2023
A2457 Xentuzumab (Anti-IGF-1) Xentuzumab (Anti-IGF-1) is a recombinant a humanized monoclonal antibody that targets IGF ligands IGF-1 and IGF-2. Xentuzumab inhibits both of IGF-1 and IGF-2 growth-promoting signalling and suppresses AKT activation. MW: 145.5 KD. Aug 10 2023
A2460 Anifrolumab (Anti-IFNAR1) Anifrolumab (Anti-IFNAR1) is a human monoclonal antibody. It is a type I interferon (IFN) receptor antagonist, that blocks the activity of type I interferon. Anifrolumab can be used in research of systemic lupus erythematosus (SLE). MW: 145.5 KD. Aug 10 2023
A2461 Sifalimumab (Anti-IFNa1) Sifalimumab (Anti-IFNa1) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. MW: 145.5 KD. Aug 10 2023
A2462 Feladilimab (Anti-ICOS / CD278) Feladilimab (Anti-ICOS/CD278) is humanized IgG4 anti-ICOS agonist monoclonal antibody. Feladilimab binds to ICOS-expressing T cells. Feladilimab has potential for its use in cancer research. MW: 145.5 KD. Aug 10 2023
A2463 Vopratelimab (Anti-ICOS / CD278) Vopratelimab (Anti-ICOS / CD278) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that binds specifically to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab exhibits antitumor immune response. MW: 145.5 KD. Aug 10 2023
A2464 Bersanlimab (Anti-ICAM1 / CD54) Bersanlimab (Anti-ICAM1 / CD54) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects. MW: 145.5 KD. Aug 10 2023
A2465 Anti-HLA-DR Anti-HLA-DR (IMMU-114) is a humanized anti-human leukocyte antigen-DR (HLA-DR) moAb, that depletes APCs and reduces alloreactive T cells. MW: 145.5 KD. Aug 10 2023
A2466 Derlotuximab (Anti-Histone H1) Derlotuximab is a recombinant human monoclonal antibody that targets DNA/histone (H1) complex. It is potentially used in the treatment of Glioblastoma multiforme (GBM), Cancers, brain, malignant glioma, Solid tumors. It is also used in certain immunoassay techniques. MW: 145.5 KD. Aug 10 2023
A2467 Telisotuzumab (Anti-HGFR / c-Met) Telisotuzumab (Anti-HGFR / c-Met) is a monoclonal antibody that targets c-Met. MW: 145.64 KD. Aug 10 2023
A2468 Onartuzumab (Anti-HGFR / c-Met) Onartuzumab (Anti-HGFR / c-Met) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity. MW: 144.64 KD. Aug 10 2023
A2469 Rilotumumab (Anti-HGF / SF) Rilotumumab (Anti-HGF / SF) is a monoclonal antibody that inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research. MW: 145.5 KD. Aug 10 2023
A2470 Anti-Hepcidin / HAMP Anti-Hepcidin / HAMP (LY2787106) is a fully humanized monoclonal antibody againsts hepcidin. It is currently in phase I human trials for cancer-related anemia. It binds to hepcidin and prevents its binding to the iron exporting protein ferroportin and prevents hepcidin-induced internalization and degradation of ferroportin and increases ferroportin-mediated iron export. MW: 145.5 KD. Aug 10 2023
A2471 Anti-HBEGF Anti-HBEGF (U3-1565) is a humanized monoclonal antibody against human heparin-binding EGF-like growth factor (HBEGF) and exhibits potential antineoplastic activity. It binds to HBEGF and blocks the binding of HBEGF to the EGF receptors which prevents EGF receptor activation and results in subsequent induction of cell growth signaling. MW: 145.5 KD. Aug 10 2023
A2472 Indusatumab (Anti-GUCY2C) Indusatumab (Anti-GUCY2C) is an monoclonal antibody that targets GUCY2C (Guanylate cyclase 2C). MW: 145.5 KD. Aug 10 2023
A2473 Talquetamab (Anti-GPRC5D) Talquetamab (Anti-GPRC5D) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab exhibits antitumor activity. MW: 145.5 KD. Aug 10 2023
A2474 Petosemtamab (Anti-GPR49 / LGR5) Petosemtamab (Anti-GPR49 / LGR5) is an monoclonal antibody that targets GPR49/LGR5. It blocks the appearance of metastases and slows the growth of primary tumors in experimental cancer models. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC). MW: 145.5 KD. Aug 10 2023
A2475 Glembatumumab (Anti-GPNMB) Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. MW: 145.5 KD. Aug 10 2023
A2476 Codrituzumab (Anti-GPC3 / Glypican-3) Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3) which is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth. MW: 150 KD. Aug 10 2023
A2477 Anti-GPA33 Anti-GPA33 (KRN330) is a monoclonal antibody that targets GPA33, a tumor-associated antigen (TAA) which is overexpressed on the surface of certain tumor cells. It exhibits potential immunostimulatory and antineoplastic activities. MW: 145.5 KD. Aug 10 2023
A2478 Glenzocimab (Anti-GP6 / Glycoprotein-6) Glenzocimab (Anti-GP6 / Glycoprotein-6) is a Fab fragment of humanized anti-GPVI monoclonal antibody. Glenzocimab inhibits collagen-induced platelet aggregation. Glenzocimab has the potential for the research of acute ischemic stroke. MW: 145.5 KD. Aug 10 2023
A2479 Racotumomab (Anti-GM3) Racotumomab (Anti-GM3) is an anti-idiotype monoclonal antibody (MAb). Racotumomab reacts to Neu-glycolyl (NeuGc)-containing gangliosides, sulfatides, and other antigens expressed in tumors. Racotumomab is an active anticancer agent for lung cancer. MW: 145.5 KD. Aug 10 2023
A2480 Anti-GFRAL Anti-GFRAL (NGM120) is a long-acting monoclonal antibody directed against glial-cell-derived neurotrophic factor (GDNF) family receptor alpha-like (GFRAL), with potential anti-anorexia and anti-cachexia activities. It binds to and blocks GFRAL activity which prevents binding of growth differentiation factor 15 (GDF15; MIC-1) to its receptor GFRAL and prevents GDF15/GFRAL-mediated signaling. MW: 145.5 KD. Aug 10 2023
A2481 Nadecnemab (Anti-GFRA3) Nadecnemab (Anti-GFRA3) is an IgG4κ antibody targeting GFRA3 (glial cell derived neurotrophic factor family receptor alpha 3). Nadecnemab can be used for research of osteoarthritis of the knee/pain. MW: 145.5 KD. Aug 10 2023
A2482 Apitegromab (Anti-GDF8 / Myostatin) Apitegromab (Anti-GDF8 / Myostatin) is a fully human monoclonal antibody that binds to human promyostatin and latent myostatin with a high degree of specificity, without binding to mature myostatin and other closely related growth factors. Apitegromab can be used for the research of neuromuscular disease including spinal muscular atrophy. MW: 145.5 KD. Aug 10 2023
A2483 Ponsegromab (Anti-GDF15 / MIC-1) Ponsegromab (Anti-GDF15 / MIC-1) is a potent and selective humanized anti-GDF15 antibody inhibitor with anti-cachexia activity. Ponsegromab binds to GDF15 and prevents the binding of GDF15 to GFRAL, thereby blocking GDF15/GFRAL-mediated signaling. Ponsegromab can be used in the research of cancers. MW: 145.5 KD. Aug 10 2023
A2484 Ecromeximab (Anti-GD3) Ecromeximab (Anti-GD3) is a human-mouse chimeric IgG1 monoclonal antibody with potential antineoplastic activity that targets ganglioside GD3, a surface antigen expressed on many malignant melanoma cells. It binds to GD3-positive cells, thereby initiating antibody-dependent cytotoxicity against GD3-positive cells. MW: 145.5 KD. Aug 10 2023
A2485 Dinutuximab (Anti-GD2) Dinutuximab (Anti-GD2) is a chimeric mouse/human monoclonal antibody that targets ganglioside GD2 and induces antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity against GD2-expressing tumor cells. It has potential antineoplastic activity. MW: 145.5 KD. Aug 10 2023
A2486 Naxitamab (Anti-GD2) Naxitamab (Anti-GD2) is a humanized monoclonal antibody targeting the disialoganglioside GD2. Naxitamab can be used in research of neuroblastoma, osteosarcoma and other GD2-positive cancers. MW: 145.5 KD. Aug 10 2023
A2487 Volagidemab (Anti-GCGR) Volagidemab (Anti-GCGR) is an antagonistic monoclonal antibody (mAb) that targets glucagon receptor (GCGR). Volagidemab can be used in the research of type 1 diabetes (T1D). MW: 145.5 KD. Aug 10 2023
A2488 Tabituximab (Anti-FZD10) Tabituximab (Anti-FZD10) is a humanized monoclonal antibody that targets frizzled class receptor 10 (FZD10). MW: 145.5 KD. Aug 10 2023
A2489 Vantictumab (Anti-FZD) Vantictumab (Anti-FZD) is a monoclonal antibody targeting the Wnt signaling pathway with potential antineoplastic activity. Vantictumab binds to certain receptors in the Wnt signaling pathway thereby preventing the activation of the Wnt signaling pathway. This results in an inhibition of cancer stem cell (CSC) activity and a subsequent inhibition of cancer cell proliferation. MW: 145.5 KD. Aug 10 2023
A2490 Anti-Fucosyl GM1 Anti-Fucosyl GM1 is a antibody that recognizes and targets the fucosyl form of ganglioside GM1. MW: 145.5 KD. Aug 10 2023
A2491 Mirvetuximab (Anti-FOLR1) Mirvetuximab (Anti-FOLR1) is a monoclonal antibody targeting FOLR1 (folate receptor 1). Mirvetuximab is the antibody moiety of novel folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). MW: 145.2 KD Aug 10 2023
A2492 Farletuzumab (Anti-FOLR1) Farletuzumab (Anti-FOLR1) is a humanized monoclonal antibody with high affinity for FRα. It is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer. MW: 144.12 KD Aug 10 2023
A2493 Anti-FLT3 / CD135 Anti-FLT3 / CD135 (IMC-EB10) is a fully human IgG1 monoclonal antibody, targeting the FLT3 tyrosine kinase receptor (CD135) with potential antineoplastic activity. It binds to FLT3 and blocks FLT3 ligand binding to FLT3 and subsequent FLT3 phosphorylation, which may result in the inhibition of FLT3-mediated signal transduction pathways. MW: 145.5 KD. Aug 10 2023
A2494 Anti-FGFR4 / CD334 Anti-FGFR4 / CD334 (U3-1784) is a human monoclonal antibody targeting FGFR4 (human fibroblast growth factor receptor 4), with potential antineoplastic activity. It blocks activation of FGFR4, which inhibits FGFR4-mediated signaling and leads to an inhibition of cell proliferation in FGFR4-overexpressing tumor cells. MW: 145.5 KD. Aug 10 2023
A2495 Vofatamab (Anti-FGFR3 / CD333) Vofatamab (Anti-FGFR3 / CD333) is a monoclonal antibody targeting FGFR3. Vofatamab blocks activation of both the wildtype and genetically activated receptor. Vofatamab can be used in the research of metastatic urothelial carcinoma (mUC). MW: 145.5 KD. Aug 10 2023
A2496 Anti-FGFR3 / CD333 Anti-FGFR3 / CD333 (LY3076226) is a human monoclonal antibody targeting FGFR3 (fibroblast growth factor receptor type 3). MW: 145.5 KD. Aug 10 2023
A2497 Bemarituzumab (Anti-FGFR2 / CD332) Bemarituzumab (Anti-FGFR2 / CD332) is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research. MW: 145.24 KD. Aug 10 2023
A2498 Aprutumab (Anti-FGFR2 / CD332) Aprutumab (Anti-FGFR2 / CD332) is a fully human FGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has the potential for solid tumors research. MW: 78.2 KD. Aug 10 2023
A2499 Burosumab (Anti-FGF23) Burosumab (Anti-FGF23) is a neutralizing antibody, targeting human fibroblast growth factor 23 (FGF23). It can be used for the research of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia. MW: 145.5 KD. Aug 10 2023
A2500 Rozanolixizumab (Anti-FcRn (FCGRT & B2M)) Rozanolixizumab (Anti-FcRn (FCGRT & B2M)) is a high-affinity humanized monoclonal antibody, targeting human neonatal Fc receptor (FcRn) and is used to the research of reducing pathogenic IgG in autoimmune and alloimmune diseases. MW: 150 KD. Aug 10 2023
A2501 Lumiliximab (Anti-FceR2 / CD23) Lumiliximab (Anti-FceR2 / CD23) is a monoclonal antibody targeting CD23, that inhibits allergen-induced responses. MW: 145.5 KD. Aug 10 2023
A2502 Emicizumab (Anti-F9 / Factor IX) Emicizumab (Anti-F9 / Factor IX) is a bispecific monoclonal antibody that bridges activated factor IX and factor X to replace the function of missing activated factor VIII, thereby restoring hemostasis. Emicizumab can be used for hemophilia A research. MW: 145.5 KD. Aug 10 2023
A2503 Garadacimab (Anti-F12 / Factor XII) Garadacimab (Anti-F12 / Factor XII) is a first-in-class, fully human IgG4 monoclonal antibody targeting activated factor XII (FXIIa). Garadacimab has the potential for hereditary angioedema research. MW: 145.5 KD. Aug 10 2023
A2504 Osocimab (Anti-F11 / Factor XI) Osocimab (Anti-F11 / Factor XI) is an antibody targeting Factor FXI. FXI inhibition may reduce the risk of thrombosis. Osocimab inhibits thrombin generation, and prolongs activated partial thromboplastin time. Osocimab exhibits anticoagulant effects. MW: 145.5 KD. Aug 10 2023
A2505 Anti-ETBR Anti-ETBR (DEDN6526A) is a humanized immunoglobulin (Ig) G1 monoclonal antibody targeting endothelin B receptor (ETBR). MW: 145.5 KD. Aug 10 2023
A2506 Patritumab (Anti-ERBB3 / HER3) Patritumab (Anti-ERBB3 / HER3) is a neutralizing monoclonal antibody targeting ERBB3. Patritumab shows a synergy with Cetuximab (HY-P9905), potently inhibits the phosphorylation of EGFR, HER2, HER3, ERK, and AKT. Patritumab also induces cell apoptosis and suppresses the growth of pancreatic, non-small cell lung cancer, and colorectal cancer xenograft tumors. MW: 145.5 KD. Aug 10 2023
A2511 Anti-EphA2 (MEDI-547) Anti-EphA2 (MEDI-547) is a fully human IgG1 monoclonal antibody that is used for targeting EphA2. It selectively binds to cells expressing the EphA2 receptor. MW: 145.12 KD. Aug 10 2023
A2512 Adecatumumab (Anti-EpCAM / TROP1 / CD326) Adecatumumab (Anti-EpCAM / TROP1 / CD326) is a full human monoclonal antibody of the IgG1 isotype, targeting human EpCAM. Adecatumumab is expressed in almost all adenocarcinomas, and its activity is not dependent of K-Ras status. MW: 145.5 KD. Aug 10 2023
A2513 Anti-ENTPD1 / CD39 Anti-ENTPD1 / CD39 (TTX-030) is a fully human monoclonal antibody directed targeting the cell surface receptor CD39. It specifically binds to the CD39 antigen and inhibits both the conversion of adenosine triphosphate (ATP) to adenosine monophosphate (AMP) and the subsequent generation of immunosuppressive extracellular adenosine in the tumor microenvironment (TME). MW: 145.5 KD. Aug 10 2023
A2514 Carotuximab (Anti-Endoglin / CD105) Carotuximab (Anti-Endoglin / CD105) is a IgG1 monoclonal antibody that blocks endoglin (CD105) and its downstream Smad signaling pathway. Carotuximab has immunomodulatory and antineoplastic actions. MW: 145.5 KD. Aug 10 2023
A2515 Parsatuzumab (Anti-EGFL7) Parsatuzumab (Anti-EGFL7) is a humanized monoclonal antibody targeting EGFL7. Parsatuzumab selectively blocks the interaction between EGFL7 and endothelial cells, potentially inhibiting vascular regrowth and reducing vascular endothelial growth factor (VEGF) inhibition. MW: 145.5 KD. Aug 10 2023
A2516 Anti-EFNA4 Anti-EFNA4 (PF-06647263) is a antibody targeting EFNA4. MW: 145.5 KD. Aug 10 2023
A2517 Begelomab (Anti-DPP4 / CD26) Begelomab (Anti-DPP4 / CD26) is a monoclonal antibody targeting DPP-4/CD26. Begelomab can be used for the research of severe refractory idiopathic inflammatory myopathy. MW: 145.5 KD. Aug 10 2023
A2518 Tamrintamab (Anti-DPEP3) Tamrintamab (Anti-DPEP3) is an ADC Antibody targeting dipeptidase 3 (DPEP3 or MBD3). DPEP3 is a glycosyl phosphatidylinositol anchored metallopeptidase that is overexpressed in ovarian tumors. Tamrintamab can specifically bind DPEP3-expressing cells to produce cytotoxicity. Tamrintamab can be used in ovarian cancer research. MW: 145.5 KD. Aug 10 2023
A2519 Navicixizumab (Anti-DLL4) Navicixizumab (Anti-DLL4) is a bispecific monoclonal antibody targeting DLL4. Navicixizumab can combine with Paclitaxel for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer. MW: 145.5 KD. Aug 10 2023
A2520 Demcizumab (Anti-DLL4) Demcizumab (Anti-DLL4) is a monoclonal antibody taregting DLL4. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models. MW: 145.5 KD. Aug 10 2023
A2521 Rovalpituzumab (Anti-DLL3) Rovalpituzumab (Anti-DLL3) is a humanized monoclonal antibody targeting delta-like protein 3 (DLL3). Rovalpituzumab can be used in the synthesis of antibody-drug conjugate (ADC), Rovalpituzumab Tesirine. Rovalpituzumab has activity against small cell lung cancer (SCLC). MW: 145.5 KD. Aug 10 2023
A2522 Anti-DKK1 Anti-DKK1 (BHQ880) is a humanized monoclonal antibody targeting Wnt antagonist Dickkopf-1 (DKK1). It binds to and inhibits DKK1, enhancing signaling through the Wnt pathway, which result in osteoblast differentiation and activation within the bone matrix and the reversal of tumor-induced osteolytic disease. Aug 10 2023
A2523 Ulocuplumab (Anti-CXCR4 / CD184) Ulocuplumab (Anti-CXCR4 / CD184) is a fully human IgG4 antibody, targeting CXCR4. Ulocuplumab induces apoptosis and inhibits CXCL12 mediated CXCR4 activation-migration of chronic lymphocytic leukemia (CLL). Ulocuplumab exhibits antitumor activity in established tumors including acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma xenograft models. MW: 144.84 KD. Aug 10 2023
A2524 Anti-CXCL8 / IL-8 Anti-CXCL8 / IL-8 (ABX-IL8) is a antibody targeting CXCL8. MW: 145.5 KD. Aug 10 2023
A2525 Eldelumab (Anti-CXCL10 / IP-10) Eldelumab (Anti-CXCL10 / IP-10) is a humanised monoclonal antibody (IgG1 type) targeting CXCL10. Eldelumab selectively binds to CXCL10 and blocks CXCL10-induced calcium flux and cell migration. Eldelumab can be used in studies of autoimmune and auto-inflammatory diseases such as rheumatoid arthritis, ulcerative colitis and crohn's disease. MW: 145.5 KD. Aug 10 2023
A2526 Quetmolimab (Anti-CX3CL1 / Fractalkine) Quetmolimab (Anti-CX3CL1 / Fractalkine) is a humanized monoclonal antibody targeting CX3CL1. MW: 150 KD. Aug 10 2023
A2530 Anti-CSF3 / G-CSF Anti-CSF3 / G-CSF (CSL324) is an antibody targeting CSF3. It is useful for studying growth factor signaling. MW: 145.5 KD. Aug 10 2023
A2531 Anti-CSF2Rb / CD131 Anti-CSF2Rb / CD131 (CSL311) is a monoclonal antibody that targets CSF2Rb and CD131. It is used in treatment of chronic inflammatory diseases where the human βc receptor is central to pathogenesis. MW: 145.5 KD. Aug 10 2023
A2532 Mavrilimumab (Anti-CSF2Ra/GM-CSFRa/CD116) Mavrilimumab (Anti-CSF2Ra/GM-CSFRa/CD116) is a monoclonal antibody that binds to the α subunit of the granulocyte-macrophage colony stimulating factor (GM-CSF) receptor and blocks intracellular signalling downstream of GM-CSF. MW: 145.5 KD. Aug 10 2023
A2533 Otilimab (Anti-CSF2 / GM-CSF) Otilimab (GSK 3196165) is an humanized monoclonal antibody targeting GM-CSF (granulocyte-macrophage colony-stimulating factor). Otilimab neutralises the biological function of GM-CSF by blocking the interaction of GM-CSF with its cell surface receptor. MW: 145.5 KD. Aug 10 2023
A2534 Lacnotuzumab (Anti-CSF1 / M-CSF) Lacnotuzumab (Anti-CSF1 / M-CSF) is a neutralizing humanized IgG1/κ monoclonal antibody targeting CSF-1, that prevents CSF-1 from activating the CSF-1R. Lacnotuzumab can be used for the research of pigmented villonodular synovitis. MW: 150 KD. Aug 10 2023
A2535 Lampalizumab (Anti-Complement Factor D) Lampalizumab (Anti-Complement Factor D) is a humanised monoclonal antibody targeting complement Factor D in the alternative complement pathway. Lampalizumab binds an exosite and sterically blocks Factor B access to the active site. Lampalizumab can be used for age-related macular degeneration (AMD) research. MW: 145.5 KD. Aug 10 2023
A2536 Avdoralimab (Anti-Complement C5aR1) Avdoralimab (Anti-Complement C5aR1) is a fully human IgGκ monoclonal antibody targeting the complement C5a receptor 1 (C5aR1), that prevents its binding to C5a. Avdoralimab can be used for complement-driven inflammatory diseases and solid tumours research. MW: 145.5 KD. Aug 10 2023
A2537 Ravulizumab (Anti-Complement C5) Ravulizumab (Anti-Complement C5) is a humanized monoclonal antibody that specifically binds with high affinity to the human complement protein C5. Ravulizumab can be used for the research of paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis. MW: 145.5 KD. Aug 10 2023
A2538 Eculizumab (Anti-Complement C5) Eculizumab (Anti-Complement C5) is a long-acting humanized monoclonal antibody targeting against complement C5. Eculizumab inhibits the cleavage of C5 into C5a and C5b and hence inhibits deployment of the terminal complement system including the formation of membrane attack complex (MAC). Eculizumab has the potential for haemolysis research. MW: 145.5 KD. Aug 10 2023
A2539 Tesidolumab (Anti-Complement C5) Tesidolumab (Anti-Complement C5) is a fully-human IgG1/λ monoclonal antibody targeting against Complement C5. Tesidolumab blocks cleavage of C5 and prevents subsequent formation of the membrane attack complex. MW: 145.5 KD. Aug 10 2023
A2540 Anti-Complement C3 Anti-Complement C3 (NGM621) is an antibody targeting Complement C3. It binds with high affinity to intact human C3. It is used in the research for treatment of Geographic Atrophy. MW: 145.5 KD. Aug 10 2023
A2541 Anti-Clusterin Anti-Clusterin (AB-16B5) is a humanized IgG2 antibody targeted against clusterin. It is an inhibitor of the epithelial to mesenchymal transition. Anti-Clusterin (AB-16B5) can be used for cancer research. MW: 145.5 KD. Aug 10 2023
A2542 Tepoditamab (Anti-CLEC12A / CD371) Tepoditamab (Anti-CLEC12A / CD371) is a bispecific monoclonal antibody that targets and binds to CLEC12A of myeloid cells and CD3 of cytotoxic T cells. Tepoditamab kills AML leukaemia mother cells and AML leukaemia stem cells, induces T cell-mediated proliferative lysis of AML cells and can be used in acute myeloid leukaemia (AML) research. MW: 145.5 KD. Aug 10 2023
A2543 Tinurilimab (Anti-CEACAM6 / CD66c) Tinurilimab (Anti-CEACAM6 / CD66c) is an monoclonal antibody targeting against CEACAM6 and CD66c. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. MW: 145.5 KD. Aug 10 2023
A2544 Tusamitamab (Anti-CEACAM5 / CEA / CD66e) Tusamitamab (Anti-CEACAM5 / CEA / CD66e) is an IgG1 monoclonal antibody that targets CEACAM5. Tusamitamab can be used to synthesize Tusamitamab ravtansine, which is a first-in-class humanized antibody-drug conjugate (ADC) that combines Tusamitamab and DM4 (a potent maytansine derivative). MW: 145.5 KD. Aug 10 2023
A2545 Anti-CEACAM1 / CD66a Anti-CEACAM1 / CD66a (CM-24) is a humanized monoclonal immunoglobulin G4 (IgG4) antibody targeting CEACAM1 and CD66a, with potential immunomodulating and antineoplastic activities. It blocks the binding of CEACAM1-expressing cancer cells to CEACAM1-expressing immune cells and abrogates CEACAM1-mediated immunosuppression. MW: 145.5 KD. Aug 10 2023
A2546 Actoxumab (Anti-Cdiff Toxin A) Actoxumab ( (Anti-Cdiff Toxin A) is a antitoxin antibody against C. difficile toxin A by neutralizing TcdA. Actoxumab prevents both the damage to the gut wall and the inflammatory response, which are associated with C. difficile. Actoxumab has synergy effect with Bezlotoxumab targeting TcdB. MW: 145.5 KD. Aug 10 2023
A2547 Anti-CDH6 / K-Cadherin Anti-CDH6 / K-Cadherin (DS-6000a) is a humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting against the tumor-associated antigen cadherin-6. MW: 145.5 KD. Aug 10 2023
A2548 Anti-CDH3 / P-cadherin Anti-CDH3 / P-cadherin (PF-03732010) is a antibody targeting p-cadherin. It binds to and inhibits the activity of p-cadherin which may inhibit tumor cell invasion and proliferation in p-cadherin expressing tumor cells. MW: 145.5 KD. Aug 10 2023
A2549 Anti-CD98 Anti-CD98 (KHK2898) is an antibody targeting CD98. MW: 145.5 KD. Aug 10 2023
A2550 Polatuzumab (Anti-CD79b) Polatuzumab (Anti-CD79b) is a monoclonal antibody which targets CD79b that is found on the surface of B cells. Polatuzumab sticks to the CD79b protein and delivers the chemotherapy compound into the cell. MW: 145.5 KD. Aug 10 2023
A2551 Milatuzumab (Anti-CD74) Milatuzumab (Anti-CD74) is a humanized monoclonal antibody targeting CD74, a integral membrane protein. Milatuzumab causes free radical oxygen generation, and loss of mitochondrial membrane potential. Milatuzumaba also decreases CD20/CD74 aggregates and cell adhesion, to lead to cell death. MW:145.5 KD. Aug 10 2023
A2552 Itolizumab (Anti-CD6) Itolizumab (Anti-CD6) is a humanized recombinant anti-CD6 monoclonal antibody (MAb) targeting the extracellular SRCR distal domain 1 of CD6. Itolizumab reduces T-cell proliferation and inhibits the production of pro-inflammatory cytokines, such as INF-γ, TNFα and IL-6. Itolizumab can be used in the research of psoriasis, rheumatoid arthritis, COVID-19. MW:145.5 KD. Aug 10 2023
A2553 Alemtuzumab (Anti-CD52) Alemtuzumab (Anti-CD52) is a humanized monoclonal antibody targeting against CD52. Alemtuzumab selectively targets the CD52 antigen to induce profound lymphocyte depletion, followed by recovery of T and B cells with regulatory phenotypes. MW:145.5 KD. Aug 10 2023
A2554 Anti-CD46 Anti-CD46 (FOR46) is a human monoclonal antibody targeting against CD46. It specifically targets and binds to a specific conformational epitope on the immune modulatory receptor CD46 expressed on certain tumor cells. MW:145.5 KD. Aug 10 2023
A2555 Bivatuzumab (Anti-CD44v6) Bivatuzumab (Anti-CD44v6) is a humanized monoclonal antibody targeting against CD44v6 that could acts as a sarcoma target for CAR-redirected CIK cells. MW:145.5 KD. Aug 10 2023
A2300 Anti-VEGFR3 / FLT4 Anti-VEGFR3 / FLT4 is a fully-human monoclonal antibody directed against (VEGFR-3; Flt-4) with antiangiogenic activity.Anti-VEGFR3 / FLT4 also plays a critical role in the embryonic vascular system development. Aug 10 2023
A2556 Ibalizumab (Anti-CD4) Ibalizumab (Anti-CD4) is a humanised IgG4 monoclonal antibody, targeting C4. It prevents HIV cell entry by binding to CD4 receptor. Ibalizumab has the potential for HIV-1 infection research. MW:145.5 KD. Aug 10 2023
A2301 Icrucumab (Anti-VEGFR1 / FLT1) Icrucumab (Anti-VEGFR1 / FLT1) is a humanized Anti-VEGFR-1 IgG1 monoclonal antibody, with potential anti-tumor and anti-metastatic agent. It also act as a therapeutic anti-angiogenic agent in different pathological contexts. Aug 10 2023
A2557 Teplizumab (Anti-CD3e) Teplizumab (Anti-CD3e) is a Fc receptor non-binding anti-human CD3 monoclonal antibody. Teplizumab reduces the loss of beta-cell function. Teplizumab can be used in the research of type 1 diabetes. MW:145.5 KD. Aug 10 2023
A2302 Anti-VEGFC Anti-VEGFC is a fully human monoclonal antibody targeting the human vascular endothelial growth factor C (VEGFC or Flt4 ligand) with potential antiangiogenic activity and lymphangiogenesis. It also prevent metastasis. MW :145.5 KD. Aug 10 2023
A2303 Anti-VEGFB Anti-VEGFB (CSL346) is an antibody targeting VEGFA. MW:150 KD. Aug 10 2023
A2559 Galiximab (Anti-CD28L / CD80) Galiximab (Anti-CD28L/CD80) is a primatized immunoglobulin G1 (IgG1) lambda monoclonal antibody targeting against the CD80 antigen. Galiximab has variable regions are primatized (cynomologous monkeys), and the constant regions are human. Galiximab can be used in research of B-cell lymphoma. MW:145.5 KD. Aug 10 2023
A2560 Anti-CD28 Anti-CD28 (FR104) is an antibody targeting CD28. MW:145.5 KD. Aug 10 2023
A2305 Ranibizumab (Anti-VEGFA) Ranibizumab (Anti-VEGFA) is a recombinant humanized IgG1 monoclonal antibody fragment that inhibits (VEGF-A) and degrades angiogenesis throughout the body and in the eye also interrupts the interaction of VEGF with its receptors, and thus prevents the subsequent growth of new blood vessels. Aug 10 2023
A2561 Ocrelizumab (Anti-CD20) Ocrelizumab (Anti-CD20) is a recombinant humanized monoclonal IgG1 antibody that selectively targets CD20 antigen present on B-cells. It is used to treat relapsing remitting multiple sclerosis. MW:145.5 KD. Aug 10 2023
A2306 otlertuzumab (Anti-TSPAN26 / CD37) Otlertuzumab (Anti-TSPAN26 / CD37) is a humanized monoclonal antibody and anti-CD37 protein therapeutic. It is a potent monospecific protein used in treatments of refractory follicular non-Hodgkin lymphoma (FL), mantle cell lymphoma (MCL), or Waldenström's macroglobulinaemia (WM) Aug 10 2023
A2562 Siplizumab (Anti-CD2) Siplizumab (Anti-CD2) is a humanized IgG1 monoclonal antibody targeting CD2. Siplizumab depletes T cells, decreases T cell activation, inhibites T cell proliferation and enriches naïve and bona fide regulatory T cells. MW:145.5 KD. Aug 10 2023
A2307 Tezepelumab (Anti-TSLP) Tezepelumab (Anti-TSLP) is a potent human IgG2 monoclonal antibody that inhibits the binding of TSLP to the TSLP receptor, and also has potent efficacy and mechanism in asthma. Aug 10 2023
A2563 Tafasitamab (Anti-CD19) Tafasitamab (Anti-CD19) is an Fc-modified, humanized monoclonal antibody that binds to the human B-cell surface antigen CD19. It is used in combination with allogeneic NK cell therapy in treatment of B-cell non-Hodgkin's lymphoma. MW:145.5 KD. Aug 10 2023
A2308 Anti-TSHR Anti-TSHR are unconjugated polyclonal antibodies derived from rabbi. Anti-TSHR are pathophysiologic, and also increases their significance in the diagnosis of autoimmune thyroid diseases and Graves' disease. Aug 10 2023
A2564 Inebilizumab (Anti-CD19) Inebilizumab (Anti-CD19) is an monoclonal antibody targeting CD19 antigen present on B cells. Inebilizumab can be used for multiple sclerosis and neuromyelitis optica research. MW:145.5 KD. Aug 10 2023
A2309 Flanvotumab (Anti-TRP1 / TYRP1) Flanvotumab (Anti-TRP1 / TYRP1) is a monoclonal antibody directed against the melanosomal membrane protein gp75 (or Tyrosinase-Related Protein 1 (TRP1)) with potential immunostimulatory and antineoplastic activities. MW: 145.5 kD. Aug 10 2023
A2565 Anti-CD163 Anti-CD163 (OR2805) is a human immunoglobulin G1 (IgG1) monoclonal antibody targeting CD163 (scavenger receptor cysteine-rich type 1 protein M130), with potential immunomodulating and antineoplastic activities. It targets and binds to CD163 expressed on immunosuppressive tumor-associated macrophages (TAMs) within the tumor microenvironment (TME), and prevents the binding of CD163 to its ligands. MW:145.5 KD. Aug 10 2023
A2566 Atibuclimab (Anti-CD14) Atibuclimab (Anti-CD14) is a chimeric monoclonal antibody targeting CD14 and is composed of murine variable and human IgG4 Fc regions. Atibuclimab attenuates LPS-induced symptoms and strongly inhibits LPS-induced proinflammatory cytokine release, while only delaying the release of the anti-inflammatory cytokines soluble TNF receptor type I and IL-1 receptor antagonist. MW:145.5 KD. Aug 10 2023
A2311 Anti-TrkA / NTRK1 Anti-TrkA / NTRK1 is a non-conjugated, rabbit-derived monoclonal antibody targeting TrkA. MW : 145.5 KD. Aug 10 2023
A2312 Vorsetuzumab (Anti-TNFSF7 / CD27L / CD70) Vorsetuzumab (Anti-TNFSF7 / CD27L / CD70) is a humanized monoclonal antibody that specifically recognizes and binds to CD70 molecular. Vorsetuzumab enhances macrophage-related phagocytosis of renal carcinoma cells and shows inhibitory efficacy against Burkitt’s lymphoma. MW : 150 kDa. Aug 10 2023
A2568 Mogamulizumab (Anti-CCR4 / CD194) Mogamulizumab (Anti-CCR4 / CD194) is a defucosylated humanized recombinant monoclonal antibody targeting CCR4. Mogamulizumab can eliminate tumor cells by antibody-dependent cellular cytotoxicity (ADCC). Mogamulizumab can be used in the research of cancers, adult T-cell leukemia/lymphoma (ATLL), cutaneous T-cell lymphoma (CTCL). MW:145.5 KD. Aug 10 2023
A2313 Dapirolizumab (Anti-TNFSF5 / CD40L / CD154) Dapirolizumab (Anti-TNFSF5 / CD40L / CD154) is a humanized immunoglobulin monoclonal antibody that targets TNFSF5. MW : 150 kDa. Aug 10 2023
A2569 Plozalizumab (Anti-CCR2 / CD192) Plozalizumab (Anti-CCR2 / CD192) is a specific humanized monoclonal antibody targeting CCR2. Plozalizumab can be used for malignant melanoma research. MW:145.5 KD. Aug 10 2023
A2314 Oxelumab (Anti-TNFSF4 / OX40L / CD252) Oxelumab (Anti-TNFSF4 / OX40L / CD252) is a human monoclonal antibody against the OX40 ligand (OX40L) with the potential to be used for asthma research. MW : 145.5 kDa. Aug 10 2023
A2571 Anti-CCL5 / RANTES Anti-CCL5 / RANTES (NI-0701) is a antibody tageting CCL5. MW:145.5 KD. Aug 10 2023
A2316 Belimumab (Anti-TNFSF13B / BAFF / CD257) Belimumab (Anti-TNFSF13B / BAFF / CD257) is a human IgG1λ monoclonal antibody that inhibits B-cell activating factor (BAFF). Belimumab can be used for systemic lupus erythematosus (SLE) research. MW : 144.56 kDa. Aug 10 2023
A2572 Anti-CCL20 Anti-CCL20 (GSK3050002) is a humanized IgG1κ antibody with high binding affinity to the human chemokine, CCL20. MW:145.5 KD. Aug 10 2023
A2317 Sibeprenlimab (Anti-TNFSF13 / APRIL / CD256) Sibeprenlimab (Anti-TNFSF13 / APRIL / CD256) is a fully humanized IgG2κ monoclonal antibody that targets the B-cell growth factor APRIL (TNFSF13), with the potential to treat IgA nephropathy (IgAN). MW : 145.5 KD. Aug 10 2023
A2573 Carlumab (Anti-CCL2 / MCP1) Carlumab (Anti-CCL2 / MCP1) is a humanised monoclonal antibody targeting CCL2 with high affinity. Carlumab can be used in cancer research, particularly in prostate cancer. MW:145.5 KD. Aug 10 2023
A2318 Anti-TNFSF12 / TWEAK Anti-TNFSF12 / TWEAK is a humanized monoclonal antibody directed against the apoptotic ligand TNF-like weak inducer of apoptosis (TWEAK) with potential antineoplastic activity. It is used to treat renal interstitial fibrosis. MW : 145.5 KD. Aug 10 2023
A2574 Nimacimab (Anti-CB1 / CNR1) Nimacimab (Anti-CB1/CNR1) is a negative-allosteric modulating monoclonal antibody targeting CB1 receptor. Nimacimab can be used for research of metabolic diseases. MW:145.5 KD. Aug 10 2023
A2575 Anti-CB1 / CNR1 Anti-CB1 / CNR1 (GFB-024) is a recombinant humanised monoclonal antinody that is used for targeting of CB1 receptor. MW:145.5 KD. Aug 10 2023
A2320 Pateclizumab (Anti-TNFSF1 / TNFb) Pateclizumab (Anti-TNFSF1 / TNFb) is a humanized monoclonal antibody that blocks and depletes anti-lymphotoxin α (LTα). It has a great potential for the treatment of rheumatoid arthritis (RA). MW : 145.5 KD. Aug 10 2023
A2576 Erenumab (Anti-CALCRL / CGRPR) Erenumab (Anti-CALCRL/CGRPR) is a fully human monoclonal antibody targeting CGRP receptor (calcitonin gene–related peptide receptor). Erenumab can be used for the prevention of episodic migraine. MW:145.5 KD. Aug 10 2023
A2321 Urelumab (Anti-TNFRSF9 / 4-1BB / CD137) Urelumab (Anti-TNFRSF9 / 4-1BB / CD137) is a fully human agonistic monoclonal antibody targeting the CD137 receptor with potential immunostimulatory and antineoplastic activities. MW : 146.5 KD. Aug 10 2023
A2577 Galcanezumab (Anti-CALCA / CGRP) Galcanezumab (Anti-CALCA/CGRP) is a humanized IgG4 monoclonal antibody targeting the CGRP ligand. Galcanezumab can be used for migraine or cluster headaches research. MW:145.5 KD. Aug 10 2023
A2322 Brentuximab (Anti-TNFRSF8 / CD30) Brentuximab (Anti-TNFRSF8 / CD30) is a chimeric monoclonal antibody targeting anti-CD30 with antineoplastic activity. It has the potential to alter the disease course of non-MF/SS CTCLs. MW : 145.38 KD. Aug 10 2023
A2578 Girentuximab (Anti-CA9 / Carbonic anhydrase 9) Girentuximab (Anti-CA9 / Carbonic anhydrase 9) is a chimeric monoclonal antibody that targets and binds to carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC). MW:145.5 KD. Aug 10 2023
A2323 Varlilumab (Anti-TNFRSF7 / CD27) Varlilumab (Anti-TNFRSF7 / CD27) is a human monoclonal antibody with activity against the CD27 receptor. It exhibits potential immunostimulating and antineoplastic activity. MW : 150 KD. Aug 10 2023
A2579 Sutimlimab (Anti-C1s) Sutimlimab (Anti-C1s) is a humanized monoclonal antibody that targets the C1s protein in the classical complement pathway. It can be used for the research of cold agglutinin disease. C1s is a serine protease which cleaves C4 and C2 to form the C3 convertase. MW:145.5 KD. Aug 10 2023
A2324 Iscalimab (Anti-TNFRSF5 / CD40) Iscalimab (Anti-TNFRSF5 / CD40) is a non-depleting IGg1 monoclonal antibody targeting CD40. Iscalimab can be used for research on Graves' hyperthyroidism and autoimmune diseases. MW : 145.5 KD. Aug 10 2023
A2580 Anti-C1q Anti-C1q (ANX005) is a recombinant antibody against C1q. It inhibits its function as the initiating molecule of the classical complement cascade. It is used in research of autoimmune and neurodegenerative diseases. MW:145.5 KD. Aug 10 2023
A2325 Vonlerizumab (Anti-TNFRSF4 / OX40 / CD134) Vonlerizumab (Anti-TNFRSF4 / OX40 / CD134) is a monoclonal antibody targeting TNFRSF4. MW : 145.5 KD. Aug 10 2023
A2581 Icatolimab (Anti-BTLA / CD272) Icatolimab (Anti-BTLA / CD272) is a recombinant human monoclonal antibody which targets human BTLA protein. It neutralizes the interaction between BTLA and HVEM(Herpesvirus entry mediator). MW :145.5 KD. Aug 10 2023
A2326 Telazorlimab (Anti-TNFRSF4 / OX40 / CD134) Telazorlimab (Anti-TNFRSF4 / OX40 / CD134) is a humanized monoclonal antibody against the OX40 costimulatory receptor on activated T cells. Telazorlimab can be used for research on autoimmune diseases. MW : 145.5 KD. Aug 10 2023
A2582 Onvatilimab (Anti-B7-H5 / VISTA) Onvatilimab (Anti-B7-H5 / VISTA) is a human IgG1κ monoclonal antibody that targets and bind to VISTA (V-domain immunoglobulin (Ig) suppressor of T-cell activation). It has an anti-tumor activity. MW : 150 KD. Aug 10 2023
A2327 Ragifilimab (Anti-TNFRSF18 / GITR / CD357) Ragifilimab (Anti-TNFRSF18 / GITR / CD357) is an anti-human glucocorticoid-induced tumor necrosis factor receptor (tumor necrosis factor superfamily, member 18; TNFRSF18; GITR; CD357) agonistic humanized monoclonal antibody with potential immune checkpoint modulating activity. MW : 145.5 KD. Aug 10 2023
A2583 Prezalumab (Anti-B7-H2 / ICOSL / CD275) Prezalumab (Anti-B7-H2 / ICOSL / CD275) is a human IgG2 monoclonal antibody targeting ICOSL and BAFF. It demonstrates studies for systemic lupus erythematosus arthritis. It is used in the research of Sjogren's syndrome cutaneous lupus erythematosus, psoriasis and systemic lupus erythematosus (SLE).MW :145.5 KD. Aug 10 2023
A2328 Belantamab (Anti-TNFRSF17 / BCMA / CD269) Belantamab (Anti-TNFRSF17 / BCMA / CD269) is a humanized monoclonal antibody directed against the B-cell maturation antigen (BCMA) that can be used in the synthesis of an antibody-drug conjugate (ADC), Belantamab mafodotin. MW : 145.5 KD. Aug 10 2023
A2329 Ianalumab (Anti-TNFRSF13C / BAFFR / CD268) Ianalumab (Anti-TNFRSF13C / BAFFR / CD268) is a fully human combinatorial antibody library (HuCAL)-derived monoclonal antibody targeting the B-cell-activating factor receptor (BAFF-R), with potential anti-inflammatory and antineoplastic activities. MW : 145.5 KD. Aug 10 2023
A2330 lexatumumab (Anti-TNFRSF10B / TRAILR2 / CD262) Lexatumumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a human agonistic TRAIL receptor 2 (TRAIL-R2, DR5, APO-2) IgG4κ type monoclonal antibody. Lexatumumab induces apoptosis in malignant mesothelioma. MW : 145.5 KD. Aug 10 2023
A2586 Enapotamab (Anti-AXL / UFO) Enapotamab(Anti-AXL / UFO) is a highly specific rabbit polyclonal antibody that targets receptor tyrosine kinase AXL (UFO). It demonstrates potent activity in immunotherapeutic strategy for the treatment of sarcomas. MW :145.42 KD. Aug 10 2023
A2331 Conatumumab (Anti-TNFRSF10B / TRAILR2 / CD262) Conatumumab (Anti-TNFRSF10B / TRAILR2 / CD262) is a human monoclonal agonist antibody against human death receptor 5 (DR5, TRAILR2) with a Kd of 1 nM and 0.8 nM for the long form and the short form of DR5, respectively. Conatumumab induces apoptosis via caspase activation. MW : 144.96 KD. Aug 10 2023
A2332 Mapatumumab (Anti-TNFRSF10A / TRAILR1 / CD261) Mapatumumab (Anti-TNFRSF10A / TRAILR1 / CD261) is a fully human IgG1 agonistic monoclonal antibody that targets tumor necrosis factor-related apoptosis-inducing ligand receptor 1 (TRAIL-R1) with apoptosis promoting and potential antitumor activities. MW : 145.5 KD. Aug 10 2023
A2588 Aducanumab (Anti-Amyloid Beta) Aducanumab (Anti-Amyloid Beta) is a selective human monoclonal antibody targeting aggregated forms of amyloid beta (Aβ). Aducanumab shows brain penetration, and can be used for Alzheimer's disease (AD) research.MW :145.5 KD. Aug 10 2023
A2333 Tomaralimab (Anti-TLR2 / CD282) Tomaralimab (Anti-TLR2 / CD282) is a humanized immunoglobulin (Ig) G4 monoclonal antibody directed against toll-like receptor type 2 (TLR2) with potential anti-inflammatory and antineoplastic activities. It has the potential for research on Myelodysplastic Syndromes (MDS). MW : 145.5 KD. Aug 10 2023
A2589 Birtamimab (Anti-Amyloid Alpha) Birtamimab(Anti-Amyloid Alpha) is an investigational monoclonal antibody that specifically and selectively targets and clear the amyloid. It can be used for treatment to remove amyloid from the vital organs, and research of light chain amyloidosis.MW :145.5 KD. Aug 10 2023
A2334 Tisotumab (Anti-Tissue factor / CD142) Tisotumab (Anti-Human F3 Recombinant Antibody) is a human IgG1 monoclonal antibody that targets tissue factor (TF). Tisotumab can be used for the research of solid tumors. MW : 145.5 KD. Aug 10 2023
A2590 Murlentamab (Anti-AMHR2) Murlentamab (Anti-AMHR2) is a humanized anti-AMHRII antibody targeting AMHRII. It suppresses tumor growth, stimulates the anti-tumor adaptive immune response through naive macrophage orientation and TAM reprogrammation, in ovarian tumor cells. MW :145.5 KD. Aug 10 2023
A2591 Cinpanemab (Anti-Alpha-synuclein) Cinpanemab(Anti-Alpha-synuclein) is a human-derived monoclonal antibody that targets and binds to α-synuclein. It can be used for the research of Parkinson's disease. MW : 146.98 KD. Aug 10 2023
A2336 Fresolimumab (Anti-TGFb1) Fresolimumab (Anti-TGFb1) is a pan-specific, recombinant, fully human monoclonal antibody directed against human transforming growth factor (TGF) beta 1, 2, and 3 with potential antineoplastic activity. MW : 145.5 KD. Aug 10 2023
A2592 Praluzatamab (Anti-ALCAM / CD166) Praluzatamab (Anti-ALCAM / CD166) is a monoclonal antibody targeting the activated leukocyte cell adhesion molecule (ALCAM/CD116). It can be used to synthesize Praluzatamab ravtansine (antibody-drug conjugates)which is used for research of cancers. MW : 150 KD. Aug 10 2023
A2337 Concizumab (Anti-TFPI) Concizumab (Anti-TFPI) is an anti-TFPI monoclonal antibody (IgG4 type) that binds to the Kunitz-type protease inhibitor (KPI) 2 structural domain of TFPI, thereby blocking the interaction of this structural domain with the FXa active site. MW : 145.5 KD. Aug 10 2023
A2593 Enibarcimab (Anti-Adrenomedullin) Enibarcimab (Anti-Adrenomedullin) is a humanised murine monoclonal immunoglobulin G1 (IgG1) antibody targeting the vasoprotective peptide adrenomedullin. It can be used for acute heart failure, COVID-19 infections and septic shock research. MW : 145.5 KD. Aug 10 2023
A2338 Ontuxizumab (Anti-TEM1 / Endosialin / CD248) Ontuxizumab (Anti-TEM1/endosialin/ CD248) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with potential anti-angiogenic and antineoplastic activities. MW : 145.5 KD Aug 10 2023
A2594 Ascrinvacumab (Anti-ACVRL1 / ALK-1) Ascrinvacumab (Anti-ACVRL1 / ALK-1) is a human IgG2 monoclonal antibody targeting ALK-1. It can be used for the treatment of hepatocellular carcinoma (HCC), in patients with advanced solid tumors. It also demonstrates its use in antiangiogenic therapy. MW : 150 KD. Aug 10 2023
A2339 Anti-TCR Anti-TCR is a monoclonal antibody targeting TCR. MW : 145.5 KD. Aug 10 2023
A2595 Bimagrumab (Anti-ACVR2B) Bimagrumab (Anti-ACVR2B) is a human monoclonal antibody targeting activin type II receptor (ActRII). It can be used for the treatment of pathological muscle loss and weakness. MW : 150 KD. Aug 10 2023
A2340 Anti-TBFbR2 Anti-TBFbR2 is a monoclonal antibody directed against transforming growth factor-beta receptor type II (TGF-beta RII) with potential antineoplastic activity. MW : 145.5 KD  Aug 10 2023
A2341 Zagotenemab (Anti-Tau) Zagotenemab (Anti-Tau) is a humanised anti-tau antibody that selectively binds and neutralises tau deposits in the brain. It has the potential to be used in Alzheimer's disease research. MW : 145.5 KD Aug 10 2023
A2342 Indatuximab (Anti-Syndecan-1 / CD138) Indatuximab (Anti-Syndecan-1/CD138) is an antibody against Syndecan-1. MW : 145.5 KD Aug 10 2023
A2343 Vandortuzumab (Anti-STEAP1) Vandortuzumab (Anti-STEAP1) is a recombinant monoclonal antibody that specifically targets STEAP1. It has potential for the treatment of prostate cancer. MW : 145.5 KD. Aug 10 2023
A2344 Bexmarilimab (Anti-STAB1) Bexmarilimab (Anti-STAB1) is a monoclonal antibody directed against common lymphatic endothelial and vascular endothelial receptor-1 (CLEVER-1; stabilin-1; FEEL-1) with an IC50 value of 4.51 nM and potential immunomodulatory and antineoplastic activities. MW : 145.5 KD. Aug 10 2023
A2345 Sonepcizumab (Anti-Sphingosine-1-phosphate) Sonepcizumab (Anti-Sphingosine-1-phosphate) is a humanized monoclonal antibody directed against sphingosine 1-phosphate (S1P) with potential antiangiogenic and antineoplastic activities. MW : 145.5 KD. Aug 10 2023
A2347 Sirtratumab (Anti-SLITRK6) Sirtratumab (Anti-SLITRK6) is a humanized Igγ2 monoclonal antibody against SLIT and NTRK-like family 6 (Slitrk6). MW : 145.5 KD. Aug 10 2023
A2348 Anti-SLC44A4  Anti-SLC44A4 is a fully human IgG2k monoclonal antibody targeting SLC44A4 (AGS-5) with potential antineoplastic activity. MW : 145.5 KD. Aug 10 2023
A2349 Anti-SLC40A1 Anti-SLC40A1 is a monoclonal antibody targeting SLC40A1. It has the potential to do research on mineral absorption, insulin receptor recycling, and transmembrane transporter activity. MW : 145.5 KD. Aug 10 2023
A2350 Lifastuzumab (Anti-SLC34A2) Lifastuzumab (Anti-SLC34A2) is a humanized monoclonal antibody targeting NaPi2b. MW : 145.5 KD. Aug 10 2023
A2351 Upifitamab (Anti-SLC34A2) Upifitamab (Anti-SLC34A2) is a humanized monoclonal antibody targeting NaPi2b. Upifitamab can be used to synthesize an ADC compound, Upifitamab rilsodotin, used in ovarian cancer research, particularly in platinum-resistant recurrent ovarian cancer. MW : 145.5 KD. Aug 10 2023
A2352 Idactamab (Anti-SLC1A5 / ASCT2) Idactamab (Anti-SLC1A5 / ASCT2) is an IgG1-κ antibody with in vivo activity across a spectrum of hematological malignancies. Idactamab can be used to prepare MEDI7247, a potent and specific ADC targeting ASCT2 (SLC1A5). MW : 145.5 KD. Aug 10 2023
A2354 Anti-SLAMF6 / CD352  Anti-SLAMF6 / CD352 is a humanized monoclonal antibody (EC-mAb) targeting CD352 (SLAM family member 6; SLAM6) with potential antineoplastic activity. MW : 145.5 KD Aug 10 2023
A2355 Anti-SIRPg Anti-SIRPg is a recombinant human antibody that act againts anti-SIRPG (anti-Signal-Regulatory Protein Gamma). MW : 145.5 KD Aug 10 2023
A2356 Refanezumab (Anti-Siglec-4a / MAG) Refanezumab (Anti-Siglec-4a / MAG) is an IgG1-type humanized monoclonal antibody directed against myelin-associated glycoprotein (MAG). Refanezumab binds to MAG and blocks MAG-mediated inhibition of axonal regeneration. MW : 145.5 KD Aug 10 2023
A2357 Vadastuximab (Anti-Siglec-3 / CD33) Vadastuximab (Anti-Siglec-3 / CD33) is a humanized monoclonal antibody targeting CD33. Vadastuximab can be used to synthesize an ADC compound, Vadastuximab talirine. MW : 150 KD. Aug 10 2023
A2358 Inotuzumab (Anti-Siglec-2 / CD22) Inotuzumab (Anti-Siglec-2 / CD22) is a humanized IgG4, κ monoclonal antibody that targets CD22. Inotuzumab can be used for the research of acute lymphoblastic leukaemia and non-Hodgkin lymphoma. MW : 144.78 kD. Aug 10 2023
A2359 Anti-Sialyl-Lewis A Anti-Sialyl-Lewis A is a human monoclonal antibody against the carbohydrate antigen sialyl-Lewis A (carbohydrate antigen 19-9; CA19-9) with potential antineoplastic activity.MW : 145.5 kD. Aug 10 2023
A2360 Dezamizumab (Anti-Serum Amyloid P / SAP) Dezamizumab (Anti-Serum Amyloid P / SAP) is a fully humanized recombinant monoclonal IgG1 anti-serum amyloid P component (SAP) antibody with potential anti-amyloid activity. MW : 144.18 kD. Aug 10 2023
A2361 Pepinemab (Anti-SEMA4D / CD100) Pepinemab (Anti-SEMA4D / CD100) is a human monoclonal antibody against SEMA4D, a signalling protein 4D (SEMA4D), which is a regulator of neuronal development and plays a role in a variety of cellular processes. MW : 145.5 kD. Aug 10 2023
A2362 Anti-SCFR / c-Kit / CD117 Anti-SCFR / c-Kit / CD117 is a humanized monoclonal antibody against the stem cell factor receptor c-Kit (SCFR) with potential antineoplastic activity. MW : 150 kD. Aug 10 2023
A2363 Anti-RTN4 / NOGO Anti-RTN4 / NOGO is an antibody acting against anti-RTN4. MW : 145.4 kD. Aug 10 2023
A2364 Palivizumab (Anti-RSV-F) Palivizumab (Anti-RSV-F) is a humanized monoclonal antibody against the fusion protein (F protein) of human respiratory syncytial virus (RSV), with prophylactic application in respiratory syncytial virus infections. MW : 145.5 kD. Aug 10 2023
A2365 Rosmantuzumab (anti-RSPO3) Rosmantuzumab (OMP-131R10) is an immunoglobulin (Ig) G1 humanized monoclonal antibody targeting human R-spondin 3 (RSPO3) with potential immunostimulating and antineoplastic activities. MW: 145.5 kD. Aug 10 2023
A2366 Zilovertamab (Anti-ROR1) Zilovertamab (Anti-ROR1) is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling with potential antineoplastic activity. MW: 145.5 kD. Aug 10 2023
A2367 Anti-ROBO1(Asclepius Technology patent anti-Robo1 CAR) Anti-ROBO1 (Asclepius Technology patent anti-Robo1 CAR) is a bispecific antigen-binding construct targeting ROBO1, with a single-chain variable region antibody fragment ScFV binding to the surface antigen of immune cells and a Slit2D2 protein fragment binding to the surface antigen Robo1 of tumour cells.MW: 145.5 kD. Aug 10 2023
A2368 Roledumab (Anti-RHD / CD240d) Roledumab (Anti-RHD / CD240d) is a human recombinant monoclonal anti-RhD antibody with the potential to prevent RhD allo-immunization. MW: 145.5 kD. Aug 10 2023
A2369 Anti-RGMC / HFE2 Anti-RGMC / HFE2 is a humanized monoclonal antibody directed against the bone morphogenetic proteins (BMPs) co-receptor hemojuvelin (HJV) with potential to treat anemia of inflammation and other forms of anemia. MW: 145.5 kD. Aug 10 2023
E1428 Mps1-IN-6 (Compound 9) Mps1-IN-6 (Compound 9) is a potent Mps1 inhibitor with IC50 of 6.4 nM. It also exhibits antiproliferative and anti-tumor activity in breast cancer cells. Aug 10 2023
E2978 TMRE TMRE (Tetramethylrhodamine ethyl ester perchlorate, TMRE perchlorate) is a non-cytotoxic cell-permeant fluorogenic dye most commonly used to assess mitochondrial function using live cell fluorescence microscopy and flow cytometry. Aug 09 2023
E1375 JKE-1674 JKE-1674 is an analog of ML-210 in which the nitroisoxazole ring is replaced with an α-nitroketoxime. It is an orally active inhibitor of glutathione peroxidase 4 (GPX4) and also is an active metabolite of GPX4 inhibitor ML-210. JKE-1674 can convert into a nitrile oxide JKE-1777. Aug 06 2023
E1432 TPH104m TPH104m is a thienopyrimidine-hydrazinyl analog that inhibits Drp1 phosphorylation and induces non-apoptotic TNBC cell death. It also significantly inhibits TNBC proliferation. Aug 06 2023
E1353 AZD1656 AZD1656 is a potent, selective and orally active activator of glucokinase. AZD1656 has the potential for type 2 diabetes research. Aug 03 2023
E1503 TRC102 (methoxyamine hydrochloride) TRC102 (methoxyamine hydrochloride, O-Methylhydroxylamine hydrochloride) is a reagent used for the preparation of O-methyl oximes or the synthesis of O-methyl oximes from aldehydes. Aug 02 2023
E1381 NX-2127 NX-2127 is a unique, potent inhibitor of BTK that prevents its functions by catalyzing the ubiquitylation and proteasomal degradation of BTK rather than via direct binding. NX-2127 stimulates T cell activation and increases IL-2 production in primary human T Cells. Aug 02 2023
E1141 KI696 KI696 is a potent and selective inhibitor of KEAP1/NRF2 interaction. KI696 induces the expression of each of the Nqo1, Ho-1, Txnrd1, Srxn1, Gsta3, Gclc genes in a dose-dependent manner. Aug 02 2023
E2995 Formamide deionized Formamide deionized(Methanamide, Formimidic acid) is a clear liquid amide derived from formic acid that serves as an essential solvent for catalytic hydrogenation reactions and acts as a reagent in the creation of diverse organometallic compounds. Aug 01 2023
E1485 IDE397 (GSK-4362676) IDE397 (GSK-4362676) is a potent inhibitor of MAT2A(methionine adenosyltransferase 2A) and exhibits anti-tumor activity in MTAP-deleted PDX models. Jul 31 2023
E1261 Chroman 1 Chroman 1 is a highly potent and selective ROCK inhibitor with IC50 of 1 pM and 52 pM against ROCK2 and ROCK1, respectively. Chroman 1 also inhibits the activity of MRCK with IC50 of 150 nM. Jul 31 2023
E2982 IFN alpha-IFNAR-IN-1 hydrochloride IFN alpha-IFNAR-IN-1 hydrochloride is a nonpeptidic, low-molecular-weight inhibitor that inhibits the interaction between IFN-α and IFNAR. IFN alpha-IFNAR-IN-1 hydrochloride inhibits modified Vaccinia virus ankara (MVA)-induced IFN-α responses in murine bone-marrow-derived, Flt3- L-differentiated pDC cultures (BM-pDCs) with IC50 value of 2-8 μM. Jul 27 2023
E1389 Eeyarestatin I Eeyarestatin I is a potent inhibitor of endoplasmic reticulum-associated protein degradation (ERAD). Eeyarestatin I also inhibits Sec61 translocon. Jul 27 2023
E1406 CRCD2 CRCD2 is an NT5C2 (cytosolic 5’ nucleotidase II) inhibitor with a kd of 70.9 μM. It enhances the cytotoxic effects of 6-MP and effectively reverses thiopurine resistance mediated by genetic and non-genetic mechanisms of NT5C2 activation in ALL. Jul 27 2023
E1427 MRT-2359 MRT-2359 is a potent degrader of GSPT1. It exhibits anti-tumor activity in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) cells. Jul 27 2023
S9468 Colestipol Hydrochloride Colestipol hydrochloride, a salt form of Colestipol, is a high-molecular-weight, insoluble, granular copolymer of tetraethylenepentamine and epichlorohydrin. It functions as an anion-exchange and resin-sequestering agent. Colestipol hydrochloride reduces cholesterol levels without affecting triglycerides. Jul 27 2023
E2988 Sulfosuccinimidyl oleate sodium Sulfosuccinimidyl oleate sodium (Sulfo-N-succinimidyl oleate sodium) is a long chain fatty acid that inhibits fatty acid transport into cells. Sulfosuccinimidyl oleate sodium is a potent and irreversible inhibitor of mitochondrial respiratory chain with IC50 of 4 μM. It inhibits CD36 mediated LCFA transport. It exhibits anti-inflammatory effect. Jul 26 2023
E2945 TMRM Perchlorate TMRM Perchlorate (T668) is a membrane-permeant, cationic, fluorescent dye that can label mitochondria and mark embryonic stem cell/induced pluripotent stem cell-derived cardiomyocytes. It is useful for the isolation of mature cardiomyocytes. It is also used as a sensitive probe for the detection of mitochondrial membrane potential. Jul 25 2023
E0162 Cupric sulfate Cupric sulfate (Copper(II) sulfate) is a salt formed by treating cupric oxide with sulfuric acid. Cupric sulfate is a lewis acid catalyst commonly used to promote acid-catalyzed organic transformations. Jul 25 2023
E2939 Didox Didox (3,4-dihydroxy-benzohydroxamic acid) is a synthetic ribonucleotide reductase (RR) inhibitor derived from polyhydroxy-substituted benzohydroxamic acid. Didox inhibits proliferation of tamoxifen-resistant breast cancer cells. Jul 23 2023
E1395 GW806742X GW806742X, is a potent inhibitor of MLKL (Mixed Lineage Kinase Domain-Like protein), and binds to the MLKL pseudokinase domain with a Kd of 9.3 μM. GW806742X retards MLKL membrane translocation and inhibits necroptosis. Jul 23 2023
E1484 PDS-0330 PDS-0330 is an inhibitor of Claudin-1, which inhibits claudin1-mediated signalling by interfering with its binding to Src. PDS-0330 exhibits an antitumor effect and enhances apoptosis in colorectal cancer cells. Jul 20 2023
E2948 β-Amyloid (25-35) β-Amyloid (25-35) (Amyloid beta-peptide (25-35), Aβ25-35, β-Amyloid peptide (25-35)) , a sequence GSNKGAIIGLM, is a highly toxic synthetic derivative of Amyloid beta-peptide (Aβ-peptides) which forms fibrillary aggregates. β-Amyloid (25-35) is involved in the pathogenesis of Alzheimer's disease. Jul 20 2023
E1322 GS-4224 GS-4224 (Evixapodlin, PD-1/PD-L1-IN 7) is an inhibitor of human PD-1/PD-L1 protein/protein interaction with an IC50 of 0.213 nM. It enhances IFN-γ and Granzyme B Production in chronic hepatitis B (CHB) CD8+ T Cells and CD4+ T Cells. It exhibits anticancer and antiviral functions. Jul 16 2023
E2958 Toluidine Blue O Toluidine Blue O (Toluidine Blue) is a thiazine dye of the quinone-imine family and is cationic in nature. Toluidine Blue O along with light-emitting diode has been used as a photosensitizer to control in vitro biofilms and to kill gram-negative bacteria. Toluidine Blue has wide applications in vital staining in living tissues and used as a special stain. Jul 13 2023
E1411 Tuvusertib Tuvusertib (M1774, ATR inhibitor 1) is a potent ATR inhibitor, which exhibits anti-proliferative and anti-tumor effects in cancer cell lines. Jul 13 2023
E2947 Recilisib Recilisib (ON01210, EX-RAD) is a radioprotectant that activates the activity of AKT and PI3K in cells. It has been studied as prophylactic (use prior to radiation exposure) and therapeutic (after exposure to radiation) drug. Jul 09 2023
E2970 Gramicidin Gramicidin from Bacillus aneurinolyticus (Bacillus brevis) is an antimicrobial peptide that destroys gram-positive bacteria. It inhibits the growth of bacteria by forming pores and channels in the cell wall, which increase its permeability to monovalent cations. Jul 06 2023
E2980 4-AMino-1-phenylpyrazolo[3,4-d]pyriMidine 4-AMino-1-phenylpyrazole[3,4-d]pyriMidine(PP 3) is an EGFR tyrosine kinase inhibitor with an IC50 of 2.7 μM. It is a negative control for the Src kinase inhibitor, PP 2. Jul 05 2023
E2965 4-Nitrophenyl-2-acetamido-2-deoxy-β-D-glucopyranoside 4-Nitrophenyl-2-acetamido-2-deoxy-β-D-glucopyranoside is a useful substrate for rapid colorimetric assay of N-acetyl-b-glucosaminidase activity in human urine. Chromogenic β-Glucosaminidase substrate yielding a yellow solution upon cleavage, employed particularly in yeasts and molds. Jul 05 2023
E2994 Sodium hydroxide Sodium hydroxide (NaOH) is a caustic reagent that is widely used to neutralize acids and prepare sodium salts of reagents. It is used in various industries, including textiles, drinking water, soaps and detergents, pulp and paper manufacturing, and as a drain cleaner.This product is a hazardous chemical (acute toxicity/flammable/skin corrosive). Please use it while wearing a protective face mask, gloves, and clothing. Jul 05 2023
E1267 MDL-800 MDL 800 is an allosteric activator of sirtuin 6 (SIRT6). It selectively activates SIRT6 deacetylase activity over SIRT1-5 and -7 and histone deacetylase 1 (HDAC1) and HDAC2-11 deacetylase activity in cell-free assays at 100 µM. It induces histone deacetylation, and reduces proliferation of BEL-7405 hepatocellular carcinoma (HCC) cells with EC50 of 90.4 µM. Jul 03 2023
E2957 N-Dodecyl beta-D-maltoside N-Dodecyl-β-D-maltoside (Lauryl Maltoside) is a derivatives of pyrene (Py). It is alkyl maltopyranoside detergent, especially in transporters and respiratory complexes. N-Dodecyl-β-D-maltoside has also been employed in applications such as in the purification and stabilization of RNA polymerase and detection of protein-lipid interactions. Jul 03 2023
E2993 Ruthenium Red Ruthenium red (Ammoniated ruthenium oxychloride) is a polycationic dye, which is a L-type calcium current (ICa) blocker. It is widely used for electron microscopy (EM) of cells, tissues and vegetative bacteria. Ruthenium red strongly reacts with phospholipids and fatty acids and binds to acidic mucopolysaccharides. Jul 03 2023
E1376 MitoSOX Red MitoSOX Red is a modified dihydroethidium (DHE) analog derived by the addition of a triphenylphosphonium group. It is a fluorescent probe used for imaging superoxide in the mitochondria of living cells. Jul 02 2023
E2971 Influenza Hemagglutinin (HA) Peptide Influenza Hemagglutinin (HA) Peptide is a synthetic peptide with an amino acid sequence of N-Tyr-Pro-Tyr-Asp-Val-Pro-Asp-Tyr-Ala-C. It is extensively used to isolate, purify, detect, and track the protein of interest in cell biology and biochemistry. It is used for competing out the anti-HA antibody binding to HA-tagged fusion proteins in immunoassays. It may also be used to to elute HA-tagged fusion proteins from an affinity column of Monoclonal Anti-HA agarose. Jul 02 2023
E2991 Gold(III) chloride trihydrate Gold(III) chloride trihydrate is a reducing agent. Gold(III) chloride trihydrate can be used for the chemical synthesis of gold nanoparticles (NP). Jul 02 2023
E2992 Oleoyl-L-alpha-lysophosphatidic acid sodium salt Oleoyl-L-alpha-lysophosphatidic acid sodium salt is an essential metabolite for membrane biosynthesis. LPA interacts with the G protein-coupled receptors (GPCRs), called the LPA receptor and mediates signaling. It acts as a endogenous agonist for LPA1 and LPA2 receptors. Jul 02 2023
D4045 Brentuximab vedotin Brentuximab vedotin (SGN-35; Adcetris,cAC10-vcMMAE) is an anti-CD30 antibody conjugated via a protease-cleavable linker to the potent anti-microtubule agent monomethyl auristatin E (MMAE). Brentuximab vedotin can be used for the research of relapsed and refractory Hodgkin lymphoma. Jun 30 2023
D4046 Telisotuzumab vedotin Telisotuzumab vedotin (Teliso-V, ABBV-399) is an antibody-drug conjugate (ADC) composed of the anti–c-Met humanized monoclonal antibody coupled to the cytotoxic monomethyl auristatin E (MMAE) through a mc-val-cit-PABC type linker. Telisotuzumab vedotin can be used for research on advanced solid tumours. Jun 30 2023
D4048 Labetuzumab govitecan Labetuzumab govitecan (IMMU-135) is a humanised anti-CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule 5) antibody linked site-specifically to the active metabolite of irinotecan SN-38 via a proprietary linker. Labetuzumab govitecan can be used for research on colorectal cancer. Jun 30 2023
D4049 Disitamab vedotin Disitamab Vedotin (RC-48 ,RC 480-ADC) is an antibody-drug conjugate(ADC) composed of anti-[ERBB2 (epidermal growth factor receptor 2, receptor tyrosine-protein kinase erbB-2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)] humanized monoclonal antibody, conjugated to monomethylauristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Disitamab Vedotin has the potential for use in solid tumors mainly in advanced breast cancer. Jun 30 2023
D4050 Datopotamab deruxtecan Datopotamab deruxtecan (DS-1062, DS-1062A, Anti-TRP2/dxd) is an antibody-drug conjugate (ADC) composed of a humanized anti-TROP2 monoclonal antibody, conjugated to topoisomerase I inhibitor, via a tetrapeptide-based linker. Datopotamab deruxtecan has the potential for use in solid tumors mainly in advanced unresectable advanced NSCLC. Jun 30 2023
D4051 Tisotumab vedotin Tisotumab vedotin (TF-011-MMAE, HuMax-TF-ADC) is an antibody-drug conjugate (ADC) composed of a fully human monoclonal antibody to tissue factor III (thromboplastin) also known as CD142, conjugated to Monomethyl Auristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinylp-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Tisotumab vedotin has the potential for use in research of solid tumors mainly in cervical cancer. Jun 30 2023
D4052 Trastuzumab MMAE Trastuzumab MMAE is an antibody-drug conjugate (ADC) composed of an anti-HER2 antibody, conjugated to Monomethyl Auristatin E (MMAE), via a Mc linker. Trastuzumab MMAE has the potential for use in research of solid tumors mainly in HER2-positive breast cancer. Jun 30 2023
D4053 Enfortumab vedotin-ejfv Enfortumab vedotin-ejfv (Padcev) is an antibody-drug conjugate (ADC) composed of an fully human anti-Nectin-4 IgG1 kappa monoclonal antibody (AGS-22C3), conjugated to Monomethyl Auristatin E (MMAE), via a protease-cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl. Enfortumab vedotin-ejfv has the potential for use in research of urothelial carcinoma. Jun 30 2023
D4054 Glembatumumab vedotin Glembatumumab vedotin (CDX-011 (DOX), CR011,CR011-vcMMAE) is an antibody-drug conjugate (ADC) composed of an fully human IgG2 monoclonal antibody (CR011) directed against glycoprotein NMB (GPNMB), conjugated to Monomethyl Auristatin E (MMAE), via a cleavable maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Glembatumumab vedotin has the potential for use in research of Breast cancer (TNBC) and advanced or metastatic melanoma. Jun 30 2023
D4055 Loncastuximab tesirine Loncastuximab tesirine (ADCT-402, RB4v1.2-SG-3249) is an antibody-drug conjugate (ADC) composed of an anti-CD19 (B lymphocyte surface antigen B4, Leu-12) chimeric monoclonal antibody , conjugated to Pyrrolobenzodiazepine (PDB) dimer SCX, via a cleavable (valine-alanine dipeptide as cathepsine B cleavage site) maleimide type linker containing a spacer PEG. Jun 30 2023
D4057 Ladiratuzumab vedotin Ladiratuzumab vedotin (SGN-LIV1A, Anti-LIV-1 ADC) is an antibody-drug conjugate (ADC) composed of humanized anti-LIV-1 antibody, conjugated to Monomethyl auristatin E (MMAE), via a proteolytically cleavable type linker. Ladiratuzumab vedotin has the potential for use in multiple carcinomas. Jun 30 2023
D4042 Depatuxizumab mafodotin Depatuxizumab Mafodotin (Depatux-M, ABT-414) is an antibody-drug conjugate consisting of an EGFR IGg1 monoclonal antibody conjugated to the tubulin inhibitor monomethyl auristatin F via a stable maleimidocaproyl link. Depatuxizumab Mafodotin is used in the treatment of recurrent EGFR-amplified Glioblastoma (GBM). Jun 29 2023
E2964 Norepinephrine tartrate Norepinephrine tartrate is a potent agonist of adrenergic receptor (AR). Norepinephrine activates α1, α2, β1 receptors. Jun 28 2023
E2950 Fat Emulsion(20%) Fat Emulsion(20%)is a safe fat emulsion that can be used as a nutritional supplement. Fat Emulsion(20%)inhibits the opening of the mitochondrial permeability transition pore and effectively protecting the heart from ischaemia-reperfusion injury. It has some potential to modulate the innate immune response. Jun 28 2023
E1217 PCLX-001 (DDD86481) PCLX-001 (DDD86481) is an orally active dual N-myristoyltransferase (NMT) inhibitor. It inhibits NMT1 and NMT2 with IC50 of 5 nM and 8 nM, respectively, in vitro. PCLX-001 inhibits early B-cell receptor (BCR) signalling, which can be used in B-cell malignancy research. Jun 28 2023
E2969 Mannan Mannan is one of the major components of the yeast cell wall. It can be used to coat the microtiter wells to quantify the levels of mannose-binding lectin (MBL) using a mannan-binding enzyme-linked immunosorbent assay (ELISA). Mannan exhibits antiproliferative, antioxidant, and immunomodulatory properties. Jun 28 2023
A2053 Monalizumab (Anti-Human CD159a) Monalizumab (Anti-Human CD159a) is a novel, first-in-class humanized immunoglobulin G4 monoclonal antibody immune checkpoint inhibitor that targets the inhibitory CD94/NKG2A receptors. Jun 28 2023
D4026 Tusamitamab ravtansine Tusamitamab Ravtansine (SAR-408701), is an antibody-drug conjugate (ADC) composed of CEACAM5 (carcinoembryonic antigen-related cell adhesion molecule ) targeting antibody and a cytotoxic maytansinoid tubulin inhibitor DM4. TUSAMITAMAB RAVTANSINE has the potential for use in research of several solid tumors. Jun 27 2023
D4027 Serclutamab talirine Serclutamab Talirine (ABBV-321), is an antibody-drug conjugate (ADC) composed of an humanized immunoglobulin G1 anti-EGFR monoclonal antibody conjugated to a pyrrolobenzodiazepine (PBD) dimer via a maleimidocaproyl-valine-alanine linker. Serclutamab Talirine has the potential for use in advanced solid tumors associated with overexpression of the epidermal growth factor receptor (EGFR) or its ligands. Jun 27 2023
D4030 Vadastuximab talirine Vadastuximab talirine (SGN-CD33A, 33A) is an antibody-drug conjugate consisting of pyrrolobenzodiazepine dimers linked to a monoclonal antibody targeting CD33, which is expressed in the majority of acute myeloid leukemia (AML) patients. Jun 27 2023
D4031 Cantuzumab mertansine Cantuzumab mertansine (HUC242-DM1, SB-408075) is an anti-MUC1 sialylated carbohydrate, tumour-associated (CA242, cancer antigen 242), humanized monoclonal antibody conjugated to maytansinoid DM1 ([N2’-deacetyl-N2’-(3-mercapto-1-oxopropyl)-maytansine]) via a reductible SPP linker [N-succinimidyl 4-(2-pyridyldithio)pentanoate]. Jun 27 2023
D4032 Cantuzumab ravtansine Cantuzumab ravtansine (IMGN242, HUC242-DM4) is an ADC. It is a humanized monoclonal antibody, huC242, covalently linked via a disulfide bond to DM4 (DM4 (HY-12454)). Cantuzumab ravtansine has broad antitumor efficacy against a range of CanAg-positive human tumor xenografts. Jun 27 2023
D4033 Ozuriftamab vedotin Ozuriftamab vedotin (BA 3021) is an antibody-drug conjugate (ADC) composed of ozuriftamab, a conditionally active biologic (CAB) antibody against receptor tyrosine kinase-like orphan receptor 2 (ROR2) conjugated to monomethyl auristatin E, with potential antineoplastic activity. Jun 27 2023
D4034 Lorvotuzumab mertansine Lorvotuzumab mertansine (IMGN901, LM) is an antibody-drug conjugate, linking an anti-mitotic agent (DM1) to an anti-CD56 antibody (lorvotuzumab). Jun 27 2023
D4036 Sofituzumab vedotin Sofituzumab Vedotin (DMUC5754A, RG-7458) is an antibody-drug conjugate (ADC) that contains the humanized IgG1 anti-MUC16 monoclonal antibody (mAb) and a potent anti-mitotic agent, monomethyl auristatin E (MMAE), linked through a protease-labile linker. DMUC5754A binds to the MUC16 extracellular domain with high affinity. Jun 27 2023
D4037 Laprituximab emtansine Laprituximab emtansine (IMGN-289) is an anti-EGFR (epidermal growth factor receptor, receptor tyrosine-protein kinase erbB-1, ERBB1, HER1, HER-1, ERBB), chimeric monoclonal antibody conjugated to maytansinoid DM1 via a succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC) linker, forming a nonreducible thioether bond. Jun 27 2023
D4038 Enapotamab vedotin Enapotamab vedotin (EnaV, HuMAX-AXL-ADC) is an AXL-specific human IgG1 antibody conjugated to the microtubule disrupting agent monomethyl auristatin E (MMAE) through a protease cleavable valine-citrulline (vc) linker. Jun 27 2023
D4039 Praluzatamab ravtansine Praluzatamab ravtansine (CX-2009) is a conditionally activated Probody drug conjugate (PDC) comprising an anti-CD166 mAb conjugated to DM4, with a protease-cleavable linker and a peptide mask that limits target engagement in normal tissue and circulation. Jun 27 2023
E1383 Cp2-SO4 Cp2-SO4 is a phenylalanine derivative which reverses interleukin 4 induced 1 (IL4I1)-dependet inhibition of T-cell proliferation with Ki of 21.2 µM. Jun 26 2023
E1313 N-Formyl-Met-Leu-Phe (fMLP) N-Formyl-Met-Leu-Phe (fMLP) is an endogenous chemotactic peptide and agonist for the formyl peptide receptor 1 (FPR1) with Ki of 38 nM. It stimulates aggregation of leukocytes. Jun 26 2023
E2951 D-Desthiobiotin D-Desthiobiotin(Dethiobiotin) is a biotin derivative used in affinity chromatography and protein chromatography. D-Desthiobiotin also can be used for protein cross-linking agent, protein and cell labeling, detection and isolation. Jun 26 2023
D4006 Anetumab-MMAE Anetumab-MMAE is an antibody-drug conjugate (ADC) composed of a human anti-mesothelin (MSLN) antibody and the anti-mitotic cytotoxic agent monomethyl auristatin (MMAE). Jun 26 2023
D4007 Clivatuzumab-MMAE Clivatuzumab-MMAE is an antibody-drug conjugate (ADC) composed of a humanized anti-mucin (MUC1) monoclonal antibody and a anti-mitotic cytotoxic agent monomethyl auristatin (MMAE). Jun 26 2023
D4009 Indusatumab vedotin Indusatumab vedotin (MLN-0264) is an antibody-drug conjugate (ADC) composed of an anti-human GUCY2C (Guanylate cyclase 2C) monoclonal antibody and a anti-mitotic cytotoxic agent, monomethyl auristatin E (MMAE). Jun 26 2023
D4010 Lifastuzumab vedotin Lifastuzumab vedotin (LIFA, DNIB0600A, RG-7599) is an antibody-drug conjugate (ADC) composed of a humanized anti-NaPi2b monoclonal antibody and an anti-mitotic cytotoxic agent, monomethyl auristatin E (MMAE) . Lifastuzumab vedotin is used in the treatment of platinum-resistant ovarian cancer. Jun 26 2023
D4011 Anetumab ravtansine Anetumab ravtansine (BAY 94-9343) is an antibody-drug conjugate (ADC) composed of a human anti-mesothelin antibody and a cytotoxic maytansinoid tubulin inhibitor DM4. Anetumab ravtansine has the potential to treat advanced solid tumors. Jun 26 2023
D4012 Polatuzumab vedotin-piiq Polatuzumab vedotin-piiq (polatuzumab vedotin, DCDS4501A, RG7596) is an antibody-drug conjugate (ADC) composed of a monoclonal antibody against CD79b (a B cell receptor component) and the anti-mitotic cytotoxic agent monomethyl auristatin (MMAE). It is used for the treatment of relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Jun 26 2023
D4013 Zilovertamab vedotin Zilovertamab vedotin (VLS-101, MK-2140) is an antibody-drug conjugate (ADC) composed of a humanised monoclonal antibody targeting ROR1 and the anti-mitotic cytotoxic agent monomethyl auristatin E (MMAE). It has potential for the treatment of lymphoid malignancies. Jun 26 2023
D4015 Farletuzumab-MMAE Farletuzumab-MMAE is an antibody-drug conjugate (ADC) composed of humanized anti-human folate receptor-alpha (FRα) and the cytotoxic agent monomethyl auristatin (MMAE) via a MC-Vc linker. It has a potent antitumor activity. Jun 26 2023
D4016 Iladatuzumab vedotin Iladatuzumab vedotin (DCDS0780A;RO7032005 ), is an antibody-drug conjugate (ADC) composed of CD79B (immunoglobulin-associated CD79 beta) antibody and cytotoxic agent monomethyl auristatin E (MMAE) conjugated through maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Iladatuzumab vedotin has the potential for B-cell non-Hodgkin lymphoma (B-NHL) research. Jun 26 2023
D4017 Pinatuzumab vedotin Pinatuzumab Vedotin (RG-7593, DCDT2980S, DCDT-2989S), is an antibody-drug conjugate (ADC) composed of CD22 (Sialic acid binding Ig-like lectin 2, SIGLEC2, SIGLEC-2, B-lymphocyte cell adhesion molecule, BL-CAM, Leu-14) antibody and cytotoxic agent monomethyl auristatin E (MMAE) conjugated through maleimidocaproyl-valyl-citrullinyl-p-aminobenzyloxycarbonyl (mc-val-cit-PABC) type linker. Jun 26 2023
D4019 Sirtratumab vedotin Sirtratumab Vedotin (ASG-15ME), is an antibody-drug conjugate (ADC) composed of SLTRK6 (SLIT and NTRK like family member 6, "SLIT and NTRK-like family, member 6") and cytotoxic agent monomethyl auristatin E (MMAE). It delivers a small molecule microtubule-disrupting agent, monomethyl auristatin E (MMAE), to tumor cells expressing SLITRK6. SIRTRATUMAB VEDOTIN has the potential for Bladder Cancer, Metastatic urothelial cancer research. Jun 26 2023
D4021 Codrituzumab-MMAE Codrituzumab-MMAE, is an antibody-drug conjugate composed of a anti-GPC3 monoclonal antibody and a cytotoxic tubulin polymerase inhibitor conjugated through MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) type linker. Jun 26 2023
D4022 Cetuximab-MMAE Cetuximab-MMAE is an antibody-drug conjugate composed of a anti-EGFR monoclonal antibody and a cytotoxic tubulin polymerase inhibitor conjugated through MC-Vc-PAB (maleimidocaproyl-valine-citrulline-p-aminobenzoyloxycarbonyl) type linker. Jun 26 2023
E2944 Norepinephrine hydrochloride Norepinephrine (Levarterenol; L-Noradrenaline) hydrochloride is a potent agonist of adrenergic receptor (AR). Norepinephrine activates α1, α2, β1 receptors. Jun 24 2023
E1327 CWI1-2 hydrochloride CWI1-2 hydrochloride is an inhibitor of IGF2BP2 that binds IGF2BP2 and inhibits its interaction with m6A-modified target transcripts, induces apoptosis and differentiation, and shows promising anti-leukemic effects. Jun 24 2023
E1249 Blebbistatin Blebbistatin is a selective inhibitor of non-muscle myosin II (NMII). It also potently inhibits several striated muscle myosins as well as vertebrate nonmuscle myosin IIA and IIB with IC50 values ranging from 0.5 to 5 μM. It promotes directional migration of corneal endothelial cells (CECs) and accelerates wound healing, and better preserves cell junctional integrity and barrier function. Jun 24 2023
E2966 Lysophosphatidylcholines Lysophosphatidylcholines are a class of chemical compounds which are derived from phosphatidylcholines. Lysophosphatidylcholine is produced from phospholipids by the action of phospholipase A2 (PLA2). It also has pro-inflammatory properties through its activation and modulation of various signaling pathways, including the ERK pathway as well as through protein tyrosine kinase and G protein-coupled receptor (GPCR) signal transduction. It plays a critical role in allergic airway disease manifestation. Jun 24 2023
E2963 Carmine Carmine (Carmine red), a natural red dye extracted from the dried females of the insect Dactylopius coccus var. Costa (cochineal). Carmine is a widely used food additive. Carmine provokes both an immediate hypersensitivity and a delayed systemic response with cutaneous expression. Jun 24 2023
E2955 Pectin Pectin is a heteropolysaccharide, derived from the cell wall of higher plants. It involves in the formation of nanoparticles as a delivery vehicle of agents. It also acts as an adsorbent, a broad-spectrum antimicrobial agent that binds to bacteria toxins and other irritants in the intestinal mucosa, relieves irritated mucosa. Jun 21 2023
E2953 MES hydrate MES hydrate is one of the Good′s buffers, the most extensively used biological buffers. MES is a zwitterionic N-substituted aminosulfonic acid with a morpholinic ring. MES hydrate has been used in the MS (Murashige and Skoog) media for growth of Arabidopsis seedlings. It has been added in the cytoskeleton buffer during immunofluorescence study. Jun 21 2023
E2952 2-Chloroacetamide 2-Chloroacetamide is a preservative and is a herbicide for both uplands and paddy fields. 2-Chloroacetamide is a biocide in agriculture, glues, paints and coatings. 2-Chloroacetamide inhibits very-long-chain fatty acid elongase. Jun 21 2023
E2956 Cytochalasin C Cytochalasin C is a cell-permeable fungal metabolite that has been found in C. globosum. Cytochalasin C is an inhibitor of actin polymerization. It induces the formation of nuclear rodlets. Jun 21 2023
D4004 Patritumab deruxtecan Patritumab deruxtecan (HER3-DXd) is an antibody-drug conjugate (ADC) composed of a fully human anti-HER3 IgG1 monoclonal antibody and a cytotixic topoisomerase I inhibitor. Patritumab deruxtecan shows anticancer activity. Jun 20 2023
D4005 Vorsetuzumab mafodotin Vorsetuzumab mafodotin (SGN-75) is an antibody-drug conjugate (ADC) composed of a humanized monoclonal antibody directed against the extracellular domain of the human CD70 molecule, and a cytotoxic tubulin polymerization inhibitor. It is used in the treatment of renal cell carcinoma. Jun 20 2023
E2940 Bromophenol Blue Bromophenol blue is an acid phthalein dye, and it is used as a tracking dye for electrophoresis. Bromophenol blue is also used as a pH indicator, with a transition range of pH 3 to 4.6. It helps to detect proteins and nucleic acids (absorbance at 610 nm), particularly when staining living tissues. Jun 19 2023
E2961 Phosphatase substrate Phosphatase substarte (4-Nitrophenyl phosphate disodium hexahydrate, p-nitrophenyl phosphate disodium hexahydrate) is widely used as a small molecule phosphotyrosine-like substrate in activity assays for protein tyrosine phosphatases. It is a colorless substrate that upon hydrolysis is converted to a yellow 4-nitrophenolate ion that can be monitored by absorbance at 405 nm. Jun 19 2023
E2954 Ethyl methanesulfonate Ethyl methanesulfonate is a DNA ethylating agent, mutagenic to plants and animals and carcinogenic in mammals. It has been used as a model alkylating agent in studies of DNA repair processes. It induces base substitutions of guanine-cytosine (G/C) to adenine-thymine (A/T). EMS also generates point mutations and single nucleotide polymorphisms in genomes. Jun 19 2023
E2967 Triethylenediamine Triethylenediamine (1,4-Diazabicyclo[2.2.2]octane, DABCO), is a caged tertiary diamine commonly used as a strong hindered amine base in chemical synthesis. It is used in the synthesis of isoxazole derivatives via dehydration of primary nitro compounds in the presence of dipolarophiles. It can also be employed as a complexing ligand and as a catalyst. Jun 19 2023
E2968 Zinc sulfate heptahydrate Zinc sulfate heptahydrate is a hydrate that is the heptahydrate form of zinc sulfate. Zinc sulfate heptahydrate is a dietary supplement used for zinc deficiency and can also accelerate the rate of healing. It is also used in prepration of zinc tris(thiourea) sulphate (ZTS), a semiorganic nonlinear optic (NLO) material that may be useful in laser fusion experiments and in second-harmonic-generation (SHG) devices. Jun 19 2023
E1421 A2ti-1 A2ti-1 is a selective and high-affinity inhibitor of annexin A2/S100A10 heterotetramer (A2t) with IC50 of 24 μM. A2ti-1 specifically disrupts the protein-protein interaction (PPI) between A2 and S100A10. It also prevents human papillomavirus type 16 (HPV16) infection. Jun 19 2023
A2051 Human IgG1 isotype control Human IgG1 isotype control is suitable for use as a non-targeting isotype control in various in vitro and in vivo studies, is the isotype control of human IgG1κ antibody. Jun 18 2023
A2052 Human IgG4 isotype control Human IgG4 isotype control is suitable for use as a non-targeting isotype control in various in vitro and in vivo studies, is the isotype control of human IgG4κ antibody. Jun 18 2023
A2124 Anti-mouse TNFα-InVivo Anti-mouse TNFα-InVivo reacts with mouse TNFα (tumor necrosis factor-alpha), a multifunctional proinflammatory cytokine. TNFα dysregulation is been implicated in a variety of diseases, including autoimmune diseases, insulin resistance, and cancer. TNFα knockout animals display defects in response to bacterial infection, characterized by defects in forming organized follicular dendritic cell networks and germinal centers with a lack of primary B cell follicles. Jun 16 2023
A2125 Anti-mouse OX40 (CD134)-InVivo Anti-mouse OX40 (CD134)-InVivo (Clone: OX-86) monoclonal antibody reacts with mouse OX-40 also known as CD134. OX-40 plays a major role in regulating both CD4 and CD8 T cell clonal expansion. Anti-mouse OX40 (CD134)-InVivo treatment strongly enhances the generation of antigen-specific effector T cells, prevents the induction of T cell tolerance, and delays tumor growth in vivo. Jun 16 2023
E2941 PIPES PIPES (1,4-Piperazinediethanesulfonic acid) is an important component of PIPES buffer agent used in biochemistry. PIPES buffer in combination with glutaraldehyde and formaldehyde helps in optimal fixation of fungal zoospores for fluorescence microscopy and electron microscopy. Jun 16 2023
E2943 Pifithrin-β Pifithrin-β (PFT β hydrobromide; Cyclic Pifithrin-α hydrobromide) is a potent inhibitor of p53 with an IC50 of 23 μM and is regarded as a lead compound for cancer and neurodegenerative disease therapy. Jun 16 2023
E2962 D-(+)-Malic acid D-(+)-Malic acid (D-Malic acid), found in apples and many other fruits and plants is an active enantiomer of Malic acid. It is a competitive inhibitor of L(-)malic acid transport. Jun 16 2023
E1382 BI 1015550 BI 1015550 is an orally active inhibitor of PDE4B with IC50 of 7.2 nM. It has good safety and potential applications in inflammation, allergic diseases, pulmonary fibrosis, and chronic obstructive pulmonary disease (COPD). Jun 15 2023
E2942 MES MES (2-Morpholinoethanesulphonic acid) is a buffering agent in biology and biochemistry. It is one of the Good's buffers, the buffer capacity ranging pH 5.5-7.0. It is broadly used to regulate pH value for plants culture medium, reagent solution, and physiological experiments. Jun 15 2023
E2933 MOMIPP MOMIPP, a macropinocytosis inducer, is a PIKfyve inhibitor. MOMIPP readily penetrates the blood-brain barrier and is moderately effective in suppressing progression of intracerebral glioblastoma xenografts. Jun 12 2023
E2919 5-Chloro-2'-deoxyuridine 5-chloro-2′-deoxyuridine (5-chlorodeoxyuridine; CldU), a thymine analog, is used to study the potential of hypochlorous acid damage to DNA and DNA precursors. Jun 12 2023
E2934 Methyl cellulose (Viscosity:100000mPa.s) Methyl cellulose ( hydroxypropyl methylcellulose, hypromellose) viscosity: 100000 mPa.s., a soluble methylcellulose ether, is used as a thickening agent, binder, film former, and hydrophilic matrix material. Jun 12 2023
E2932 SI-2 Hydrochloride SI-2 hydrochloride (EPH 116 hydrochloride) is an inhibitor of Steroid receptor coactivator 3 (SRC-3), with IC50 of 3–20 nM, it can significantly inhibit breast tumor growth. Jun 12 2023
E1345 HS148 HS148 (DAPK3 inhibitor HS148) is a selective inhibitor of DAPK3 with Ki of 119 nM Jun 06 2023
E2925 2,2-Diphenyl-1-picrylhydrazyl 2,2-Diphenyl-1-picrylhydrazyl (DPPH) is a stable free radical that can be used to measure the radical scavenging activity of antioxidants. The odd electron of nitrogen atom in DPPH is reduced by receiving a hydrogen atom from antioxidants to the corresponding hydrazine. Jun 04 2023
E1431 Lirafugratinib Lirafugratinib (RLY-4008) is an orally active and selective inhibitor of FGFR2. Jun 01 2023
E2912 MEHP MEHP (Phthalic acid mono-2-ethylexyl ester) is a competitive inhibitor of CYP2C9 with IC50 of 6.37 μM. Jun 01 2023
P1120 GLP-1(7-36), amide acetate GLP-1(7-36), amide acetate is a major intestinal hormone that stimulates glucose-induced insulin secretion from β cells. Jun 01 2023
E1221 CIA1 CIA 1 (COUP-TFII inhibitor A1) is a specific inhibitor of the nuclear receptor COUP-TFII with IC50 of 1.2 μM to 7.6 μM in prostate cancer cell lines. May 31 2023
E1328 TP-1454 TP-1454 is an activator of PKM2 with AC50 of 10 Nm in biochemical assays.TP-1454 modulates tumor-immune responses by destabilizing T-regulatory cells. May 30 2023
E1391 SP 600125, negative control SP 600125, negative control (JNK inhibitor II, negative control) is a methylated analog of SP 600125 and inhibits JNK2 and JNK3 with IC50 of 18 µM and 24 µM, respectively. May 30 2023
E2923 Bile Extract Porcine Bile extract porcine (Ox bile extract) is used as a supplement in brain heart infusion (BHI) medium to culture Listeria monocytogenes LO28. It is also used to investigate the survival of probiotic bacteria through the gastric-small intestine. May 30 2023
E1305 RBN013209 RBN013209 is a potent inhibitor of CD38 with an IC50 of 0.01-0.1 μM for human CD38. It can be used for the research of cancer. May 28 2023
E1256 Ibotenic acid Ibotenic acid((RS)-Ibotenic acid; DL-Ibotenic acid) is a neuroexcitatory amino acid originally isolated from Amanita species. It exhibits agonist activity at both N-methyl-D-aspartate (NMDA) and trans-ACPD) or metabolotropic quisqualate (Qm) receptor sites. May 28 2023
E2914 5,6-Dichlorobenzimidazole 1-beta-D-ribofuranoside 5,6-Dichlorobenzimidazole riboside(DRB) is a nucleoside analog that inhibits several carboxyl-terminal domain (CTD) kinases including casein kinase II and CDKs. It trigger p53-dependent apoptosis of human colon adenocarcinoma cells without inducing genotoxic stress to healthy cells. May 28 2023
E2924 BCIP BCIP (BCIP p-toluidine salt, X-phosphate p-toluidine salt) is a synthetic chromogenic substrate used for the sensitive colorimetric detection of alkaline phosphatase activity. May 25 2023
E1398 Rilematovir Rilematovir (JNJ-678, JNJ-53718678) is an antiviral agent that inhibits respiratory syncytial virus (RSV) with EC50 of 1.2 nM in HBECs. Rilematovir is also a fusion protein inhibitor. May 25 2023
E2917 ABTS ABTS (ABTS diammonium salt, AzBTS-(NH4)2) is a substrate for horseradish peroxidase (HRP) conjugate. It has commonly been used to assess antioxidant capacity in the Trolox equivalent antioxidant capacity (TEAC) assay. May 24 2023
E1386 KP-457 KP-457 (TNF-α-converting enzyme) is a selective inhibitor of ADAM17 with IC50 of 11.1 nM/L (cell-free assay). It also cleaves various molecules such as GPIbα, GPV, and TNF-α. May 24 2023
E2920 3-Aminopropyltriethoxysilane 3-Aminopropyltriethoxysilane (γ-Aminopropyltriethoxysilane) is an aminosilane commonly used for biomolecule immobilization on silicon and silicon derivatives such as silicon nitride (Si3N4). May 24 2023
E2918 Sesame Oil Sesame oil is a supplement that has anti-inflammatory and antioxidant properties, which make it effective for reducing atherosclerosis and the risk of cardiovascular disease. May 24 2023
E2921 Diethyl Pyrocarbonate Diethyl pyrocarbonate is a potent, non-specific inhibitor of RNase. It has been useful as an in vitro agent, relatively specific for binding to imidazole of histidine. It inhibits central chemosensitivity in rabbit and can modify Ser, Thr, His and Tyr residues. May 22 2023
E2922 Formamide Formamide (Methanamide; Formimidic acid) is a clear liquid amide derived from formic acid. It allows for the denaturation and renaturation of nucleic acids at room temperature. Formamide-induced DNA denaturation when combined with detection of denatured DNA with a monoclonal antibody (MAb) makes it possible to specifically identify the apoptotic cells. May 22 2023
E2913 Fast Green FCF Fast Green FCF (FD&C Green No. 3; Food green 3; C.I. 42053) is a sea green triarylmethane food dye. It is a dye used to stain proteins for IEF (isoelectric focusing) and SDS-PAGE. When bound to proteins, Fast Green FCF fluoresces near infrared (absorption maximum: 624 nm). Fast Green FCF staining is linear over a wider range of protein concentrations compared to Brilliant Blue R. May 22 2023
E2926 A-1155463 A-1155463 is a highly potent and selective BCL-XL inhibitor with EC50 of 65 nM in H146 cells. May 22 2023
E2911 UZH2 UZH2 is a potent and selective METTL3 inhibitor with an IC50 value of 5 nM in TR-FRET assay. May 22 2023
E1348 E-7386 E-7386 is a selective inhibitor which inhibits interaction between CBP/beta-catenin with IC50 value of 0.0484 μM in HEK293 cells. May 22 2023
E2916 Sudan Black B Sudan Black B is a fat-soluble diazo dye and a histochemical stain. Sudan Black B can be used for staining of neutral triglycerides and lipids. May 22 2023
E2915 Ovalbumin (257-264) Ovalbumin (257-264) is a class I (Kb)-restricted peptide epitope of ovalbumin (OVA) and has been used to trigger T cell activation in immunology studies. May 22 2023
E1346 HS94 HS94 (DAPK3 inhibitor HS94) is a selective inhibitor of DAPK3 with Ki of 126 nM, >20-fold selectivity over Pim kinases. May 21 2023
A2123 Rat IgG2a isotype control-InVivo Rat IgG2a isotype control-InVivo can be used as an isotype-matched control for rat IgG2a antibodies. May 21 2023
E2890 CHIR-090 CHIR-090 is a potent and tight-binding inhibitor of the LpxC deacetylase. It also binds to E. coli LpxC with a Ki of 4.0 nM. May 18 2023
S9931 Enpatoran Hydrochloride Enpatoran (M5049) hydrochloride is a potent, orally active, and dual TLR7/8 inhibitor with IC50s of 11.1 nM and 24.1 nM, respectively, in HEK293 cells. May 14 2023
E2895 Sodium Bicarbonate Sodium bicarbonate(Armex Blast Media Flow Formula XL, BI-CF 40E, BI-H 40E, Bakeshure 180, Sodium Hydrogen Carbonate, Sodium hydrogen carbonate) is a biochemical reagent used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions. May 09 2023
E2897 Glutaraldehyde Glutaraldehyde(Glutaric dialdehyde, Pentane-1,5-dial) is an effective biochemical reagent used as a protein crosslinker, enzyme immobilization microscopy, histochemistry, and cytochemistry.This product is a hazardous chemical (acute toxicity/flammable/skin corrosive). Please use it while wearing a protective face mask, gloves, and clothing. May 09 2023
E2905 DIRECT RED 80 Direct Red 80 (Sirius Red) is a polyazo dye used principally in staining methods for collagen and amyloid. Direct Red 80 does not release benzidine upon degradation and is safer than many traditional direct dyes. May 08 2023
E1220 CBR-470-1 CBR-470-1 is an inhibitor of the glycolytic enzyme phosphoglycerate kinase 1 (PGK1). CBR-470-1 is also a non-covalent Nrf2 activator. CBR-470-1 protects SH-SY5Y neuronal cells against MPP+-induced cytotoxicity through activation of the Keap1-Nrf2 cascade. May 08 2023
E1300 SJ6986 SJ6986 is a CRBN modulator and specifically degrades GSPT1/2, with a DC50 of 2.1 nM (Dmax 99%) for GSPT1. May 08 2023
E2910 bisBenzimide H 33258 Trihydrochloride bisBenzimide H 33258 Trihydrochloride(Hoechst 33258 trihydrochloride; H 33258 trihydrochloride) is a marker dye in Hoechst series. Hoechst is A live nuclear marker dye. It binds to the grooves in the DNA double strand, which tends to be A/ T-rich DNA strand. Although it binds to all nucleic acids, the A/ T-rich double strand DNA significantly enhances fluorescence intensity. Therefore, Hoechst dye can be used for living cell labeling. The fluorescence intensity of Hoechst dye increases with the increase of pH of solution. It exhibits anti-tumor activity IC50 of 51.31±4.56 μM in HeLa cells. May 07 2023
S7850 Lipopolysaccharides Lipopolysaccharides (LPSs, Endotoxin,LPS) is an endotoxin derived from the outer leaflet of the outer membrane of Gram-negative bacteria. Lipopolysaccharides consists of an antigen O-specific chain, a core oligosaccharide and lipid A. Lipopolysaccharides is a pathogenic associated molecular pattern (PAMP) that activates the immune system. Lipopolysaccharides activates TLR-4 on immune cells. Lipopolysaccharides induces secretion of cell migrasome. May 07 2023
E2903 2,4-dihydroxybenzaldehyde 2,4-Dihydroxybenzaldehyde exhibits antimicrobial as well as antioxidant properties. May 06 2023
E2908 1-PHENYL-2-THIOUREA 1-PHENYL-2-THIOUREA(N-Phenylthiourea, PTU, Phenylthiocarbamide) is an inhibitor of tyrosinase (Tyr). 1-PHENYL-2-THIOUREA blocks pigmentation and improves optical transparency in zebrafish (Danio rerio) embryo. May 04 2023
E2896 3,4-Dichlorophenyl isothiocyanate 3,4-Dichlorophenyl isocyanate(1,2-Dichloro-4-isothiocyanatobenzene) is a chemical compound used as a chemical intermediate and in organic synthesis. Apr 28 2023
E2907 1-Thioglycerol 1-Thioglycerol(Mercaptopropanedioltech) is an inhibitor of glycerol kinase activity. It stimulates the synthesis of porphyrin in aerobically growing Escherichia coli.  Apr 28 2023
E2901 (-)-Isoproterenol hydrochloride (-)-Isoproterenol hydrochloride is an agonist of beta-adrenergic receptor. (-)-Isoproterenol hydrochloride is also used in the treatment of bradycardia; bronchodilator. Apr 28 2023
E1276 MK-0159 MK-015(Compound 37) is an inhibitor of CD38. MK-0159 inhibits human, mouse, and rat CD38 (cell-free assays) with IC50 values of 22, 3, and 70 nM, respectively. MK-0159 increases NAD+ (nicotinamide adenine dinucleotide) and reduces ADPR (adenosine diphosphate ribose) in whole blood and heart. Apr 28 2023
E2904 Poly(vinyl alcohol) Poly(vinyl alcohol) is an artificial polymer that is used in many industries, such as textile, paper industry, and food packaging industry due to its high chemical and thermal stability. Poly(vinyl alcohol) is also an excellent source for fiber, polymer, textile, surface, organic. Apr 28 2023
E2909 L-Ascorbic acid 2-phosphate sesquimagnesium salt hydrate L-Ascorbic acid 2-phosphate sesquimagnesium salt hydrate is a vitamin C derivative. L-Ascorbic acid 2-phosphate sesquimagnesium salt hydrate increases alkaline phosphatase (ALP) activity and expression of runx2A in hASCs during the osteogenic differentiation. Apr 28 2023
E2898 ε-poly-L-lysine HCl ε-poly-L-lysine (ε-PL) is a naturally occurring poly(amino acid), which possesses excellent antimicrobial activity and has been widely used in food and pharmaceutical industries.This product is very susceptible to moisture, please keep it sealed! Apr 28 2023
E0214 Pachymic acid Pachymic acid(3-O-Acetyltumulosic acid) inhibits the activity of CYP2C9 with the IC50 of 21.25 µM. Apr 26 2023
E2900 Sodium palmitate Sodium palmitate(Palmitic acid sodium) is a common saturated fatty acid and produced during fatty acid synthesis. Sodium palmitate enhances lipogenesis and cellular steatosis in various cell lines. Apr 26 2023
E2894 Penicillin-Streptomycin Penicillin-Streptomycin is used to prevent microbial contamination of cell culture during long-term in vitro cell culture maintenance. 100× solution stabilized with 10,000 units penicillin and 10 milligrams streptomycin per milliliter, suitable for cell culture applications. Apr 26 2023
E2893 Triton X-114 Triton(TM) X-114 (Triton X-114) is a nonionic detergent used in biochemical applications for solubilizing and separation of intrinsic membrane proteins because of its reversible phase separation property. Apr 25 2023
E2902 Sodium Pyruvate Sodium Pyruvate(Sodium 2-oxopropanoate) is a compound produced in the glycolytic pathway. Sodium Pyruvate is a free radical scavenger that can scavenge ROS. Apr 25 2023
E2899 MG132 SSS MG132 SSS(Z-Leu-Leu-Leu-al, MG132) is a potent proteasome and calpain inhibitor with IC50 of 100 nM and 1.2 μM, respectively. Apr 25 2023
E2906 Tetrazolium Red Tetrazolium Red(2,3,5-Triphenyltetrazolium chloride, TPTZ, TTC) is a dye and has been successfully used for early histochemical diagnosis of myocardial infractions. Apr 25 2023
E1339 HPPE HPPE is a specific nonelectrophilic and physiological Bach1 inhibitor via heme-binding sites of Bach1 protein, derepresses Bach1-mediated repression. Apr 22 2023
E2892 L-ALANYL-L-TYROSINE L-ALANYL-L-TYROSINE(H-Ala-Tyr-OH) is a tyrosine derivative. Apr 20 2023
E1351 NF-κΒ activator 1 NF-κΒ activator 1(Compound 32) is a potent NF-κΒ activator, with an EC50 of 0.9 μM. Apr 20 2023
E1368 PD173212 PD173212(Compound 11) is a selective N-type voltage sensitive calcium channel (VSCC) blocker, with an IC50 of 36 nM in IMR-32 assays. Apr 17 2023
E2891 Dxd Dxd(Exatecan derivative for ADC) is a potent  DNA topoisomerase I inhibitor, with an IC50 of 0.31 μM. Apr 17 2023
E1312 DPH DPH is a potent cell permeable c-Abl activator, with an EC50 of 794 nM. Apr 17 2023
E1342 Sebetralstat Sebetralstat(KVD900) is a plasma kallikrien inhibitor. Apr 17 2023
S8908 AB680 AB-680 is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73. Apr 11 2023
E1332 EG-011 EG-011 is a potent Wiskott-Aldrich syndrome protein (WASP) activator. Apr 11 2023
E2885 Suc-Ala-Ala-Pro-Phe-pNA Suc-Ala-Ala-Pro-Phe-pNA(Suc-AAPF-pNA) is a chromogenic p-nitroanilide (pNA) substrate with the Km of 1.7 mM. Apr 11 2023
E0437 ZAP-180013 ZAP-180013 is a inhibitor of zeta-chain-associated protein kinase 70 (ZAP-70) with an IC50 of 1.8 μM. Apr 11 2023
E2887 MS023 hydrochloride MS023 hydrochloride(Compound 3) is a potent, selective and cell-active inhibitor of human type I protein arginine methyltransferases (PRMT), with IC50 values of 30, 119, 83, 4 and 5 nM for PRMT1, PRMT3, PRMT4, PRMT6, and PRMT8, respectively. Apr 03 2023
S0808 Ketohexokinase inhibitor 1 Ketohexokinase inhibitor 1 (PF-06835919, MDK1846) is a potent inhibitor of ketohexokinase (KHK) with IC50 of 8.4 nM and 66 nM for KHK-C and KHK-A, respectively. Mar 29 2023
S8802 Delgocitinib (JTE-052) Delgocitinib (JTE-052) is a specific  JAK inhibitor with IC50s of 2.8, 2.6, 13 and 58 nM for JAK1, JAK2, JAK3 and Tyk2, respectively. Mar 29 2023